Somewhere in a Singapore operating theatre this week, a surgeon will inject a few milligrams of green powder dissolved in sterile water into a patient’s bloodstream. Under a near-infrared camera, the compound, indocyanine green, will light up the patient’s blood vessels and tissue perfusion in real time: a glowing map of where blood is flowing and where it is not. The surgeon uses that map to decide where to cut, what to reconnect, and whether a newly joined section of bowel will survive. The dye has been in clinical use since the 1950s. The camera, the regulatory approvals, the distribution network and, increasingly, the data captured around each procedure belong to a company most Singapore investors had never heard of before December 2025.

UltraGreen.ai Limited listed on the SGX Mainboard on 3 December 2025 at US$1.45 per share, the largest non-REIT listing in Singapore since 2017 [12]. It sells roughly 83% of all indocyanine green (”ICG”) vials used in the United States and about 94% of those used in Europe, with no approved substitute for the fluorescence-guided surgery (”FGS”) indications it dominates [2]. It earned an 85.0% gross margin in FY2025. Its revenue has compounded at 43% a year since FY2022. As at 10 June 2026 the shares trade at US$1.42 [1], 2% below the IPO price and 24% below the February peak of US$1.86.

The market’s implied verdict is that this is a fully priced, mid-growth medtech: at US$1.42, roughly 18x our estimate of FY2026 earnings, against the premium multiples global medtech peers command, which published comp sets put anywhere from about 20x to 32x forward [8]. We think that verdict rests on a misreading of one income statement. FY2025’s reported numbers simultaneously overstate the group’s tax burden, through a one-time US$8.5 million provision that is the subject of a pending exemption application, and understate its interest income, because the US$150.0 million of IPO proceeds arrived in the final month of the financial year and earned almost nothing. One distortion reverses mechanically in FY2026; the other awaits a ministerial ruling, with both outcomes computable today. Together they could add roughly US$13–15 million of net profit, a 20–24% uplift on the underlying FY2025 base of US$63.8 million, before a single additional vial is sold.

This article works through three questions in sequence. First, are FY2025 earnings temporarily depressed? We will show the arithmetic says yes, and quantify it. Second, does UltraGreen’s US pricing hold through the hospital purchasing cycle? That is genuinely open, and we will name the one undisclosed variable that matters most. Third, can the ICG cash engine fund a credible platform business in data and imaging? That is conditional, and we will treat it as optionality rather than earnings. Along the way we will also explain why the share price fell 24% from its peak, why we think much of that fall was macro rather than company-specific, and what one number, due in August 2026, would make us abandon the thesis entirely.

From Frame Relay to fluorescent dye

Ravinder Sajwan, 64, did not invent anything UltraGreen sells. That is worth stating plainly at the outset, because the company’s moat makes more sense once you stop looking for the patent. Sajwan’s career is a Silicon Valley operator’s résumé: a 2,400bps modem design early on, a universal network-testing device acquired by Tektronix, senior technical roles at StrataCom, whose Frame Relay technology Cisco bought for US$4 billion in 1996, then the co-founding of Acclaim Communications, sold to Level One for US$120 million in 1998, shortly before Intel bought Level One for US$2.2 billion [3][19]. Between telecoms and medtech came a long, lucrative interlude producing 5-Hour Energy drinks, a business connected to founder Manoj Bhargava, which threw off dividends that capitalised the family’s Renew Group [3].

The ICG story began, by Sajwan’s own telling, around 2013, when he encountered the dye through a German medical device company using it to measure holes in hearts [3]. What he saw was not a molecule but a market structure. ICG itself is an old, unpatentable compound; Sajwan has compared it to matcha powder, an everyday-seeming ingredient with an outsized value per use [19]. The product is cheap to make, sells for a small fraction of the cost of the surgery it supports, and is protected not by intellectual property but by regulatory approvals, manufacturing accreditation, distribution relationships and surgeon habit. From 2015, Renew built UltraGreen by buying, partnering with and consolidating the companies that held those positions: the moat was assembled, not invented [3]. The group even founded the International Society of Fluorescence-Guided Surgery, a surgeon education body that, whatever its scientific merits, functions commercially as a standard-of-care flywheel for ICG procedures [19].

The capital structure history matters for what comes later in this article, so we set it out here. UltraGreen took no outside investors at all until 2025, when 65 Equity Partners (a Temasek-backed vehicle investing from a fund with an explicit mandate to groom companies for SGX listings) and Vitruvian Partners invested in a pre-IPO round [10]. Before that, in November 2024, the company issued a US$142.8 million promissory note to its immediate holding company RGPL, in effect a distribution to the controlling shareholder funded by an IOU, which pushed group equity negative (total equity at 31 December 2024 was negative US$26.0 million). In August 2025, the note was settled by issuing RGPL 142.8 million new shares at US$1.00 apiece. In the same pre-IPO window the company paid US$39.8 million of FY2025 dividends to its pre-listing shareholders and sold its UltraLinQ cardiology software business for a US$23.7 million gain. Then came the December IPO: US$150.0 million of primary proceeds at US$1.45 per share, within a roughly US$400 million total offering including a US$237.5 million cornerstone tranche taken up by sixteen institutions, among them abrdn, AIA, Eastspring and Lion Global [11][12].

The debut was respectable but not euphoric: the stock opened at US$1.51, touched US$1.62 intraday, and closed at US$1.52 [12]. Within nine trading days it was at US$1.31, and the stabilising manager deployed its full 20.7 million share mandate; the over-allotment option was never exercised [13]. The stock then rallied to US$1.86 by 23 February 2026, sold off through a risk-averse March, and slid to a US$1.20 low in late May after a first-quarter print the market misread [7], both of which we return to below; it sits at US$1.42 as we write [1]. A listing that was priced at 28.6x FY2024 earnings [12] now trades, on our normalised arithmetic, at a multiple in the high teens against earnings that have since grown.

What the company actually sells

UltraGreen is best understood as three layers stacked on one molecule.

The first layer is the dye itself, and it is almost the whole income statement today. The group sells ICG vials under the IC-GREEN brand in the US and Verdye elsewhere, through two geographic segments. DxG–Americas generated US$106.5 million of net revenue in FY2025, 74.8% of the group total, up 23.9% year on year. DxG–Rest of the World generated US$31.0 million, up 40.7%. Volumes tell the same story with less noise: 667,800 vials shipped in the Americas in FY2025 and 319,900 elsewhere, 987,700 in total, up 13.2% on FY2024. Cumulatively the group had sold about 5.3 million vials since 2015 as at June 2025 [11]. Gross margin on all of this was 85.0% in FY2025, up from 75.5% in FY2022, a function of price increases falling through to a largely fixed cost of goods.

The second layer is hardware: the IC-Flow imaging system, a handheld near-infrared camera that makes the dye visible. UltraGreen’s German subsidiary Diagnostic Green GmbH is the license holder and manufacturer of record. The camera is not currently a profit centre; it is an ecosystem device, and the group’s Asia strategy makes that explicit. In Asia, UltraGreen will lease cameras to hospitals rather than sell them, lowering the entry cost for adoption while keeping the recurring vial sales and, importantly, the procedure data [10]. Camera manufacturing is being relocated from Germany and Ireland to Singapore, at the group’s MacPherson headquarters [10]. Commercial responsibility is split between two Chief Commercial Officers, one for the Americas and one, Fidelma Callanan, based in Ireland, covering everything else; the Asia build-out reports to her [10].

The third layer is the platform ambition that justifies the “.ai” in the name: the UltraGreen Data Platform, the PerfusionWorks perfusion-analytics software acquired with Denmark’s Perfusion Tech ApS (the remaining 72.6% was bought in June 2025 for US$5.6 million net of cash, adding US$3.7 million of goodwill and US$8.2 million of intangibles), and a small UltraGreen Data Systems (”UGDS”) segment created in 2025 from retained UltraLinQ staff. UGDS also distributes biosensor products from LifeSignals Inc., an associate of the controlling shareholder’s private group, a related-party arrangement we examine in the governance section. The platform layer is currently a cost: UGDS recorded US$0.4 million of revenue and a US$1.6 million operating loss in FY2025, and PerfusionWorks is targeted for commercial launch in 2027, a management target rather than a committed date. The regulatory groundwork is further along than the revenue line suggests: the IC-Flow system and the UltraGreen Data Platform carry US 510(k) clearance and CE marking, and PerfusionWorks has been filed for approval in Europe, with management indicating a potential European launch as early as 2026 and progress through the EU MDR and FDA pathways during the year. In April 2026 the group also branded its cardiology distribution business UltraGreen Cardiac Technologies, the commercial wrapper for the LifeSignals biosensor arrangement. There is also Ferronova, a 26.9%-owned Australian associate developing iron-oxide nanoparticle devices for sentinel lymph node biopsy, an adjacent modality that costs the group roughly US$0.5 million a year through the associates line. We note it here and set it aside: it is not material to the valuation.

One business is deliberately absent from this list. UltraLinQ, the cardiology image-management software the group sold in August 2025 for a US$23.7 million gain, contributed US$4.4 million of revenue in FY2025 before disposal and US$6.7 million in FY2024. Reported FY2025 revenue of US$142.4 million therefore overstates the continuing perimeter; the comparable core figure is US$137.9 million. We use the core figure throughout this article when we discuss growth.

The industry: a standard of care still in its first quarter

Fluorescence-guided surgery is one of those rare medical technologies whose clinical evidence base is enormous while its adoption remains shallow. More than 20,000 peer-reviewed publications and over 780 clinical trials involve ICG [5], and the dye has US FDA approval history stretching back decades. Yet FGS penetration is still below 25% of addressable procedures in the United States, and lower again in Asia-Pacific [8]. At UltraGreen’s April 2026 AGM, the CEO put the addressable market for just the four core procedures, laparoscopic cholecystectomy, colorectal surgery, breast sentinel lymph node biopsy and breast reconstruction, at roughly 10 million surgical procedures a year, of which the group currently serves a small fraction, with procedure growth running at mid-to-high single digits. Frost & Sullivan frames the same runway in dollars: it sizes the global ICG market at about US$173 million in 2024, against a total addressable market of roughly US$925 million were FGS and ICG adopted across every eligible procedure, which leaves the category only about 19% penetrated [2].

The competitive map is unusually concentrated. By Frost & Sullivan’s count, UltraGreen held about 68% of the global ICG market by vials and 63% by revenue in 2024, with 83% of US vials and a 94% share in Europe [2]; Sajwan has put the US figure at 85% in interviews [3]. The company’s revenue is roughly 2.6 times that of the second-largest player [18]. In the US, the remaining ~17% of the vial market belongs to Stryker Corp, the Michigan-based devices group [4]. Daiichi Sankyo, the original Japanese incumbent, retains only a minor global role [4]. There is no other FDA-approved fluorescent agent for the broad FGS indications ICG covers; emerging agents target specific procedures, and management’s stated view at the AGM was that ICG’s safety profile keeps it the default across the majority of use cases.

Two industry developments in 2026 bear directly on the investment case. The first is regulatory: UltraGreen’s approval footprint expanded from 35 territories in 2024 to 45 by mid-2026. The composition of those approvals deserves precision, because dye and camera travel on separate regulatory tracks. The Verdye dye itself was approved in the Philippines (December 2025) and Singapore (May 2026); the March 2026 four-country sweep across India, Thailand, the Philippines and Bangladesh, like the December 2025 Malaysia clearance, covers the IC-Flow V2 imaging system, with the dye still to follow in most of those markets. The camera approvals lay regulatory groundwork; meaningful revenue in those territories waits on the corresponding ICG registrations, and the company says approvals are being sought in roughly 20 further markets across Asia and the Middle East. Asia is the growth frontier, and the entry indications are deliberately chosen for emerging-market epidemiology: diabetic foot ulcer assessment and lymphedema, ahead of the surgical oncology uses that dominate Western volumes. Sajwan’s framing of the wound-care opportunity is worth quoting: “Five per cent penetration of the diabetic foot ulcer market is twice our current total addressable market.” [9]

The second development is the misfortune of the only US competitor. On 11 March 2026, a hacking group calling itself Handala, claiming Iran-linked motives, attacked Stryker’s Microsoft IT environment; the company’s SEC filing disclosed disruption to order processing, manufacturing and shipping [20]. Recovery was quick by the standards of such incidents: electronic ordering was restored for customers by 26 March, with most manufacturing sites and critical lines back and order reconciliation still under way [21], and by 9 April the company reported itself fully operational [25]. Brief as it was, the disruption was not trivial: Stryker’s amended SEC filing formally determined the incident had a material impact on its first-quarter 2026 operations and financial results, while leaving full-year guidance intact [25]. Hospitals buying a consumable that sits on the critical path of scheduled surgery prioritise supply reliability above almost everything, and a two-week ordering outage is long enough to force substitution decisions. We treat the possibility that displaced Stryker orders flowed to UltraGreen as a hypothesis bounded by that two-week window, to be tested by the next volume print, not as an accrued benefit; the timing arithmetic is in the deep dive. But the episode illustrates the asymmetry of this market: when 83% leans on 17%, disruption at the small player consolidates the large one.

The moat: three layers, one weak seam

Asserting a moat is cheap; the financial record either corroborates it or it does not. UltraGreen’s record corroborates three distinct layers of advantage, and exposes precisely where the structure is least tested.

The first layer is regulatory and clinical entrenchment. ICG is not proprietary, and management says so plainly: at the April 2026 AGM the CEO identified the group’s advantages as its regulatory approvals, manufacturing processes, ownership of the FDA drug master file, and accumulated clinical data, not the molecule. A would-be competitor needs an approved abbreviated new drug application, accredited sterile manufacturing, and a reason for surgeons to switch a consumable that costs a rounding error within a surgical bill. IC-GREEN has been FDA-approved since 1959 and remains the Reference Listed Drug other ICG products are measured against (we develop this point, and what the FDA register shows about would-be generics, in the risks section), and the publication and training flywheel around the group’s surgeon society raises the switching bar each year.

The second layer is distribution. In the US, the Big Three pharmaceutical wholesalers, Cencora, McKesson and Cardinal Health, collectively accounted for 67.8% of group revenue in FY2025. We will argue later that this concentration is more benign than it looks, because wholesalers are logistics and credit conduits rather than buyers with pricing power. But as a barrier it is real: shelf position inside the ordering systems of effectively every US hospital is something a new entrant cannot replicate quickly at any price.

The third layer is the one the income statement proves: pricing power, exercised in three rounds and absorbed each time. UltraGreen raised US prices by an average of 60% per vial in August 2023 and another 30% in April 2024, then implemented a further round of US pricing initiatives in the third quarter of 2025 that lifted US average selling prices 22% to about US$158 per vial that year. Over the period the global blended ASP went from US$70.3 per vial in FY2022 to US$139.3 in FY2025 [4], and volumes did not fall; Americas vials grew from 470,400 in FY2022 to 667,800 in FY2025, and total vials from 699,600 to 987,700. A 98% cumulative increase in the blended ASP met 41% volume growth over the same three years. Demand for ICG is, on this evidence, about as price-inelastic as consumables get, which is what you would expect for a product that enables a procedure billed at two or three orders of magnitude above the vial price.

The weak seam runs through the second and third layers where they meet:

Read more

The first is the completion of the Ann Arbor Dental Surgery acquisition, announced on 10 June. The second, from 5 June, is the FY2025 profit guarantee results for Aoxin Q&M’s three legacy northern China subsidiaries: all met, and the last outstanding shortfall from the pre-FY2023 period has been repaid in full.

A quick note on scope: Ann Arbor did not appear in our initiation article. It is one of three small Singapore bolt-on acquisitions (alongside Sengkang Dental Surgery, completed January 2026, and Southbank Private Limited / TEETH @ Tiong Bahru, binding MOU February 2026) that Q&M has been running in parallel with the headline international deals. Each is too small individually to feature in an S$130M thesis, and none changes the international expansion story. But together they confirm that the Singapore accretion engine, the model that built Q&M from one clinic to 110+ over thirty years, is still running while management pursues the larger bets.

Neither event is material in isolation. Together they clear two items that were sitting open on the bear checklist.

Read more

Walk into the Rolex boutique on the casino floor at Crown in Perth, or into Tong Building at the top of Orchard Road in Singapore, and the experience is engineered to feel timeless. A salesperson who knows your collection. A display of steel sports models you cannot simply buy off the shelf. A waiting list that is itself a status object. None of it looks like a listed company, and that is the point. The business behind that boutique floor is one of the oldest continuously operating luxury watch retailers in Asia, and it has been run by the same family for forty-six years.

The Hour Glass Limited (SGX:AGS) was founded in 1979 by Dr Henry Tay and Dato’ Dr Jannie Tay. It listed on the Singapore Exchange in 1988 and has not raised a dollar of equity from public markets in more than three decades. For the financial year ended 31 March 2026 it earned a headline net profit of S$179.5 million on revenue of S$1,338 million, both records, and it closed the year with no bank debt or bonds for the first time in at least a decade. Its book value per share has risen every single year for seven consecutive years, from S$0.86 to S$1.67. At the 3 June 2026 close of S$2.63, the market values the whole company at roughly S$1,685 million.

The most interesting fact about The Hour Glass right now is the acquisition it completed in 2025, and the reason the seller gave for selling. In a deal worth AUD90 million, The Hour Glass bought THGRAU, the Australian Rolex authorised-dealer business previously owned by Kennedy Watches & Jewellery: four Rolex flagship boutiques in Melbourne, Sydney and Perth. The seller, James Kennedy, told the Australian Financial Review that the timing was right to sell the licence because Rolex “may sell directly to shoppers in the future” [1]. An informed seller cashed out of the exact relationship The Hour Glass paid AUD90 million to acquire, and told the press why. That tension is the question the institutional-length version of this analysis sets out to resolve in full; here we lay out why the franchise behind it is real, and where the market may be giving it too little credit.

That tension is the question the institutional-length version of this analysis sets out to resolve in full; here we lay out why the franchise behind it is real, and where the market may be giving it too little credit. Link below.

Forty-Six Years, Zero Equity Raises

The Hour Glass began in 1979 as a single boutique. Dr Henry Tay, a Monash-trained doctor who had practised before moving into business, and Dato’ Dr Jannie Tay built the company around an idea unusual for its time and place: sell luxury Swiss watches in Southeast Asia as objects of taste rather than as commodities, in retail environments that matched the brands’ own standards. The two founders were husband and wife, married in 1969, and they built The Hour Glass together for three decades before divorcing in 2010; both have remained substantial shareholders since, and their son Michael Tay now leads the group. Jannie Tay is today often known as Jannie Chan. The watch trade was already in Dr Tay’s family: his forebears ran Lee Chay & Co on North Bridge Road from 1946, one of the Singapore retailers Rolex appointed in 1950, so the group’s Rolex relationship is closer to seventy-five years old than to the company’s own forty-six [14]. The name itself sets the character of the company. An hour glass measures time by letting it run out grain by grain, a fitting emblem for a business that sells mechanical timekeeping and thinks in decades.

The company listed in 1988, and the most telling fact about the thirty-eight years since is a negative one: it has not issued a single new share to raise capital. Growth has been funded from retained earnings and modest borrowing that has now been fully repaid. A retailer that expands across eight countries without diluting its owners is doing something deliberate.

The growth came in layers. The first Australian boutique opened on the Gold Coast in 1988, at Marina Mirage. The Thai business that became THG Prima Times was built as a joint venture and is now a 49 per cent associate spanning Bangkok and, more recently, Vietnam. Japan followed, with a Ginza presence dating to the 1990s. The two acquisitions that matter most to the current story are recent: Mansors Jewellers in Auckland in February 2020, New Zealand’s oldest authorised Rolex retailer, as part of a New Zealand entry of more than NZ$80 million that also took in two Auckland commercial properties; and THGRAU in Australia in 2025. Both were Rolex dealerships, and both were acquired with Rolex’s explicit blessing.

Michael Tay, Dr Henry Tay’s son, became sole Group Managing Director in April 2020, taking day-to-day management into the pandemic. The timing matters: he assumed full control at the bottom, ran the business through the extraordinary boom of FY2022 and FY2023, through the correction of FY2024 and FY2025, and into the record FY2026. That is a complete cycle under one leader, and the company came out of it with more cash, less debt, and a larger network than it entered with. His own description of how the business is built is the one worth remembering: “It’s like kueh lapis, where you bake layer by layer. After that, you will have multiple layers, and our business is just like that” [9].

What The Hour Glass Actually Does

For reporting purposes The Hour Glass has one business segment: the retail and distribution of watches, jewellery and other luxury products across Singapore, Malaysia, Thailand, Vietnam, Hong Kong, Japan, Australia and New Zealand. It sells brands including Rolex, Patek Philippe, Tudor, Cartier, Hublot and F.P. Journe. There are no factories and no own-brand product of consequence. The company buys watches at wholesale and sells them at retail, and the entire economics of the business sit in that spread, in the inventory it carries to earn it, and in the relationships that determine which watches it is allowed to sell at all.

Geographically the group reports two segments. Southeast Asia and Oceania produced S$1,165 million of FY2026 revenue, about 87 per cent of the total; North East Asia, principally Japan and Hong Kong, produced S$174 million, about 13 per cent. There is no Mainland China operation, which over the last two years has been a feature rather than a gap: Mainland China and Hong Kong were the two worst markets in the global Swiss watch trade, and The Hour Glass does not sell into either at scale.

One distinction matters for reading the numbers. THGRAU, the Australian Rolex business, is wholly owned and fully consolidated, so its revenue and costs flow straight into the group accounts. THG Prima Times, the 49 per cent Thai and Vietnamese associate, is not controlled, so accounting rules bring in only the group’s share of its profit, S$15.6 million in FY2026, not its revenue. A reader who misses that distinction will misread both the growth and the risk.

A Shrinking Industry, Concentrating Upward

The backdrop is a Swiss watch industry contracting in aggregate while the top of it holds up. Swiss watch exports fell to CHF26.0 billion in 2024, down 2.8 per cent in value and 9.4 per cent in volume, then to CHF25.6 billion in 2025, a second consecutive annual decline [2][3]. The pain has been concentrated in Greater China: after Mainland China exports collapsed 25.8 per cent in 2024, 2025 brought a further 12.1 per cent fall there and a 6.5 per cent decline in Hong Kong, while the United States held up to become the single largest destination at about 17 per cent of all Swiss watch exports [3]. Fewer watches, more expensive ones: mix is moving upward.

The secondary market tells the same story. The Bloomberg Subdial Watch Index, which tracks resale prices of the most heavily traded Rolex, Patek Philippe and Audemars Piguet models, fell about 6 per cent in 2024 to a three-year low, then recovered about 8 per cent in 2025 on stronger holiday demand [4][5]. For a retailer, the secondary market is a sentiment gauge and a margin signal: when resale prices rise, retail demand is firm and discounting is absent; when they fall, the grey market widens.

Singapore as a market remains healthy. The Singapore Tourism Board reported 16.9 million international visitor arrivals in 2025, up 2.3 per cent, and record tourism receipts of S$32.8 billion for the full year, [7]; shopping has historically accounted for roughly a third of those receipts, with watches a named category in the STB breakdown. Chinese visitors were the largest source market at 3.1 million arrivals. A Singapore-headquartered luxury watch retailer with no direct Mainland exposure, capturing Chinese demand as it travels rather than at home, is positioned more sensibly in 2026 than it might have looked five years ago.

Behind the tourism numbers is a structural driver: new wealth is concentrating in The Hour Glass’s home market. Single family offices receiving tax incentives from the Monetary Authority of Singapore rose from about 400 at the end of 2020 to roughly 1,400 by the end of 2023 and continued toward 2,000 through 2024, the principals drawn heavily from China, India and Indonesia [11]. Knight Frank’s 2026 Wealth Report projects the global ultra-high-net-worth population to grow about 27 per cent over the five years to 2031, with several of The Hour Glass’s markets among the fastest: Australia close to 60 per cent, Vietnam 59 per cent, and Indonesia, a key source of its Singapore clientele, around 82 per cent [12]. This is a slow tailwind rather than a quarterly catalyst, but it puts the group’s flagship boutiques in the path of the new wealth arriving on their doorstep.

The Moat: Relationships You Cannot Buy

The competitive advantage of The Hour Glass has four parts, and most of them cannot be bought at any price.

The first is the brand relationships themselves. The right to sell Rolex and Patek Philippe as an authorised dealer is not for sale on the open market. It is granted, slowly, to retailers the maisons trust, and withdrawn from those they do not. The Hour Glass has held its Rolex relationship for about seventy-five years, since the founder’s family firm was among the retailers Rolex appointed in 1950, and operates one of roughly eighty Patek Philippe mono-brand boutiques in the world. A competitor with unlimited capital cannot simply buy an equivalent position; it would have to be invited into it over many years, and the brands have every incentive to keep the invitations few.

The second is the family, and it is the part most easily underestimated from a spreadsheet. The Hour Glass’s relationships with Rolex and Patek Philippe were built by the Tay family across forty-six years, through downturns weathered without dumping inventory and through consistent representation of the brands at the highest level. When Rolex approved the Mansors acquisition in 2020 and the THGRAU acquisition in 2025, it was approving transactions by people it knew, not by an abstract listed entity. Any change of ownership would introduce a transition risk that the current structure avoids entirely. This is the one competitive advantage in the business that cannot be acquired, replicated, or read off a balance sheet.

The third is the balance sheet as a strategic instrument. Zero financial debt, S$157.5 million of cash and S$225 million of unencumbered property give the company the capacity to act when a motivated seller appears and competitors are retrenching. That property is not a recent manoeuvre: the group bought its first building in Australia around 1992 and assembled the S$225 million position over more than thirty years, to occupy rather than to trade. That is exactly what happened with THGRAU: The Hour Glass built balance-sheet strength through the boom while others over-extended, then deployed it when Kennedy decided to exit.

The fourth part is the one most easily missed, because it produces little revenue and almost no headline: The Hour Glass is the regional curator of the ultra-premium independent watchmakers. Alongside Rolex and Patek Philippe, the group carries names such as F.P. Journe, Akrivia, Urwerk and MB&F, brands that Cortina and the mainstream Southeast Asian retailers do not stock. Its credentials here run deep: the group once owned the watchmakers Gerald Genta and Daniel Roth outright, buying them in the 1990s and selling both to Bulgari in 2000 [15]. It has also been one of MB&F’s original retail partners since the brand’s early days, stayed with it through the lean years, and now co-operates the world’s first MB&F Lab in Singapore, the kind of flagship partnership a new entrant cannot buy [16]. These watches are not allocated on a waiting list and are not arbitraged on the grey market; they are placed with collectors who have demonstrated taste and a relationship with the retailer, which means they carry the highest margins in the business with no brand quota and no competing regional retailer. The group’s ambition to be “the watch world’s leading cultural retail enterprise” is built on this layer, through collector events and the free IAMWATCH public lectures that cultivate a younger, more educated audience long before its members have the budget to buy. That audience is the client pipeline for the next five to ten years, and spending today to build it is the kind of long-horizon thinking that compounds a business over decades. With the group reporting a single segment, this layer cannot be sized from the disclosures; it is unpriced optionality and a competitive position no regional rival holds, not a number anyone can yet put in a model.

Where the moat is weaker is worth stating plainly. The brand relationships that cannot be bought also cannot be owned: they are licences, not property, and the maisons hold the right to change the terms. The family that built the trust is also the single point of failure if succession is mishandled. And the balance sheet that funds acquisitions earns a low operating return while it waits. The closest listed comparison, Cortina Holdings (SGX:C41), runs a similar model at a materially lower margin, roughly 6.6 per cent net against The Hour Glass’s roughly 12 per cent on recurring earnings [10]. The premium The Hour Glass earns is real, but it has to keep being earned through brand concentration and mix.

A sharper version of the same question comes from Hong Kong. Emperor Watch & Jewellery (HKEX:0887), a listed Greater China retailer that carries the same top brands, Rolex and Patek Philippe included, trades far more cheaply than The Hour Glass on every headline measure, and it is not a failing business: its revenue and profit both grew in the year to December 2025 [13]. The reasons it trades where it does are precisely the things The Hour Glass is not. Its recent profit growth is led by gold jewellery rather than watches, which makes it a less pure read on the watch franchise. It is concentrated in Hong Kong, Macau and Mainland China, the part of the market most exposed to the structural questions over Chinese luxury demand, where The Hour Glass spreads across eight markets and has just added Australia. And it is a tightly controlled family company that retains most of its earnings rather than returning them, with a 60 per cent controlling stake and related-party dealings, the kind of structure the market has long discounted. The Hour Glass is family-controlled too, but it has not issued a share in thirty-eight years and cancels the stock it buys back. The cheaper peer is real, and an investor who wants Greater China watch exposure at a low multiple can find it there. What they cannot find there is the combination of brand concentration, better geographies and capital discipline that the rest of this article describes.

The Scoreboard: Seven Years of Rising Book Value

The seven-year record holds the whole story in one table: a doubling of revenue through a boom, a real correction in the middle, and a return to record earnings, with book value per share rising in every single year regardless of what the profit line did.

The arc reads in four parts. FY2022 and FY2023 were the boom: revenue jumped above the billion-dollar mark, gross margin peaked at 33.6 per cent, and headline profit reached S$174 million as the pandemic-era frenzy for waitlisted steel sports models ran at full force. FY2024 and FY2025 were the correction: the secondary market normalised, sentiment softened, a New Zealand deferred-tax charge bit, and headline profit fell 22 per cent from the FY2023 peak to S$136 million. FY2026 was the re-acceleration: revenue rose 15 per cent to a record S$1,338 million and headline profit reached a record S$179.5 million, helped by the consolidation of THGRAU.

The single number that survives all four phases is book value per share. It rose from S$0.86 to S$1.67 across the seven years, an increase of 94 per cent, compounding at roughly 11.7 per cent a year, and it rose in the correction years as well as the boom years. A retailer that keeps growing its net asset value per share through a 22 per cent earnings drawdown is retaining and reinvesting capital faster than the cycle can erode it. That is the financial signature of the business.

One caution on the headline profit belongs here. The FY2026 figure of S$179.5 million includes a S$20.3 million non-cash gain from revaluing the investment-property portfolio upward, which under Singapore accounting standards runs through the income statement. Strip it out and recurring profit is nearer S$162 million. The reported 9.4 times earnings is therefore closer to 10.5 times on recurring earnings, which matters for how cheap the stock really is.

Capital Allocation: Paid Every Year, Never Diluted

It is tempting to look at the 2.3 per cent yield and dismiss The Hour Glass as nothing special for income. That misreads it. The dividend is the residual left after the company funds inventory, boutiques, property, buybacks and the occasional acquisition, and the residual has a remarkable record: paid every single year, without exception, through the global financial crisis, the FY2016 to FY2018 luxury downturn [17], and the COVID closures of FY2020. In the boom years it has gone further, paying special dividends on top of the ordinary one, including a one-time special in the FY2008 boom that was four times the size of that year’s final dividend.

The global financial crisis shows the model under stress. FY2009 headline profit fell 57 per cent, but S$14.1 million of that was a one-off impairment on a listed investment unrelated to watch retail; the core business fell only about 13 per cent and recovered above its pre-crisis peak the very next year, with the dividend maintained throughout. Across fifteen years, book value per share has compounded at roughly 11 per cent a year on a split-adjusted basis, rising through every downturn. A shareholder who bought during the FY2016 luxury downturn, when the stock traded around or below S$0.60 split-adjusted, would have more than quadrupled their capital by today’s S$2.63, before a single dividend.

None of that came from yield. It came from a business that reinvests retained earnings at a mid-teens return on equity, has not issued a new share to raise capital in over three decades, and has been shrinking its share count rather than growing it, from about 705 million shares after the 2014 subdivision to roughly 646 million today, including S$112.3 million of treasury shares cancelled outright in FY2026. The 2.3 per cent yield is the by-product of that machine, not the reason to own it.

The Two Things the Market Has Not Yet Tested

Two specific developments sit behind the FY2026 numbers, and neither has been seen across a full clean year yet.

The first is THGRAU. The Australian Rolex business consolidated from 30 April 2025, so FY2026 captured only eleven months of it, and the purchase-price allocation was still provisional at the half-year. FY2027 will be the first clean twelve-month contribution, and the first year in which the audited standalone economics of the four boutiques are visible. The Southeast Asia and Oceania segment grew by S$167 million in FY2026, and THGRAU is the dominant contributor, although organic growth, currency and other movements are folded into the same segment line, so a clean THGRAU-only figure is not available until the FY2026 annual report is filed, expected in July 2026.

The second is the conversion of multi-brand stores into single-brand boutiques. The clearest delivery so far is the Patek Philippe Boutique Tokyo Ginza, which opened on 29 January 2025, one of roughly eighty Patek mono-brand boutiques worldwide and the second in Japan, built at around 200 square metres from the shell of the former multi-brand store [8]. A mono-brand conversion deepens the relationship with the maison, removes cannibalisation between brands on the same floor, and signals a franchise credential a new entrant cannot match. The capital cost is limited to fit-out, and the benefit shows up as mix rather than as a new revenue line, which is part of why it is easy to miss.

We have built the segment-level arithmetic on what a full year of THGRAU plus the conversion programme does to forward earnings, and it produces a figure that sits meaningfully above what the trailing numbers imply. The detailed forward build, and what it does to the valuation, is held back from this article. What can be said here is that the gap between the trailing multiple and the forward economics is the heart of the case, and it is the part the market has the least basis to have priced, because the audited numbers do not yet exist.

The One Risk That Matters Most

If the bull points are real, so is the central risk, and it is the same transaction that drives the upside. The Hour Glass paid AUD90 million for THGRAU and put S$66.5 million of it on the balance sheet as “distribution rights” with an indefinite useful life, an accounting treatment that says the asset does not wear out. The man who sold it said he sold precisely because that future looked uncertain, that Rolex “may sell directly to shoppers in the future” [1]. The buyer booked permanence; the seller cited impermanence as his reason for leaving.

The uncomfortable part is the contract. The actual agreement between Rolex and the THGRAU boutiques is not public, but comparable Rolex authorised-dealer agreements that have surfaced elsewhere typically allow either party to terminate without cause on short notice. An asset carried as indefinite-life on the balance sheet may, in contractual reality, sit on a notice period measured in weeks. Set against that is the pattern of behaviour: Rolex has not, in any documented case, internalised a major mono-brand flagship dealer of the kind The Hour Glass now runs, its chief executive said publicly in November 2025 that it intends to keep authorised dealers as its primary channel [6], and it approved not one but two acquisitions by The Hour Glass in five years. The same variable, Rolex’s assessment of The Hour Glass as a partner, drives both the downside and the upside. The realistic risk is not dramatic termination but slow erosion, through allocation and capex pressure and the ordinary margin cycle of luxury retail. The full risk register, and the specific signals that would break the thesis, are deliberately held back from this shorter analysis; this is the one risk every holder should understand.

Valuation: Why the Headline Multiple Is Not the Whole Story

At the 3 June 2026 close of S$2.63, The Hour Glass trades at 9.4 times reported earnings, or about 10.5 times once the property revaluation is stripped out, at 1.58 times book value, and on a total shareholder yield of about 3.1 per cent including buybacks. None of that is a deep-value signal. Ten-and-a-half times recurring earnings for a debt-free, high-quality luxury watch retailer is a fair-to-modest price, not an obvious bargain, and the honest version of the case does not pretend otherwise.

The reason the stock is interesting anyway is what sits behind the earnings. A buyer at S$2.63 is acquiring a business with zero financial debt, S$157.5 million of cash, S$225 million of investment property carried at fair value, and a S$107.1 million stake in the Thai associate, none of which earns an operating return in the recurring profit line but all of which is real asset backing. The working capital is disciplined too, which matters for a watch retailer where cash can get trapped in slow-moving stock: The Hour Glass turns its inventory about 2.4 times a year against roughly 1.8 times at its listed peer Cortina, both on their latest FY2025 accounts, tying up materially less cash per dollar of sales. A sum-of-parts that values the operating business on earnings and adds the cash, property and associate at sensible haircuts produces a range of implied values that brackets the current price, with the downside protected by the assets rather than by the multiple. Those assets are not dollar-for-dollar, to be clear: the property is illiquid and tax-affected, the 49 per cent stake in the Thai associate cannot be monetised without selling it, and the thin family float means minorities depend on the family’s capital-allocation choices rather than on any forced distribution. They cushion the downside; they do not set a hard floor. The full sum-of-parts build, the bear-base-bull range, and the resulting implied value are deliberately held back from this article. The conclusion that can be shared is the shape of it: a modest, asset-protected downside against a wider upside that depends on the THGRAU full year and the acquisition optionality delivering.

The Bottom Line

The Hour Glass is a high-quality, balance-sheet-protected luxury watch retailer at a fair price. It is debt-free, it has compounded book value per share at roughly 11 per cent a year for fifteen years, it has paid a dividend every single year through three downturns without once raising equity, and it holds Rolex and Patek Philippe relationships that no amount of capital can simply buy. It is not an obvious bargain at roughly 10.5 times recurring earnings, and the protection on the downside comes from the cash and property rather than from the multiple. The near-term upside comes from the first full year of THGRAU, the mono-brand conversion programme, and the optionality of a third Rolex acquisition the balance sheet can already fund. The longer-term upside comes from two things the earnings screen cannot see: a curated-independent position no regional competitor occupies, and a structural wave of new Asian wealth concentrating in the group’s home market.

The central tension is the one the seller handed us. The buyer booked the Rolex distribution rights as permanent; the seller left because he thought they were not. The reconciliation is the family: the relationship that earned two acquisition approvals in five years is the same relationship that makes outright expropriation unlikely, and it is the one asset in this business that cannot be valued from a balance sheet. Whether that is enough, at this price, to make the stock more than a fair-value holding depends on the forward earnings build and the valuation range that this article has deliberately stopped short of. The franchise is real. What it is worth, to the dollar, is the question the full analysis answers.

The forward earnings build, the complete sum-of-parts and implied value, the full risk register and the specific signals to monitor are available in the institutional-length version of this analysis. Link below.

Notes on Data Integrity

1. Source of FY2026 figures. Drawn from The Hour Glass’s unaudited condensed full-year results filed with SGX in May 2026 and the H1 FY2026 half-year results. The full FY2026 Annual Report, with complete notes, is expected around July 2026, so the THGRAU purchase-price allocation and standalone economics, the THG Prima Times FY2026 financials, and the detailed investment-property composition remain provisional.

2. Recurring earnings are author-derived. Recurring profit strips the S$20.3 million property fair-value gain and its deferred tax, and is an approximation.

3. THGRAU contribution. The S$167 million segment increase is the total segment movement, not a verified THGRAU-only figure.

4. Rolex agreement terms. The reference to short-notice termination is drawn from comparable public Rolex dealer agreements in other jurisdictions, not from the THGRAU contract, which is not public.

5. Market data. Retrieved on 3 June 2026 via yfinance (AGS.SI). The peer comparison with Emperor Watch & Jewellery uses operating figures from Emperor’s FY2025 annual report (year ended 31 December 2025) [13], not a data vendor.

6. Macro context. Singapore family-office figures are from the Monetary Authority of Singapore and the wealth-growth projections from Knight Frank’s 2026 Wealth Report, used as context rather than valuation inputs.

7. Analytical independence. No third-party analyst research, rating or price target was used as an input; the conclusions derive from primary filings and market data.

References

[1] Primrose Riordan, "Kennedy family sells off Rolex dealership to Singapore," The Australian Financial Review, 27 June 2025. https://www.afr.com/companies/retail/kennedy-family-sells-off-rolex-dealership-to-singapore-20250625-p5ma97

[2] Federation of the Swiss Watch Industry, 2024 export statistics, 30 January 2025. https://www.fhs.swiss/eng/2025_01_30_00_statistics.html

[3] Federation of the Swiss Watch Industry, 2025 export statistics, 29 January 2026. https://www.fhs.swiss/eng/2026_01_29_statistics.html

[4] Bloomberg, "Rolex, Patek, Audemars Piguet Used-Watch Prices Hit Three-Year Low," 7 January 2025. https://www.bloomberg.com/news/articles/2025-01-07/rolex-patek-audemars-piguet-used-watch-prices-hit-three-year-low

[5] Bloomberg, "Luxury Watch Prices Hit a Two-Year High in the Secondary Market," 8 January 2026. https://www.bloomberg.com/news/articles/2026-01-08/luxury-watch-prices-hit-a-two-year-high-in-the-secondary-market

[6] Rolex CEO Jean-Frédéric Dufour at Dubai Watch Week, November 2025. https://news.centurionjewelry.com/articles/detail/rolex-ceo-says-brand-will-stick-with-authorized-dealers-limits-retail-expansion

[7] Singapore Tourism Board, 2025 full-year tourism performance (16.9 million visitor arrivals; record S$32.8 billion in tourism receipts), announced at the Tourism Industry Conference 2026 on 8 May 2026. https://stan.stb.gov.sg/content/stan/en/tourism-statistics.html

[8] The Hour Glass, "Patek Philippe Boutique Ginza Tokyo." https://www.thehourglass.com/story/patek-philippe-ginza-tokyo-boutique

[9] Samantha Chiew, "The Hour Glass sees lower demand amid market uncertainties; sticks to fundamentals," The Edge Singapore, 24 October 2024. https://www.theedgesingapore.com/news/luxury/hour-glass-sees-lower-demand-amid-market-uncertainties-sticks-fundamentals

[10] Cortina Holdings (SGX:C41) FY2026 results, SGX filings.

[11] Monetary Authority of Singapore, single family office incentive data and the speech "Building a Stronger Tomorrow: Family Offices in our Flourishing Wealth Management Landscape," 16 September 2024. https://www.mas.gov.sg/news/speeches/2024/building-a-stronger-tomorrow---family-offices-in-our-flourishing-wealth-management-landscape

[12] Knight Frank, The Wealth Report 2026 (20th edition, April 2026; global and country ultra-high-net-worth growth projections to 2031). https://www.knightfrank.com/research/reports/wealthreport

[13] Emperor Watch & Jewellery Limited (HKEX:0887), Annual Report for the year ended 31 December 2025 (results announced 25 March 2026).

[14] The Hour Glass, "Our Rolex History" (Lee Chay & Co, North Bridge Road, from 1946; Rolex appointment 1950). https://www.thehourglass.com/rolex/our-rolex-history

[15] Federation of the Swiss Watch Industry, "Bulgari to acquire Gerald Genta and Daniel Roth," 5 July 2000 (acquired from The Hour Glass). https://www.fhs.swiss/eng/2000-07-05_44.html

[16] "Maximilian Büsser on the MB&F Lab and venturing beyond watchmaking," Tatler Asia, 2022 (MB&F Lab founded and operated in partnership with The Hour Glass; Singapore the largest MB&F collector community). https://www.tatlerasia.com/style/watches/mbf-lab-maximilian-busser-creative-process-venturing-beyond-watchmaking-interview

[17] The Hour Glass, FY2019 Annual Report, five-year financial highlights (FY2015–FY2019), showing the revenue and profit decline into the FY2017–FY2018 trough and the FY2019 recovery.

All The Hour Glass financial figures are sourced from SGX filings and the company’s investor relations site.

IMPORTANT DISCLAIMERS

This article is published for informational and educational purposes only. It does not constitute financial or investment advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The author is not a licensed financial adviser under the Financial Advisers Act 2001 of Singapore. This content is exempt from the requirements of the Singapore Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication. This publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, readers should consult a licensed financial or investment adviser in their relevant jurisdiction. Past performance is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author holds no position in The Hour Glass (SGX: AGS) as of the date of publication. This does not constitute a recommendation. This publication has received no compensation from The Hour Glass or any related party.

Walk into the Rolex boutique on the casino floor at Crown in Perth, or into Tong Building at the top of Orchard Road in Singapore, and the experience is engineered to feel timeless. A salesperson who knows your collection. A display of steel sports models you cannot simply buy off the shelf. A waiting list that is itself a status object. None of it looks like a listed company, and that is the point. The business behind that boutique floor is one of the oldest continuously operating luxury watch retailers in Asia, and it has been run by the same family for forty-six years.

The Hour Glass Limited (SGX:AGS) was founded in 1979 by Dr Henry Tay and Dato’ Dr Jannie Tay. It listed on the Singapore Exchange in 1988 and has not raised a dollar of equity from public markets in more than three decades. For the financial year ended 31 March 2026 it earned a headline net profit of S$179.5 million on revenue of S$1,338 million, both records, and it closed the year with no bank debt or bonds for the first time in at least a decade. Its book value per share has risen every single year for seven consecutive years, from S$0.86 to S$1.67. At the 3 June 2026 close of S$2.63, the market values the whole company at roughly S$1,685 million.

The most interesting fact about The Hour Glass right now is the acquisition it completed in 2025, and the reason the seller gave for selling. In a deal worth AUD90 million, The Hour Glass bought THGRAU, the Australian Rolex authorised-dealer business previously owned by Kennedy Watches & Jewellery: four Rolex flagship boutiques in Melbourne, Sydney and Perth. The seller, James Kennedy, told the Australian Financial Review that the timing was right to sell the licence because Rolex “may sell directly to shoppers in the future” [1]. An informed seller cashed out of the exact relationship The Hour Glass paid AUD90 million to acquire, and told the press why. That is the central tension of this company, and most of this article is an attempt to work out what it is worth.

The headline valuation looks cheap. Nine-point-four times earnings for a debt-free, record-earning, family-run franchise sounds like a bargain. It is not quite that. Backing out a S$20.3 million non-cash property revaluation that runs through the income statement, recurring earnings are nearer S$162 million, which puts the recurring multiple closer to 10.5 times. That is a fair price, not an obvious bargain. The case for the stock does not rest on the multiple being wrong. It rests on three things the multiple does not capture: a balance sheet with zero financial debt and S$225 million of real estate sitting behind the earnings; the first full year of the THGRAU acquisition, which has not yet been tested across twelve months; and a quiet programme of converting multi-brand stores into single-brand boutiques that improves the mix without showing up as a separate line.

Behind those near-term features sits a slower story the earnings screen cannot see at all. The brief that underwrites this stock is fundamentally defensive: the balance sheet protects the downside, and THGRAU drives the near-term upside. The offensive case is structural and longer-dated. The Hour Glass is not only a Rolex and Patek Philippe distribution machine. It is the Southeast Asian curator of the ultra-premium independent watchmakers that serious collectors graduate into, and it sits in the path of the fastest-growing pool of new wealth in the world. Whether those features are worth paying up for, and how durable the Rolex relationship at the centre of the near-term case really is, is the question the rest of this piece works through.

Read more

Sunright’s own share price, meanwhile, has pulled back 15.6% from our 7 May 2026 publication close of S$0.895 to S$0.755 as of 30 May 2026. The operating asset improved. The price fell. The entry is better.

This note runs the data, checks the thesis breakers, refreshes the look-through valuation, and identifies what to watch next.

The numbers

The 9M PBT swing, from a RM8.4 million loss to a RM9.1 million profit, is not a marginal result. It is a full-cycle reversal on three quarters of data, covering the most operationally intensive months of the fiscal year. Revenue growth of 3% to RM161.3 million is incremental rather than transformative, but the cost-structure improvement did the heavier lifting: other expenses declined 15% (RM8.9 million lower year-on-year) from cost reductions in utilities, repairs and maintenance, and lower fair-value losses on investment securities. Employee expense fell 3% or RM1.8 million. Depreciation rose 8% as newly commissioned machinery and test equipment entered service.

The sequential read is softer: Q3 profit before tax of RM2.4 million was below Q2’s RM4.1 million. Management attribute this to a RM2.3 million net fair-value loss on investment securities (the equity portfolio KESM holds on its balance sheet) and the absence of a RM0.8 million impairment reversal that boosted Q2. Revenue was flat quarter-on-quarter (RM53.3 million versus RM54.9 million). The operating business has not deteriorated; the sequential dip is non-operating noise from the investment portfolio and one-time items.

Thesis breaker check

Five watchlist triggers were established at the time of the initiation.

Two consecutive flat or negative-growth revenue quarters. Q3 revenue grew 1% year-on-year (RM53.3 million versus RM52.8 million). Q2 grew 7% year-on-year. Neither quarter is flat or negative. ✓

Full-year FY2026 KESM revenue below RM215 million. Nine months produced RM161.3 million. Q4 requires RM53.7 million to clear the threshold, in line with Q3’s RM53.3 million and requiring no acceleration. ✓ On track.

FY2026 attributable net profit below RM4 million. Nine months produced RM6.6 million attributable. This threshold is cleared for the full year absent a material Q4 impairment. ✓

Employee/revenue ratio above 44%. Nine-month employee expense of RM61.9 million against RM161.3 million revenue gives 38.4%. This is well below the 44% structural-labour trigger. Operating leverage is running in the right direction. ✓

Total FY2026 dividend substantially above 6 sen. The interim dividend of 6.0 sen per share was paid on 28 October 2025. No additional dividend was declared in Q3. ✓ Consistent with reinvestment thesis.

None of the five triggers fired. All are tracking in the expected direction.

What management said for the first time

In prior quarterly announcements, KESM management described demand improvements in general terms: volume growth, customer mix, utilisation trends. In Q3 FY2026, the filing uses specific language in both the individual quarter and year-to-date discussions: “primarily driven by higher demand for the Group’s services in artificial intelligence (AI) related chips.” This is the first explicit AI attribution in a primary Bursa filing.

For the look-through thesis on Sunright, this matters. The initiation framed KESM’s AI exposure as probabilistic: a plausible demand driver validated externally by Aehr Test Systems’ USD 41 million hyperscale win, but not yet confirmed by the operating entity’s own language. That confirmation has now arrived. The RM28.4 million of outstanding capex commitments, layered on top of the RM39.5 million already deployed in 9M, reflect management’s confidence that the demand is durable enough to justify a capacity build-out ahead of the revenue.

The prospects section of the filing adds context: worldwide semiconductor revenue is expected to exceed USD 1.3 trillion in 2026, up 64% from 2025, driven by AI processing, data centre networking and power, and memory price inflation. AI semiconductors are projected to account for nearly 30% of total semiconductor revenue. KESM’s customer introductions are described as “closely aligned” with this cycle.

Look-through and valuation refresh

The headline compression since publication: S71 is down 15.6% while the operating entity improved. At publication, the core valuation tension was a 1.52x P/Attributable NAV on the SGX versus 0.58x P/Book on Bursa. That gap has narrowed modestly from the S71 side: the SGX multiple compressed to 1.28x as the price pulled back from near the 52-week high. The Bursa discount edged up marginally to 0.60x on slightly higher book value. The structure of the trade is unchanged: the KESM discount and the net cash floor are the same; the premium you pay for that optionality is lower.

The look-through decomposition at current prices: Sunright’s 48.41% KESM stake is worth S$31.9 million at Bursa market (versus S$30.7 million at publication). Subtract that from the S$92.7 million market cap and the implied value of Sunright’s Singapore parent entity (equipment manufacturing, management fees, and S$0.55/share in net cash) is S$60.8 million. The attributable book attributable to the non-KESM parent is roughly S$22 million. Implied ex-KESM P/Book: 2.74x, compressed from 3.6x at publication. The anomaly is smaller than it was; it persists.

The convergence-trade math: if KESM rerated to 1.0x book (MYR 7.97, +68% from MYR 4.74), Sunright’s KESM stake rises to S$53.6 million, a S$21.7 million uplift, or S$0.177 per Sunright share. At S$0.755, that delivers S$0.932, within range of the 52-week high. That scenario has not changed since the initiation; the book value it targets has grown, and the starting price is lower.

What to watch next

KESM Q4 FY2026 (estimated filing September 2026) is the confirmation quarter. If Q4 revenue holds at RM53 million or above, full-year FY2026 KESM revenue clears the RM215 million threshold. If PATMI holds near Q3’s quarterly rate, full-year attributable net profit will land around RM8 million, double the RM4 million minimum. The Q4 filing will also resolve whether a final dividend is declared for FY2026: any step-up above the 6 sen interim total would be the first dividend increase since FY2024.

Sunright FY2026 full-year results (estimated September–October 2026) will provide the consolidated picture: Sunright Singapore equipment revenue, intercompany management fees, and the attributable share of KESM’s full-year performance on one statement. That is the filing where the bull case (group revenue above S$90 million, attributable net profit above S$5 million) either clears or doesn’t.

Bottom line

KESM Q3 FY2026 is an operationally clean result: profitable through nine months, AI demand explicitly confirmed in primary filing language, capex tripled with capacity commitments signalling confidence in forward volume, and all five thesis breakers untriggered. S71 at S$0.755 offers the same structural optionality as the initiation, with the SGX/Bursa multiple gap intact and the net cash floor at S$0.55/share, at a meaningfully lower premium. The sequential Q3 dip was non-operating; the operating business is holding. The Q4 KESM result in September is the next binary.

Data integrity notes

Sunright’s latest published filing is the 1HFY2026 Condensed Interim Financial Statements (31 January 2026). The attributable NAV/share of S$0.588 used in the valuation table reflects that filing. KESM book value is updated to the Q3 FY2026 figure (30 April 2026). There is a one-quarter timing mismatch between the two book values; it is immaterial to the analysis.

FY2025 full-year KESM capex (RM16.0 million) is sourced from the KESM FY2025 Annual Report cash flow statement.

MYR/SGD conversion at 0.323 throughout, consistent with the published initiation. Exchange rate fluctuations affect the look-through valuation arithmetic; this rate has been stable in the RM3.09–3.10/S$1 range in the period since publication.

References

[1] KESM Industries Berhad, “Unaudited Third Quarterly Report on Consolidated Results for the Financial Quarter Ended 30 April 2026”, Bursa Malaysia filing, 28 May 2026.

[2] KESM Industries Berhad, “Unaudited Second Quarterly Report on Consolidated Results for the Financial Quarter Ended 31 January 2026”, Bursa Malaysia filing, 10 March 2026.

[3] Sunright Limited, “Condensed Interim Financial Statements and Dividend Announcement for the Half-Year Ended 31 January 2026”, SGX filing, 13 March 2026.

[4] Sunright (S71.SI) and KESM Industries Berhad (9334.KL), share price and market data via Yahoo Finance, retrieved 30 May 2026. https://finance.yahoo.com/quote/S71.SI / https://finance.yahoo.com/quote/9334.KL

IMPORTANT DISCLAIMERS

This article is published for informational and educational purposes only. It does not constitute financial or investment advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The author is not a licensed financial adviser under the Financial Advisers Act 2001 of Singapore, nor a licensed adviser under the Capital Markets and Services Act 2007 of Malaysia. This content is exempt from the requirements of the Singapore Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication. This publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, readers should consult a licensed financial or investment adviser in their relevant jurisdiction. Past performance is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author holds no position in the securities discussed and has not traded in them in the 30 days prior to publication, unless otherwise stated. This publication has received no compensation from any company discussed, or any related party.

On 25 September 2025, a small Singapore-listed dormitory operator did something unusual. It took fourteen of its best-stabilised assets, dropped them into a newly constituted real estate investment trust, and listed that trust on the same exchange where the parent had been trading for two decades. Centurion Accommodation REIT (SGX:8C8U) began trading at S$0.88 a unit. Centurion Corporation Limited (SGX:OU8), the sponsor, retained 42.9% of the new trust, kept full ownership of the trust's manager, and pocketed approximately S$520 million in cash for the assets it had handed over.

Eight months later, the trust is up. The sponsor’s share price is up. Both are up less than they should be if the market understood what just happened.

The easy version of this story is that Centurion’s share price has rallied from S$0.96 at the start of 2025 to S$1.46 at the 16 May 2026 close, a 52% move, and that the rally exhausted the mispricing. We disagree. The rally was the market crediting Centurion for executing the listing. It was not the market repricing what the listing structurally created: a Singapore-listed dormitory operator that now earns three streams of recurring income from one corporate vehicle, owns a directly-held bed count larger than the trust it sponsors, and still trades at 1.0x book and 11x trailing earnings, as if none of that had happened.

The rally was also not a smooth march upward. The market’s initial reading of the CAREIT IPO was bearish for the sponsor: OU8 drifted from S$1.50 in late September 2025 to roughly S$1.34 by late October 2025, even as CAREIT itself rose 16% from its S$0.88 issue price to S$1.02 in its first week of trading. The bear interpretation was straightforward — the best-occupancy assets had been carved out into CAREIT (the Initial Portfolio’s Singapore PBWA assets ran at 99.2% occupancy in FY2024 versus 94.0% for the broader sponsor group), leaving Centurion holding the residual lower-occupancy and ramping properties. Two things contradicted that read. Joint Chairman Han Seng Juan personally bought 300,000 OU8 shares at an average S$1.46 across 29 and 30 September 2025 — the family was buying, in size, into the drawdown. And the operating results since have vindicated the buyers: CAREIT beat its IPO forecast on every metric in its first reporting period, and Centurion’s own 1Q 2026 revenue rose 30% year on year. The asset-quality-dilution fear did not show up in the numbers. The recovery to S$1.46 since is partial credit for what the listing structurally created — but only partial.

We ran the look-through arithmetic on Centurion at the 16 May 2026 closing price of S$1.46. The sum of its three pillars, the directly-held portfolio of c.53,000 beds, the asset-management business running CAREIT, and the 42.9% unitholding in CAREIT itself, produces a fair value materially above the market price. The full numerical verdict, the segment-by-segment fair-value build, the forward earnings model, and the probability-weighted implied value are the subject of a companion institutional-length analysis published separately. Link below.

From one dormitory to three continents

Centurion as we know it today began in 2011, when a small Singapore-listed media-and-optical-storage company called SM Summit Holdings was reverse-acquired by Centurion Properties, a private vehicle controlled by two maternal cousins, Loh Kim Kang David and Han Seng Juan. Loh and Han had built their wealth in Singapore stockbroking, both spending years at UOB Kay Hian, both with stints at Hong Kong subsidiaries. The reverse takeover gave them a listed shell. What they put into it was a single purpose-built worker dormitory in Toh Guan, Singapore, with 5,300 beds.

Fifteen years later, the portfolio is materially larger. As at 30 June 2025, before the CAREIT spin-off, the Centurion sponsor group held 70,291 beds across 37 operating purpose-built accommodation assets, comprising 65,390 beds of purpose-built worker accommodation, 4,501 beds of purpose-built student accommodation, and 400 build-to-rent apartments. By 31 March 2026, after the CAREIT spin-off and a subsequent quarter of portfolio activity, Centurion’s directly-owned operating portfolio stood at 24 assets with c.52,993 beds per the 1Q 2026 Business Update (5 Singapore PBWA, 13 Malaysia PBWA, 1 Hong Kong PBWA, 2 Hong Kong PBSA, 1 Australia PBSA, 1 UK PBSA, and 1 Xiamen BTR), complemented by 16 managed assets with c.28,395 beds (CAREIT’s 15 plus Castle Gate Haus in the Centurion Student Accommodation Fund). The geographic spread went from Singapore-only to Singapore, Malaysia, Australia, the United Kingdom, Hong Kong SAR, and China.

A note on jargon before we continue. Centurion operates in two distinct accommodation segments and we will use the industry shorthand throughout: PBWA stands for purpose-built worker accommodation, the formal name for the licensed dormitories that house migrant construction, marine, and industrial workers (in Singapore, in Malaysia, and now in Western Australia for resource-sector workers). PBSA stands for purpose-built student accommodation, the formal name for the private-sector student housing typically located near universities (in Centurion's case, the United Kingdom, Australia, and Hong Kong). The third segment, build-to-rent (BTR) apartments, is a smaller category covering longer-stay rental housing for working professionals (Centurion's Xiamen property).

The inflection points were structural. In 2014, Centurion entered the United Kingdom PBSA market through the Dwell Student Living brand. In 2017, it added US student housing through a private fund structure. In 2020, the COVID-19 pandemic and the well-publicised migrant-worker dormitory outbreak forced a wholesale reset of Singapore's PBWA regulatory framework: the Foreign Employee Dormitories Act licensing regime, the Improved Dormitory Standards, and ultimately the New Dormitory Standards that will apply to all Singapore PBWAs by 2040. Centurion responded by buying or building NDS-compliant capacity early. Westlite Ubi became operational in December 2024 as the first fully NDS-compliant Centurion dormitory in Singapore. New blocks at Westlite Toh Guan (1,764 beds) and Westlite Mandai (3,696 beds) obtained their temporary occupation permits in October 2025 and January 2026 respectively.

Then in 2025, the largest single move. On 7 January 2025, the company announced it was exploring the establishment of a REIT. Listing application went in by July. Cornerstone book closed with sixteen institutional investors. The IPO was oversubscribed by 30 times on the public tranche and 16 times overall. CAREIT began trading on 25 September 2025 at S$0.88 a unit, with Centurion as sponsor and Centurion Asset Management Pte Ltd, a wholly-owned subsidiary, as manager. Fourteen assets were spun in: five Singapore PBWAs, eight United Kingdom PBSAs in the Dwell portfolio, and one Australian PBSA. The forward purchase of EPIISOD Macquarie Park in Sydney completed in January 2026 for A$345 million, taking CAREIT's portfolio to 15 assets and c.28,266 operational beds at 31 March 2026 per the 1Q 2026 Business Update (or c.30,246 including the 1,980-bed Mandai Expanded Capacity retained until 31 December 2030 pending FEDA license).

What remained at Centurion is the larger portfolio — 24 directly-held operating assets totalling 52,993 beds at 31 March 2026, spanning six markets:

• Singapore PBWA — 5 assets, 15,156 beds (ASPRI-Westlite Papan plus four Westlite Quick-Build Dormitories)

• Malaysia PBWA — 13 assets, 36,006 beds (eight long-standing Westlite properties plus five Harum Megah-rebranded assets acquired September 2025)

• Hong Kong — 3 assets, 653 beds (Westlite Sheung Shui PBWA; Dwell Prince Edward and Dwell Ho Man Tin PBSAs)

• Australia PBSA — 1 asset, 597 beds (Dwell Village Melbourne City)

• United Kingdom PBSA — 1 asset, 181 beds (Dwell Garth Heads, Newcastle)

• China BTR — 1 asset, 400 apartments (Centurion-Cityhome Gaolin, Xiamen)

Two Australian Key Worker Accommodation assets added in April 2026 (Karratha and South Hedland, 446 beds combined) take the post-1Q snapshot to c.26 assets and c.53,439 beds. The US PBSA assets were disposed in March 2026, completing Centurion’s exit from the United States. A c.7,000-bed PBWA development at Nusajaya, Iskandar, Johor is under exploration with NS Corp and is not yet operational. Westlite Toh Guan and Westlite Mandai sit inside CAREIT and are addressed under Pillar 3 below.

The shape of the business changed. Pre-September 2025, Centurion was an operator. Post-September 2025, Centurion is an operator, an asset manager, a property manager, and the largest unitholder in a separately-listed REIT. The strategy that took fifteen years to build did not change in 2025. What changed is the form in which it monetises.

What Centurion actually is now

The consolidated financial statements obscure the structure, and the structure is the point.

Centurion Corporation owns three things operationally. The first is the 24-asset directly-owned portfolio described above, totalling c.52,993 beds at 31 March 2026 (c.26 / c.53,439 including the April 2026 Australian additions), generating operating revenue from per-bed rentals. The second is the asset-management business, comprising Centurion Asset Management Pte Ltd (100% owned, manager of CAREIT) and the property management companies (100% owned, contracted property managers for CAREIT and increasingly for third-party owners). The third is a 42.9% unitholding in CAREIT itself, the SGX-listed REIT that Centurion sponsored.

The market’s mental model of Centurion is often that “CAREIT is the main business now; OU8 is the leftover holding company.” The bed-count picture is precisely the opposite. Of the c.81,388 operational beds in Centurion’s universe at 31 March 2026, 52,993 (65%) are directly owned and operated by Centurion, 28,266 (35%) are held in CAREIT (and Centurion owns 42.9% of those, equivalent to c.12,124 beds on a look-through basis), and 129 (<1%) sit in CSAF (Castle Gate Haus, Newcastle). A further c.3,548 beds across Singapore are under third-party property management agreements. CAREIT is the high-quality, stabilised, externally-financed slice. Centurion is the larger, broader, more diversified, and faster-growing whole.

These three pieces generate three flavours of income. The directly-owned portfolio produces operating profit. The asset-management business produces recurring fee income (base manager fee, performance fee, acquisition and divestment fees, property manager fees). The CAREIT unitholding produces investment income (Centurion’s 42.9% pro-rata share of CAREIT’s distributions). All three flow through Centurion’s consolidated income statement. But here is where it gets technical: CAREIT itself is consolidated into Centurion’s accounts, not just equity-accounted, because Centurion controls CAREIT through its 100% ownership of the manager. So 100% of CAREIT’s revenue appears on Centurion’s revenue line, 57.1% of CAREIT’s profit gets stripped out at the non-controlling interest line, and what remains at the bottom is Centurion’s economic share.

The non-controlling interest line on Centurion's balance sheet tells the story. At end-FY2024, NCI was S$82.9 million. At end-FY2025, three months after the CAREIT listing, NCI was S$939.7 million. That is a more than tenfold jump in a single year, reflecting the 57.1% of CAREIT's net assets attributable to non-Centurion unitholders that now sits inside Centurion's consolidated balance sheet.

Centurion's reported FY2025 revenue rose 17% to S$295.9 million. FY2026 is set to land materially higher, driven by five incremental items: Westlite Mandai's transition from equity-accounted associate to fully consolidated via CAREIT (the largest single contributor); the new Mandai block running for a full year; EPIISOD Macquarie Park's master-lease income for a full year; the Harum Megah Malaysian portfolio's first full year; and the two Australian Key Worker Accommodation assets for a partial year — offset by the US PBSA disposal. Putting these together, FY2026 consolidated revenue should land between approximately S$355 million and S$390 million (+20% to +32% YoY). The 1Q 2026 print of S$89.4 million annualises to about S$358 million, the lower end of this range before EPIISOD and the April 2026 Australian additions ramp into the full-year run-rate. The market sees the +17% FY2025 print and reads it as the steady-state run-rate; the FY2026 print is set up to land considerably higher.

A casual reader of the FY2025 press release sees revenue +17%, net profit -63%, EPS -67%, and concludes Centurion is in trouble. The actual story is that the FY2024 IFRS net profit was inflated by a S$219 million fair value gain on the Singapore PBWA portfolio that did not recur, while core profit (excluding fair value movements and one-off transaction costs) grew 9% from S$99.3 million to S$108.6 million. But the reader has to know to look at core profit, not IFRS profit, and most readers don't.

Three markets, three cycles

Centurion operates in three distinct industries that share one structural feature: each is undersupplied in professionally managed, regulation-compliant accommodation for a specific resident profile that has limited substitutes.

Singapore PBWA hosts approximately 460,300 work permit holders in the Construction, Marine Shipyard and Process industries as at June 2025, all of whom require licensed dormitory accommodation under the Foreign Employee Dormitories Act (figure varies with the construction cycle) [9]. After the 2020 dormitory outbreak, the Ministry of Manpower introduced new standards: Improved Dormitory Standards (IDS) as an interim measure, and New Dormitory Standards (NDS) as the long-run requirement. The Dormitory Transition Scheme (DTS), articulated in MOM’s 17 January 2026 press release [1], requires approximately 900 existing migrant worker dormitories housing roughly 200,000 workers to transition to IDS by 2030, with NDS by 2040 for early adopters. Crucially, dormitories that convert from 16 residents per room to 12 reduce their licensed bed capacity by 25% for the same building, so industry-wide bed capacity contracts during the 2026–2030 transition. Operators who cannot or will not retrofit lose their licences.

Centurion's positioning here is its single strongest competitive feature. The largest NDS-compliant PBWA capacity in Singapore — Westlite Ubi, Westlite Toh Guan with its new block, Westlite Mandai with its Expanded Capacity, Westlite Woodlands and Westlite Juniper — sits inside CAREIT, with the four Westlite Quick-Build Dormitories adding directly-owned NDS-compliant capacity at Centurion. The moat is the recycling platform rather than the legal-entity location of any individual building: Centurion develops the NDS-compliant pipeline, drops the stabilised asset into CAREIT, retains the manager fee on it for the life of the REIT, and recycles the proceeds. While competitors are losing licensed capacity, the Centurion–CAREIT platform is adding compliant capacity at scale — the new Toh Guan block contributed c.1,764 beds in October 2025 and the new Mandai block c.3,696 beds in January 2026 at the CAREIT-owned properties. Approved retentions of legacy capacity at the same sites preserve operating revenue during the transition: 664 beds at Toh Guan until 31 December 2028, and 1,980 beds at Mandai until 31 December 2030. Demand is anchored by Singapore's construction cycle: the BCA forecasts total construction demand of S$47 billion to S$53 billion in 2026, declining slightly to S$39 billion to S$46 billion annually through 2027 to 2030 [2].

Malaysian PBWA is a different story. Malaysia hosts approximately 2.4 million documented foreign workers, and enforcement of Act 446 (the Employees’ Minimum Standards of Housing, Accommodations and Amenities Act 1990) has intensified through 2024, 2025 and into 2026, with a “comply-or-lose-licence” mandate for Centralised Labour Quarters now reportedly in effect particularly across Selangor and the Klang Valley [3]. The Multi-Tier Levy Mechanism was implemented 1 March 2026 [4]. The maximum accommodation rental cap was revised to RM150 per worker per month [5]. Centurion is the largest privately-owned PBWA operator in Malaysia by bed count, with capacity exceeding 20,000 beds. The September 2025 acquisition of Harum Megah added six operating dormitories in Johor, expanding Malaysian capacity by approximately 25% in a single transaction.

Global PBSA, primarily UK and Australia, is undersupplied at the structural level. Australia hosts approximately 1.6 million enrolled university students against a total PBSA bed count of only approximately 90,000 beds. The Student Accommodation Council estimates that 84,000 new PBSA beds are needed by 2026, but only 7,700 are in the pipeline [6]. CAREIT’s acquisition of EPIISOD Macquarie Park at A$345 million for 732 beds (A$471,000 per bed) reset Australian PBSA pricing expectations and drew Singaporean REIT and European pension capital into the segment [7]. Centurion’s directly-held Australian pipeline includes c.644-bed EPIISOD North Melbourne (1H 2027), c.472-bed Perth (4Q 2027), and c.675-bed Mackenzie Melbourne. The UK is the most cautious market: Unite Group, the UK’s dominant pure-play PBSA REIT, trades at approximately 51% discount to NTA per share and has guided 2026 EPS down 12.6% versus 2025 [8]. Centurion’s UK assets have so far outperformed (98% occupancy FY2025), but the CAREIT prospectus already factors in mid-single-digit UK revenue decline in FY2026.

What cannot be copied

Centurion’s competitive position rests on four sources of durable advantage.

First, regulatory positioning in Singapore. Singapore’s PBWA market is licensed under the Foreign Employee Dormitories Act. New PBWA capacity requires a licence granted on a per-site basis after compliance with the New Dormitory Standards. NDS compliance is expensive: higher floor area per resident, larger common facilities, more demanding fire safety and infection control infrastructure. New entrants face a structural cost disadvantage relative to operators who have already amortised the compliance cost across a portfolio. Centurion controls the largest NDS-compliant PBWA portfolio in Singapore as at 1Q 2026 — most of it inside CAREIT, where Centurion is the manager and the 42.9% unitholder, with the four Westlite Quick-Build Dormitories adding directly-owned NDS-compliant capacity at Centurion.

Second, sticky corporate customer relationships. The PBWA customer in Singapore is not the individual worker but the employer. Major construction companies, marine contractors, and shipbuilders contract with dormitory operators for multi-year leases covering thousands of workers. Switching costs are real: a contractor moving its workforce between dormitories incurs operational disruption, transport logistics changes, and contract renegotiation. Centurion’s customer base of more than two decades includes most of the major Singapore construction names. CAREIT CEO Tony Bin disclosed in November 2025 [14] that renewal rates run above 85% on the Singapore PBWA portfolio, with roughly 60% of residents staying for more than five years.

Third, brand verticalisation in PBSA. The new EPIISOD premium PBSA brand, launched July 2025, complements the existing mainstream Dwell Student Living brand. The first EPIISOD property, EPIISOD Macquarie Park in Sydney (732 beds), commenced operations in January 2026. Two brands at two price points captures the full spectrum of student demand, whereas a single-brand operator captures only one segment.

Fourth, the sponsor-REIT capital recycling mechanism. The CAREIT structure gives Centurion a permanent capital recycling mechanism that did not exist before September 2025. Centurion develops or acquires an asset on its own balance sheet, stabilises operating performance over one to three years, then offers the stabilised asset to CAREIT under the right-of-first-refusal agreement. CAREIT pays Centurion a market-clearing price, generating revaluation gain on the way out, and Centurion redeploys the proceeds into the next development. The arithmetic only works if CAREIT trades at or above 1.0x P/B (currently 1.25x), if CAREIT has capital access (clean balance sheet post-IPO), and if the asset stabilises within Centurion's tolerance. All three conditions are intact as at May 2026. The model is the moat because no other Singapore-listed PBWA operator has built one.

The financial scoreboard

The six-year picture for Centurion, drawn from the published 5-Year Summaries in the FY2023 and FY2025 Annual Reports.

Three patterns are worth surfacing.

Revenue compounded at 18.2% per annum from FY20 to FY25. Top-line growth is the cleanest signal in the scoreboard because it is unaffected by fair value movements, deferred tax, or any of the items that distort net profit. 1Q 2026 revenue was up 30% YoY at S$89.4 million, which annualises to a FY2026 run-rate of approximately S$370 million before any additional capacity adds. Full-year FY2026 reported revenue should print materially higher, driven by full-year CAREIT consolidation versus three-month FY2025 consolidation.

Core profit attributable to shareholders compounded at 21.4% per annum from FY20 to FY25. The core profit measure adjusts for fair value movements and one-off transactions including the S$12.5 million of CAREIT listing costs in FY2025. Even after stripping out the FY2024 fair value gain of S$219 million that inflated reported IFRS profit, core profit continues to compound. Core EPS grew 9% YoY in FY2025 despite the asset spin-off.

Attributable NAV per share has more than doubled in five years. From 72 cents at end-FY2020 to 146.6 cents at end-FY2025, Centurion’s per-share equity has roughly doubled, supported by retained earnings and the FY2024 revaluation uplift on the Singapore PBWA portfolio. At the 16 May 2026 share price of S$1.46, Centurion trades at 0.996x book, basically at NAV.

Three pillars, priced as one

Here is the central tension. The market is pricing Centurion at 1.0x book and 11x trailing earnings. Those are operator multiples. They make sense for a single-pillar dormitory operator.

But Centurion is no longer a single-pillar operator. It is three things at once.

Pillar one is the directly-held portfolio: 24 operating assets, c.52,993 beds across six markets at 31 March 2026, generating operating revenue from per-bed rentals. This is the legacy operator business, just with more geographic diversity and a younger asset profile after the FY2024–FY2025 capacity adds.

Pillar two is the asset-management business. Centurion Asset Management Pte Ltd, wholly-owned, earns fees from CAREIT under the Trust Deed. The fee economics are detailed in the CAREIT prospectus: a base manager fee, a performance fee tied to DPU growth versus prospectus-projected DPU, acquisition and divestment fees, and property manager fees on each asset. The property managers, also Centurion-owned, additionally earn 2% of gross revenue plus 5% of NPI on each PBWA asset, and 4% of gross revenue on each PBSA asset. The same management platform additionally manages two private funds and, more recently, third-party PBWA properties for which Centurion bears no balance sheet capital. We have run the FY2026 fee math against CAREIT’s projected distributable income and built an estimate of the business’s annual fee revenue and operating profit. We do not run those numbers in this article; the multiple applied to value it is treated in a separate write-up.

Pillar three is the unitholding. As at 31 December 2025, Centurion held approximately 42.9% of CAREIT’s 1.722 billion units, equivalent to 738.6 million units worth S$805 million at the 16 May 2026 closing CAREIT price of S$1.09. After the proposed Dividend in Specie of 84.1 million units to Centurion shareholders (1 CAREIT unit per 10 OU8 shares), Centurion will hold approximately 38% of CAREIT. The CAREIT distribution income flowing to Centurion at the 42.9% stake against FY2026 projected distributable income gives an annual income figure of approximately S$48.8 million; post-Dividend in Specie this drops to approximately S$43.2 million. We have built a forward earnings model for CAREIT’s contribution to Centurion’s consolidated economics; the precise figures are not detailed here. The early operating evidence is encouraging: CAREIT’s first standalone reporting period (25 September to 31 December 2025) beat the prospectus forecast on every metric — DPU 1.739 cents versus forecast 1.630 cents (+6.7%), PBWA occupancy 97.6% versus forecast 95.8%, PBSA occupancy 99.1% versus forecast 97.3%, and aggregate leverage and financing costs better than forecast.

Adding the three pillars at market-observable values and applying credible multiples produces a per-share fair value materially above the 16 May 2026 close of S$1.46. The exact figure, and the segment-by-segment build that produces it, is not run in this article. What we will say here is that across the central case, the conservative case, and the optimistic case, the implied valuation lands above the current market price by a margin large enough to be worth understanding.

Why the market hasn’t priced this yet

Three explanations, in descending order of analytical weight.

The first is technical. The consolidated financial statements obscure the structure. A casual reader of Centurion’s FY2025 press release sees revenue +17%, net profit -63%, EPS -67%, and concludes Centurion is in earnings decline. The actual story is the opposite (one-time fair value gain in FY2024 distorted the prior year; underlying core earnings grew 9%) but the reader does not pause to do the adjustment. The CAREIT consolidation amplifies this by introducing NCI swings that further confuse non-specialist readers. The accounting is correct under SFRS(I) 10; the analytical inference from the reported numbers, without adjustment, is misleading.

The second is structural. Singapore institutional capital is concentrated in REITs as such, not in REIT sponsors. CapitaLand Investment is the exception, with the scale, brand, and S$125 billion AUM to attract institutional flows in its own right. Mid-cap REIT sponsors below CapitaLand Investment do not have a clean comp set on SGX; investors who like sponsor economics tend to buy the underlying REITs. CAREIT itself trades at 1.25x P/B and roughly 6% yield, attracting yield-seeking capital. The same investors do not necessarily buy OU8 alongside.

The third is governance. The cousin-controlled Loh-Han structure is unusual on SGX. Family-controlled mid-caps often trade at small but persistent discounts to non-family-controlled comparables of similar quality. The discount reflects governance risk pricing, a structural factor rather than evidence of any specific incident. The single material governance risk we monitor is the structural exposure to related-party transactions between Centurion family vehicles and the listed entities, which is the central risk we hold visible to readers of this article. The additional flip triggers tied to CAREIT unit price, Singapore occupancy levels, lock-up expiry dynamics, and ROFR cliff thresholds are not enumerated here.

The gap will close progressively, not immediately. The catalysts are CAREIT establishing a DPU track record supporting the manager fee economics, Centurion's directly-held pipeline (Australian PBSA, Malaysian Iskandar 7,000-bed development) demonstrating execution, any future drop-down transactions confirming the recycling model, and the analyst community modelling Centurion as a sponsor rather than a pure operator. By end-FY2026, with one full year of CAREIT operating performance and the projected DPU run-rate demonstrated, the market should be in a position to model the look-through more confidently.

The bottom line

Centurion at the 16 May 2026 close of S$1.46 prices a single-pillar dormitory operator. The September 2025 CAREIT IPO turned it into a three-pillar platform. The dormitory operator alone, valued on operator multiples, is worth roughly where it trades. The same business, framed as the operator-plus-manager-plus-unitholder it actually now is, is worth materially more. The transition from one frame to the other is where the analytical crux lies.

The full quantitative verdict, the forward earnings model, the look-through sum-of-the-parts, the scenario-weighted implied value, and the complete flip-trigger register are published in our institutional-length analysis. Link below.

Notes on the data

Three items material to readers of this article.

1. The detailed valuation arithmetic is treated separately. This article makes the case for the business and the structural argument. The segment-by-segment forward earnings model, the look-through sum-of-the-parts valuation across bull-base-bear scenarios, the probability-weighted implied value, and the complete flip-trigger register are written up in a separate piece.

2. Direct operating portfolio fair value is triangulated, not disclosed. Centurion’s consolidated financial statements present investment properties at fair value in a single line item that combines Centurion-direct properties with CAREIT properties post-consolidation. The split is not separately disclosed; our valuation segment derives the breakdown by deduction from segment data and from CAREIT’s standalone disclosures.

3. DPS history for FY2020 to FY2022 is not aggregated in published 5-Year Summaries. Individual half-year and full-year dividend announcements exist on SGXNet for those years but were not aggregated for this article. Marked as “n/d” in the scoreboard.

4. Post-publication correction (2026-05-29/31) — Westlite Toh Guan and Westlite Mandai are CAREIT-owned; portfolio totals re-anchored to the 1Q 2026 Business Update; three further factual corrections (Centurion management feedback). Centurion management noted that Westlite Toh Guan and Westlite Mandai are owned by CAREIT, and that the new redevelopment blocks at each property sit within the respective assets and are therefore also CAREIT-owned. CAREIT’s IPO Initial Portfolio comprises five Singapore PBWAs — Westlite Toh Guan, Westlite Woodlands, Westlite Ubi, Westlite Mandai and Westlite Juniper. The new block at Toh Guan (1,764 beds, October 2025) and the new block at Mandai (3,696 beds, January 2026) sit at those CAREIT-owned properties. Several passages in this article counted the new blocks in Centurion’s directly-owned bed total; they belong in CAREIT instead.

   The initial correction restated the directly-held portfolio from “24 assets, c.53,107 beds” at publication to “c.22 assets, c.47,600 beds”. The principle was right; the arithmetic was not. The 53,107-bed figure had incorrectly included the new blocks (5,460 beds combined) on the Centurion side but had also omitted Westlite Tampoi (5,790 beds) and Westlite Senai II (3,700 beds) from the directly-held list, so the headline magnitude was approximately right by coincidence. The 13 May 2026 1Q 2026 Business Update resolved the composition cleanly: at 31 March 2026 the directly-held portfolio is 24 assets totalling 52,993 beds, comprising 5 Singapore PBWA, 13 Malaysian PBWA, 1 Hong Kong PBWA, 2 Hong Kong PBSAs, 1 Australia PBSA, 1 UK PBSA, and 1 Xiamen BTR. Including the April 2026 Australian Key Worker Accommodation additions, the post-1Q snapshot is c.26 assets and c.53,439 beds. CAREIT’s portfolio is correspondingly 15 assets and c.28,266 operational beds (or c.30,246 including the 1,980-bed Mandai Expanded Capacity retained until 31 December 2030 pending FEDA license).

   The numerical thesis does not change. With thanks to Centurion management for the correction and to the 1Q 2026 Business Update for the definitive numbers.

5. Post-publication correction (2026-05-29) — FY2026 revenue bridge and Malaysian revenue weighting (Centurion management feedback). Centurion management noted that the FY2026 revenue bridge in the original article — which attributed roughly +S$160 million of ‘mechanical lift’ to the difference between three months and twelve months of CAREIT consolidation — was wrong, because most of the CAREIT-bound assets had been on Centurion’s revenue line for the full FY2025 (either as direct subsidiaries, as a 51%-owned consolidated subsidiary in the case of Westlite Ubi (held through Centurion-Lian Beng (Ubi) Pte Ltd at 51% Centurion / 49% Lian Beng Group per the Final Prospectus), or as a master-lease arrangement in the case of Westlite Juniper). The genuinely incremental items in FY2026 are Westlite Mandai’s transition from 45% equity-accounted associate to fully consolidated via CAREIT (an accounting transition that lifts the gross revenue line by approximately S$12 to S$19 million as Mandai’s pre-new-block annual revenue enters the line for a full year for the first time, plus a further S$14 to S$20 million from the new Mandai block running for a full year — without proportionally lifting attributable earnings, because Centurion’s economic share of Mandai net income drops modestly from 45% to ~42.9%); the new Mandai block running for a full year; EPIISOD Macquarie Park’s master-lease income for a full year; the Harum Megah Malaysian portfolio’s first full year; and the new Australian Key Worker Accommodation assets, offset by the US PBSA disposal. The realistic FY2026 revenue range is S$355 million to S$390 million (+20% to +32% YoY), not the S$420 million to S$460 million range cited in the article. The Harum Megah contribution has been re-sized against the disclosed acquisition figures (six Johor PBWA properties, 7,197 beds, RM110.8 million purchase price), with the implied per-bed economics of roughly S$650 to S$800 of revenue per bed per year putting Harum Megah’s annualised revenue at approximately S$5 to S$6 million. Centurion management also clarified that Malaysian PBWA generates materially lower SGD revenue per bed than Singapore PBWA — operating margins and ROIC are comparable, but Malaysian rents in local terms are lower and the Ringgit translates at a lower rate — so the bed-count comparison between Centurion-direct and CAREIT understates the revenue-weighted asymmetry. The thesis (look-through implied value materially above the market price across central, conservative and optimistic cases) does not change, because the SOP build relies on Layer 1 property value, Layer 2 fee economics and Layer 3 CAREIT market value, not on the FY2026 revenue bridge. What changes is the size and pace of the FY2026 catalyst the article was pointing to. The full quantitative restatement is set out in the institutional-length version (data-integrity note 13). With thanks to Centurion management for the clarification.

References

[1] Ministry of Manpower, “Applications for Dormitory Transition Scheme grant to open from 1 Mar to 31 Aug to help existing dormitories meet improved standards”, MOM press release, 17 January 2026. https://www.mom.gov.sg/newsroom/press-releases/2026/0117-dts-grant

[2] Centurion Corporation Limited, “Centurion Reports 30% Revenue Growth to S$89.4 Million in 1Q 2026”, SGX filing, 13 May 2026.

[3] UU.com.my, “Act 446 Malaysia Compliance Guide for Employer”, 2026. https://www.uu.com.my/act-446-malaysia-compliance-guide/

[4] Free Malaysia Today, “Multi-tier levy for foreign workers delayed to 2026”, 31 July 2025. https://www.freemalaysiatoday.com/category/nation/2025/07/31/multi-tier-levy-for-foreign-workers-delayed-to-2026

[5] Osadi Malaysia, “Malaysia Updates Act 446 Accommodation Rental Cap to RM150”, February 2026. https://osadi.com.my/malaysia-updates-act-446-accommodation-rental-cap-to-rm150/

[6] Australian Broker News, “Student housing surge in 2026 opens rich finance pipeline for Aussie brokers”, 2026. https://www.brokernews.com.au/news/breaking-news/student-housing-surge-in-2026-opens-rich-finance-pipeline-for-aussie-brokers-288866.aspx

[7] Cushman & Wakefield Australia, “Purpose-Built Student Accommodation in Australia”, December 2025. https://www.cushmanwakefield.com/en/australia/news/2025/12/purpose-built-student-accommodation-in-australia

[8] Motley Fool UK, “After tanking 46.5%, this FTSE 250 stock offers me an 8.1% dividend yield”, 3 May 2026. https://www.fool.co.uk/2026/05/03/after-tanking-46-5-this-ftse-250-stock-offers-me-an-8-1-dividend-yield/

[9] Centurion Corporation Limited, “Annual Report 2025: Evolving with Purpose”, SGX filing, 6 April 2026.

[10] Centurion Accommodation REIT, “Condensed Interim Financial Statements and Distribution Announcement for the Financial Period from 12 August 2025 (Date of Constitution) to 31 December 2025”, SGX filing, 23 February 2026.

[11] Centurion Accommodation REIT, “Prospectus dated 18 September 2025”, lodged with the Monetary Authority of Singapore.

[12] Centurion Corporation Limited (OU8.SI), share price and market data via Yahoo Finance, retrieved 16 May 2026. https://sg.finance.yahoo.com/quote/OU8.SI/

[13] Centurion Accommodation REIT (8C8U.SI), unit price and market data via Yahoo Finance, retrieved 16 May 2026. https://sg.finance.yahoo.com/quote/8C8U.SI/

[14] Julian Wong, “CAREIT CEO: The human touch behind Centurion’s living spaces”, The Edge Singapore, 14 November 2025. https://www.theedgesingapore.com/news/kopi-c-company-brew/careit-ceo-human-touch-behind-centurions-living-spaces

IMPORTANT DISCLAIMERS

This article is published for informational and educational purposes only. It does not constitute financial or investment advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The author is not a licensed financial adviser under the Financial Advisers Act 2001 of Singapore. This content is exempt from the requirements of the Singapore Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication. This publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, readers should consult a licensed financial or investment adviser in their relevant jurisdiction. Past performance is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author holds a long position in Centurion Corporation (SGX: OU8) as of the date of publication. This does not constitute a recommendation. This publication has received no compensation from Centurion Corporation or any related party.

On 25 September 2025, a small Singapore-listed dormitory operator did something unusual. It took fourteen of its best-stabilised assets, dropped them into a newly constituted real estate investment trust, and listed that trust on the same exchange where the parent had been trading for two decades. Centurion Accommodation REIT (SGX:8C8U) began trading at S$0.88 a unit. Centurion Corporation Limited (SGX:OU8), the sponsor, retained 42.9% of the new trust, kept full ownership of the trust’s manager, and pocketed approximately S$520 million in cash for the assets it had handed over.

Eight months later, the trust is up. The sponsor’s share price is up. Both are up less than they should be if the market understood what just happened.

The easy version of this story is wrong. The easy version is that Centurion’s share price has rallied from S$0.96 at the start of 2025 to S$1.46 at the 16 May 2026 close, a 52% move, and that the rally exhausted the mispricing. We disagree. The rally was the market crediting Centurion for executing the listing. The market has not yet credited Centurion for what the listing created: a Singapore-listed dormitory operator that now earns three streams of recurring income from one corporate vehicle, owns a directly-held bed count larger than the trust it sponsors, and trades at 1.0x book and 11x trailing earnings as if none of that had changed.

Read more

In October 2025, PropNex Limited (SGX:OYY) traded at S$2.63 [3]. On 19 May 2026 it closed at S$1.83 [3]. Seven months, a 30% drawdown, and the market has settled on a clean explanation. New private home launches in Singapore are guided down 17% in 2026. Project marketing commissions are PropNex’s largest revenue line. The market has done the obvious arithmetic, marked the stock down, and moved on.

That arithmetic is incomplete.

There are 13,500 Housing Development Board flats becoming eligible to be sold in 2026. They were bought five years ago at S$400,000 to S$600,000. Their current market value is 30% to 50% higher. The five-year minimum occupation period (the MOP, in Singapore property parlance) is the gate the government places between purchase and resale to deter speculation. When MOP releases, owners gain the legal right to monetise. Most do not sell immediately. But a meaningful share do, and most of those buy something else. The transaction is rarely a single sale; it is a chain. One household decision generates an HDB seller-side commission, a private buyer-side commission, and sometimes a rental commission while the private completes. Up to three fees from a single MOP exit.

This year’s MOP cohort is 69% larger than last year’s. That number, 13,500 versus 8,000 in 2025, is not a forecast. It is a mechanical consequence of when those flats were completed, which was the 2020 to 2021 COVID-era construction acceleration. It cannot be revised away.

PropNex earns from six segments. New launches were 39% of FY2025 revenue. The other 61% — private resale, HDB resale, rental, landed, and commercial — feeds directly off the MOP-driven upgrader chain. The market is pattern-matching to “launches down equals PropNex down” without doing the segment-level arithmetic.

This article makes the case for the franchise: what PropNex is, why it compounds, and why the market’s peak-cycle read deserves scrutiny. It stops short of the verdict — the precise FY2026 earnings range, the valuation scenarios, and the complete risk register belong to the longer analysis here.

Twenty-six years from one-man shop to S$1.4bn franchise

PropNex was founded in November 2000 by Ismail Gafoor, who is today executive chairman. The first decade was unglamorous: PropNex was one of several mid-sized Singapore agencies competing against ERA, OrangeTee, HSR and others, none of them dominant. The inflection arrived in 2010 with the formation of the Council for Estate Agencies, which tightened licensing requirements for both agencies and individual salespersons. For a fragmented industry, this raised the cost of legitimacy. PropNex spent the following ten years building a training and compliance infrastructure that turned this cost into an entry barrier for new competitors.

The SGX listing on 2 July 2018 priced at S$0.535 per share pre-bonus. On a post-bonus-adjusted basis, the IPO price is approximately S$0.27. The listing gave PropNex a currency for incentive grants and forced disclosure that strengthened developer credibility. The May 2023 bonus issue (one-for-one, doubling the share count to 740 million) deepened liquidity. All per-share figures in this article are restated post-bonus.

The most consequential recent event was the 2023 succession from Ismail Gafoor to Kelvin Fong as chief executive officer. Fong had spent his career at PropNex and rose internally from agency leader to deputy CEO to CEO. Gafoor moved to executive chairman with responsibility for strategy and capital allocation. This was a structured handover from a founder to an internal successor; not a reactive external hire. The founder remains in the building, the agency leadership layer remains intact, and the firm’s operating model was not disturbed.

The compound since IPO is steady rather than explosive. The 2018 IPO price of S$0.27 (post-bonus adjusted) versus today’s S$1.83 [3] represents roughly a 28% CAGR over 7.9 years, before the dividends paid along the way. Most of this return is franchise growth, not multiple re-rating.

What you actually own at S$1.83

PropNex is not a property company in any conventional sense. It does not own development sites. It does not carry inventory. It has S$1.6 million of fixed assets against S$1,116 million of FY2025 revenue. The economic engine is an asset-light intermediary at scale. PropNex’s licensed estate agency contracts with 14,333 self-employed salespersons [6], who pay PropNex a share of every commission they earn. PropNex’s share averages 12% to 14% across all transactions. There is no salary line for the salesforce because there are no salaries.

What this means in practice: when you buy a share of PropNex, you are not buying a slice of property or a slice of inventory. You are buying a slice of a business that takes a small cut of every property transaction one of its agents closes. The more agents the company has, and the more property changes hands in Singapore, the more cuts get taken. The capital required to add the next agent is essentially zero. This is the rare combination that makes an asset-light intermediary worth a meaningful premium to book value when it has scale, and worth very little when it does not. PropNex is at the scale end.

The six-segment FY2025 revenue mix matters because the cycle thesis turns on it.

Project Marketing was S$434 million (39%), Private Resale S$234 million (21%), Rental S$191 million (17%), HDB Resale S$153 million (14%), Landed Resale S$62 million (5%), and Commercial and Industrial S$34 million (3%). The market is anchored on Project Marketing because new launches are guided down 17% in 2026. The other 61% of revenue is where the upgrader chain operates.

International operations (Indonesia, Malaysia, Vietnam, Cambodia, Australia) are immaterial to the investment case. PropNex is functionally a pure Singapore residential agency.

Why the largest agency keeps getting larger

PropNex has 14,333 agents as at 12 May 2026 [6]. ERA Realty Network, the second-largest, has 8,891 [6]. Huttons has 5,760 [6]. OrangeTee has 3,163 [6]. PropNex is 1.6 times the size of its nearest competitor and the gap is widening, not narrowing. Total registered salespersons in Singapore are approximately 37,467, so PropNex employs nearly 38% of the industry [6].

The salesforce gap is the moat. A new agent surveying Singapore’s brokerage options sees PropNex’s project marketing pipeline (over half of FY2025 new launches were PropNex-marketed) as a steady inflow of inbound leads that flow to its own agents. New agents at PropNex earn more in their first eighteen months than at smaller agencies because they have lead access. This attracts more agents, which wins more project mandates, which generates more leads. It is a flywheel that has compounded for ten years.

There is also a relationship layer that is harder to see from outside. When a Singapore developer launches a new private project, they typically appoint two to four marketing agencies. PropNex sits on the list for the vast majority of major launches because the relationships have been built across many years and many launches. The developers know, from track record, that PropNex’s salesforce can clear 500 to 1,000 units in a launch weekend. PropNex has consistently been the lead or co-lead marketing agency at the largest private residential launches each year, including most of the major FY2025 and 1Q FY2026 launches. This is not a relationship you can buy with a marketing budget. It takes a decade.

ERA’s salesforce of 8,891 is broadly the same range as it was five years ago. The market is consolidating in PropNex’s favour, not against it.

The competitive battle is active — and PropNex is winning it on net. The Singapore agency industry is in a visibly active recruitment phase, and a fair read of the moat case has to acknowledge both sides. In March 2026, ERA’s CEO Marcus Chu launched the “ERA +1 initiative” — each ERA agent asked to recruit one newcomer this year — and ERA disclosed at the same event that 54% of its new agent joiners in 2025 came from PropNex; a former PropNex top earner (Rayne Chua) joined ERA in February 2026 with approximately 80 agents under her [16]. Two months later, PropNex announced the return of Adrian Lim, co-founder of PropertyLimBrothers, alongside 37 PLB salespersons — a homecoming for Lim, who had been a top-performing PropNex leader from 2010 to 2022 [17]. The net result: PropNex’s CEA-registered salesforce grew from 14,202 in February 2026 to 14,333 on 12 May 2026 [6], while ERA’s count declined from 8,828 (February 2025) to 8,427 (January 2026). The salesforce gap has widened, not narrowed. The competitive battle is real and active; PropNex is winning it on net.

PropNex’s overall market share across all segments was 62.5% in FY2023 (the most recent Frost & Sullivan number) [7] and has remained in a similar range through FY2025 per PropNex’s own business-slide commentary. By segment, PropNex held 65.8% of private resale, 64.7% of HDB resale, 49.7% of landed resale, 47.9% of new launches, and 35.9% of private leasing [7].

One framing point that protects the franchise: Singapore residential transactions are predominantly agent-mediated. By our analytical estimate, roughly 85% to 90% of HDB resale and 90% to 95% of private resale clear through a licensed estate agent rather than directly between owner and buyer. The structural reasons are genuinely Singapore-specific — HDB regulatory complexity (CPF disbursements, Ethnic Integration Policy quota checks, valuation procedures), the per-transaction stake at S$1.5m-plus median private prices, and active CEA professionalisation since 2010. The for-sale-by-owner channel exists but is small.

What that scale advantage looks like in dollars. ERA's listed parent is APAC Realty Limited (SGX:CLN), which filed its FY2025 results in February 2026 and provides a clean audited side-by-side. PropNex's revenue is 1.65× APAC Realty's (S$1,116m versus S$676m). PATMI is 3.42× (S$70m versus S$21m), because PropNex's larger scale spreads overhead across roughly twice the revenue base — net margin of 6.3% versus 3.0% [13]. The dividend comparison cuts two ways and is worth stating precisely. PropNex pays 9.50 cents per share against APAC Realty's 4.50 cents — a 2.11× gap in absolute per-share payout. But APAC Realty trades at roughly a third of PropNex's share price (S$0.555 versus S$1.83), so on a yield basis the smaller company is ahead: APAC Realty's trailing yield is about 7% to 8% against PropNex's 5.2%. The per-share figure measures payout scale; the yield measures income return. Gross margins are within ten basis points of each other (10.3% versus 10.4%), so the operating-margin divergence comes entirely from overhead intensity, not from commission economics. The agent-count gap is the input; the net-margin gap is the output.

The five-year scoreboard

Three observations from the table. Gross margin moves within a narrow band of about 150 basis points across the full cycle, between 9.1% in FY2024 and 10.6% in FY2021, because costs scale with revenue when commissions are the dominant line. The company did not lose money even at the FY2024 trough; it earned S$40.9 million of PATMI on S$783 million of revenue.

Second, the dividend has been a constant signal. The payout ratio has been 80% or higher for at least four of the last five years. FY2024 paid more than earned (140% payout including the special anniversary dividend) and FY2025 paid 99.9% of earnings. The dividend has not been cut through the trough years. PropNex’s track record across the FY2023 to FY2024 trough was to draw on cash to honour the headline DPS rather than cut it.

Third, the salesforce has grown every year. From 10,796 at end-2021 to 13,945 at end-2025 is a 6.6% CAGR. The acceleration in 2025, from 12,636 to 13,945 or a 10.4% rise, is notable. The 1.6x gap over ERA has widened, not compressed.

Returns on equity are headline-extraordinary at approximately 58% for FY2025. Return on equity is the profit produced by every dollar of book equity the company holds. PropNex’s number is high not because margins are wide (net margin is 6.3%) but because the equity base is small; the company distributes almost every dollar it earns as dividend, so nothing accumulates. This is the precise economic characteristic of an asset-light intermediary at scale: you can add a thousand agents next year without funding new capital.

One quiet structural tailwind worth noting before the cycle discussion. PropNex earns a percentage of transaction value across every segment. When Singapore property prices rise — and the Urban Redevelopment Authority’s Private Property Price Index has risen roughly 38% over the six years to end-2025, with the HDB Resale Price Index up a similar magnitude [4][5] — the absolute commission per transaction rises proportionally, even if volumes are flat. The franchise compounds even in flat-volume years.

The mispricing: where the market may be too bearish

This is the heart of the investment case. The market is pricing PropNex on the assumption that FY2026 earnings collapse the way FY2023 did, when project marketing led the cycle down. Run the numbers segment by segment and that assumption does not hold up, for three structural reasons.

First, the 4Q25 backlog. Singapore’s revenue recognition convention runs three to four months behind the option-to-purchase exercise. A meaningful share of the strong October to December 2025 launch sales lands in 1H26 results regardless of what FY2026 launch volumes do. The first half of 2026 is, in revenue terms, already partly written.

Second, the segment mix. Project marketing is 39% of revenue. The other 61% — private resale, rental, HDB resale, landed, commercial — is driven by volumes that management guides as flat to growing, not falling. A 17% decline in one segment that is 39% of the business is not a 17% decline in the business.

Third, the MOP wave. This is the structural event the market is under-weighting. The 13,500 HDB flats reaching their five-year minimum occupation period in 2026 are a mechanical supply event, 69% larger than the 2025 cohort. Not every MOP-eligible flat goes to market — the Ministry of National Development has published year-by-year cohort conversion data showing what share of each cohort actually transacts [10][11] — but a meaningful share does, and each one tends to generate a chain of commissions for PropNex across the HDB seller-side and the follow-on private purchase.

One clarification, because it matters: the 13,500 figure is the standard 5-year MOP cohort. The newer 10-year MOP regime, covering Prime Location Public Housing (introduced November 2021) and the Plus and Prime tiers (introduced under the August 2024 BTO framework reform), has not yet reached MOP and will not start clearing that gate until the mid-2030s [12]. The 2026 cohort is entirely standard 5-year MOP flats.

We ran the segment-level arithmetic through every revenue line: project marketing net of the 4Q25 backlog, the MOP wave modelled across three conversion-rate scenarios anchored to the MND’s published cohort data, and the resale, rental, landed and commercial segments built up individually. The result is a FY2026 earnings range that is materially higher than what the current share price implies. The gap between the two — between what the market is pricing and what the segment build produces — is where the value sits.

The full segment-by-segment build, every revenue line modelled, the MOP conversion scenarios laid out in a sensitivity table, the FY2026 revenue bridge, and the resulting PATMI range set against the market-implied number, is not laid out in this article. The full build is here.

What you pay at S$1.83

Two things in this table are worth unpacking for what they tell you about the downside.

P/Attributable NAV of 11.66x looks expensive, and it is the wrong multiple. P/Attributable NAV is the share price divided by the company’s book value per share. Book value is what is left over on the balance sheet after twenty-five years of distributing most earnings as dividends. For an asset-light intermediary like PropNex, the book value is a residual accounting number, not the economic value of the franchise. The salesforce of 14,333 agents, the project marketing relationships, the brand, the training infrastructure: none of these sit on the balance sheet. Comparing PropNex’s 11.66x P/NAV to a property developer’s P/NAV of around 1x is a category error. The right multiple for an intermediary is earnings-based.

Enterprise value over trailing PATMI is 17.2x, meaningfully lower than the 19.2x trailing P/E. The simple reason for the gap: PropNex sits on S$144 million of net cash, equivalent to S$0.20 per share or roughly 10% of the market capitalisation. When you back that cash out (which is what an acquirer would do), the multiple you are paying for the actual operating business drops from 19.2x to 17.2x. That cash is the margin of safety: it is idle on the balance sheet, available to fund the dividend through any cyclical trough, and not currently being used to generate earnings, so it represents real per-share value that the trailing P/E understates. The share price, market capitalisation, and the multiples derived from them are as at the 20 May 2026 close [3]; net cash, NAV, and DPS are from PropNex’s FY2025 audited results.

The yield, at least, is unambiguous. At the S$1.83 close [3] and an FY2025 DPS of 9.5 cents, the trailing yield is 5.2%. PropNex’s track record across the FY2023 to FY2024 trough was to pay out 92.9% then 140% of earnings, drawing on cash to honour the headline DPS. A scenario in which PropNex actually cuts the dividend would require a multi-year sustained earnings decline of 35% or more, which would also imply a broader Singapore residential market collapse that has not occurred in the recent two decades. The yield, in other words, is durable.

The risk that matters

Every investment case has a central risk, and PropNex’s is specific: a government cooling measure that targets the HDB resale-to-private upgrader chain.

Singapore’s government has actively managed the residential property cycle since the 1990s. The toolkit includes additional buyer’s stamp duty (ABSD), seller’s stamp duty, loan-to-value limits, and minimum occupation periods. The April 2023 ABSD package — which raised the rate on Singapore citizens’ second-property purchases from 17% to 20% and the foreigner rate from 30% to 60% — drove the FY2023 to FY2024 transaction trough that PropNex’s earnings reflect [14][15]. The MOP wave thesis turns on owners’ ability to sell their MOP-eligible flats and buy private property. A new measure that attacks that chain (a further ABSD increase on citizens’ second properties, or an extension of the HDB MOP period) would compress the thesis directly.

There is a reassuring data point here. In early May 2026, the government did act on the property market, but on executive condominiums specifically, doubling the EC minimum occupation period from five to ten years and scrapping the deferred payment scheme [8][9]. This package targets ECs, not HDB. The 13,500 HDB flats reaching MOP in 2026 are unaffected. More importantly, it signals that the government’s current preference is for surgical, single-segment intervention rather than blanket cooling, which is a positive signal for PropNex’s broader resale lines. It is not, however, an all-clear: the government has demonstrated it is in active intervention mode, and a follow-on HDB-targeted measure cannot be ruled out.

The bottom line

PropNex at S$1.83 is a high-quality Singapore residential agency franchise that the market has marked down on a peak-cycle read. The franchise case is not in dispute: a 14,333-agent salesforce that is 1.6 times its nearest competitor and still growing, 64% market share, asset-light economics that produce a ~58% return on equity, S$0.20 per share of net cash, and a dividend that has not been cut through the worst two years of the recent cycle. The competitive benchmarking against APAC Realty shows the scale advantage is real and compounding: same commission economics, double the net margin, roughly ten times the net cash.

The investment question is whether the market’s 30% drawdown correctly prices FY2026. The market is anchored on the 17% guided drop in new private home launches. The segment-level work (the 4Q25 recognition backlog, the segment mix where 61% of revenue is not new launches, and the 13,500-flat MOP wave) suggests the market may be pricing in a steeper decline than the franchise’s actual revenue structure warrants. The gap between the market-implied earnings and the segment-built earnings is the opportunity, if it is real.

This article has made the franchise case in full. What it leaves for the longer analysis is the quantification — the precise FY2026 earnings range, the forward valuation, the scenario-weighted price levels, and the complete four-trigger risk register — drawn from the same research base and the same figures, fully built out.

If the franchise case above has convinced you that PropNex is worth understanding properly, the institutional-length version is where the analysis is finished.

Data integrity notes

Correction (21 May 2026): An earlier version framed PropNex's higher per-share dividend (9.50 cents vs APAC Realty's 4.50 cents) as the number that matters "for a yield-oriented investor." That was misleading. Because APAC Realty trades at roughly a third of PropNex's share price, APAC Realty carries the higher dividend yield — about 7% to 8% on its FY2025 dividend, against PropNex's 5.2%. The dividend figures themselves were correct; the per-share gap measures payout scale, not income return. With thanks to the reader who flagged it.

All financial figures in this article are from PropNex’s SGX-filed press releases and audited financial statements FY2021 to FY2025 [1][2]. Industry agent counts are from the Council for Estate Agencies registry as cited in PropNex’s FY2025 business slides [6]. Market share figures are Frost & Sullivan FY2023 (the most recent comprehensive published baseline) [7] cross-referenced against PropNex’s own market-share disclosures in business slides. FY2026 guidance is PropNex’s own management guidance from the 27 February 2026 press release [1]. Share price and market data are from Yahoo Finance, retrieved 20 May 2026 [3]. APAC Realty comparison figures are from APAC Realty’s SGX-filed Condensed Interim Financial Statements 2H/FY2025 [13].

The MOP wave conversion analysis referenced in this article is anchored to the Ministry of National Development’s published parliamentary written answer covering HDB cohort conversion data for 2011 through 2020 [10][11]. The agent-mediated share estimates (85–95%) are our analytical inferences, not published statistics; Singapore does not publish a clean for-sale-by-owner share figure. Research notes from brokerage firms covering PropNex were read during the research process for context but are not cited in this article.

References

[1] PropNex Limited, “FY2025 Full Year Results Announcement”, SGX press release, 27 February 2026.

[2] PropNex Limited, “FY2025 Business Update Slides”, SGX filing, 27 February 2026.

[3] PropNex Limited (OYY.SI), share price and market data via Yahoo Finance, retrieved 20 May 2026. https://finance.yahoo.com/quote/OYY.SI/

[4] Urban Redevelopment Authority of Singapore, “Private Residential Property Price Index, 4Q2025”, quarterly release, January 2026. https://www.ura.gov.sg/Corporate/Media-Room/Media-Releases

[5] Housing Development Board, “HDB Resale Price Index, 1Q2026”, quarterly release, April 2026. https://www.hdb.gov.sg/about-us/news-and-publications/press-releases

[6] Council for Estate Agencies, “Registered Salespersons Statistics”, as at 20 February 2026. https://www.cea.gov.sg/aceas/public/svc101/

[7] Frost & Sullivan, “Singapore Real Estate Agency Industry Report — FY2023 Market Share Analysis”, commissioned by PropNex, 2024.

[8] Ministry of National Development of Singapore, statement on executive condominium scheme revisions (MOP extension from five to ten years, deferred-payment-scheme withdrawal, first-timer quota raised to 90%), early May 2026. https://www.mnd.gov.sg/newsroom

[9] Chong, Xin Wei, “New EC rules to cool prices: MOP doubled to curb flipping, no more deferred payments, and more units for first-timers”, The Business Times, May 2026. https://www.businesstimes.com.sg/property/new-ec-rules-cool-prices-mop-doubled-curb-flipping-no-more-deferred-payments-and-more-units-first

[10] Ministry of National Development of Singapore, “Written Answer on data on number of HDB flats eligible for resale and sold within one year, five years and ten years after five-year Minimum Occupation Period”, Parliamentary Q&A. https://www.mnd.gov.sg/newsroom/parliament-matters/q-as

[11] Ong, Ryan J., “13.4% Of BTO Flats Were Sold Within A Year Of MOP: What Does It Mean For Homebuyers?”, Stacked Homes, 22 September 2021. https://stackedhomes.com/editorial/13-4-of-bto-flats-were-sold-within-a-year-of-mop/

[12] Housing & Development Board, “Eligibility for Selling a Flat” — official policy page describing the MOP framework (5-year MOP for standard BTO flats; 10-year MOP for Prime Location Public Housing, Plus and Prime tiers). https://www.hdb.gov.sg/managing-my-home/selling-a-flat/eligibility

[13] APAC Realty Limited (SGX:CLN), “Condensed Interim Financial Statements for the six months and full year ended 31 December 2025”, SGX filing, February 2026 (FileID 875635). https://www.sgx.com/securities/company-announcements?value=APAC%20REALTY%20LIMITED&type=company

[14] Inland Revenue Authority of Singapore (IRAS), “Additional Buyer’s Stamp Duty (ABSD)” — historical rates schedule. https://www.iras.gov.sg/taxes/stamp-duty/for-property/buying-or-acquiring-property/additional-buyer’s-stamp-duty-(absd)

[15] Urban Redevelopment Authority of Singapore, quarterly residential transaction statistics — used to triangulate the historical transaction-volume response to ABSD tightening packages. https://www.ura.gov.sg/Corporate/Media-Room/Media-Releases

[16] Ho, Jovi, “ERA Singapore’s new initiative could double its salesforce this year”, The Edge Singapore, 24 March 2026. Source for the ERA +1 initiative announcement, Rayne Chua defection, and ERA salesforce counts. https://www.theedgesingapore.com/cityandcountry/property/era-singapores-new-initiative-could-double-its-salesforce-year

[17] PropNex Limited, “37 PropertyLimBrothers Salespersons, Including Co-Founder Adrian Lim, join PropNex”, press release, 13 May 2026. Source for the Adrian Lim/PLB return and the 14,333 CEA-registered salesforce figure as at 12 May 2026. https://www.propnex.com/news-details/12481/37-propertylimbrothers-salespersons-including-co-founder-adrian-lim-join-propnex

IMPORTANT DISCLAIMERS

This article is published for informational and educational purposes only. It does not constitute financial or investment advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The author is not a licensed financial adviser under the Financial Advisers Act 2001 of Singapore. This content is exempt from the requirements of the Singapore Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication. This publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, readers should consult a licensed financial or investment adviser in their relevant jurisdiction. Past performance is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author may or may not hold positions in the securities discussed. No compensation has been received from any company mentioned in this article.

In October 2025, PropNex Limited (SGX:OYY) traded at S$2.63 [8]. On 19 May 2026 it closed at S$1.83 [8]. Seven months, a 30% drawdown, and the consensus has settled on a clean explanation. New private home launches in Singapore are guided down 17% in 2026. Project marketing commissions are PropNex’s biggest revenue line. The market has done the obvious arithmetic, marked the stock down to a cycle-trough multiple, and moved on.

That arithmetic is incomplete.

There are 13,500 Housing Development Board flats becoming eligible to be sold in 2026. They were bought five years ago at S$400,000 to S$600,000. Their current market value is 30% to 50% higher. The five-year minimum occupation period (the MOP, in Singapore property parlance) is the gate the government places between purchase and resale to deter speculation. When MOP releases, owners gain the legal right to monetise. Most do not sell immediately. But a meaningful share do, and most of those buy something else. The transaction is rarely a single sale; it is a chain. One household decision generates an HDB seller-side commission, a private buyer-side commission, and frequently a rental commission while the private completes. Up to three fee events from a single MOP exit.

This year’s MOP cohort is 69% larger than last year’s. That number — 13,500 versus 8,000 in 2025 — is not a forecast. It is a mechanical consequence of when those flats were completed, which was the 2020 to 2021 COVID-era construction acceleration. The cohort size is therefore set in advance and not subject to forward revision.

PropNex earns from six segments. New launches were 39% of revenue in FY2025. The other 61%, comprising private resale, HDB resale, rental, landed, and commercial, feeds directly off the MOP-driven upgrader chain. Inside the company’s own FY2026 guidance, four of these six segments are flat to up. The one segment that is guided down hard, new launches, is buffered for the first half of 2026 by a S$434 million order book of 4Q25 project marketing sales that has not yet been recognised. Singapore’s developer recognition convention runs three to four months behind option-to-purchase exercise. That revenue is already in the chute.

The stock is being priced as if FY2026 PATMI prints a sharp decline from FY2025’s record S$70.4 million. The supply data, the segment mix, and the recognition lag say something closer to flat. At S$1.83 the equity carries S$0.20 of net cash per share, a 5.2% trailing yield, and a 99.9% payout that survived FY2023’s earnings trough at 92.9%. The peak-cycle thesis assumes management cuts the dividend if earnings fall. The track record says they do not. The 14,333-agent salesforce [11], 1.6 times the size of the next competitor, is a scale advantage that is unlikely to be replicated quickly.

This is the question this long-form deep dive sets out to answer. Is PropNex Limited at S$1.83 a cyclical stock priced for the wrong cycle, or a permanent franchise priced at a fair discount to its peak? The arithmetic, run through every segment from new launches to commercial leasing, says the answer is mostly the former. But the margin of safety is narrower than the headlines suggest, and the flip triggers are sharp enough that this is not a position to take and forget.

Read more

The company behind those desks, though, has drawn far less scrutiny than the product it sells. On 22 May 2026, JustCo Holdings Limited lists on the SGX Mainboard, and the offer document gives us the first proper look at the numbers. The headline tension is visible from the first page. JustCo is raising S$100 million in gross proceeds. In its most recent financial year it earned a net profit of US$2.7 million. A raise of that size against a profit of that size implies the market is being asked to pay a very full price, and it invites the comparison every flexible-office IPO now has to answer: is this the next WeWork story, or something sturdier? We read the prospectus to find out.

From JustOffice to JustCo

JustCo began in 2011, not 2018. The 2018 date on the prospectus cover is when the current holding company was incorporated; the business is older. Founder Kong Wan Sing started it with two co-founders as “JustOffice”, a single 3,132 square foot space in Samsung Hub in the heart of the Singapore CBD. The bet was simple: office supply was tight, rents were rising, and the way companies wanted to use space was changing faster than traditional leases allowed.

Growth came in stages. Between 2017 and 2019, equity from Sansiri, GIC and Frasers Property turned a Singapore operator into a regional one, and JustCo expanded into Australia, Taiwan, Thailand, South Korea and Japan at a pace of roughly one new centre every three weeks. The pandemic was the first real test: occupancy fell to just above 60% at the worst of it. The company’s response is worth noting, because it is the opposite of the WeWork playbook. JustCo exited mainland China and Indonesia rather than defend every market. Today it operates 54 centres across 12 cities, with around 37,500 workstations, and it sells under three brands: The Collective at the luxury end, JustCo as the core premium product, and the boring office as an essentials line.

What the offer actually contains

The offer is 32,092,000 new shares at S$0.94 each, with a further 5,319,000 vendor shares available through an over-allotment option. Sitting alongside it is a much larger cornerstone tranche of 74,291,000 shares. Together the new shares raise S$100.0 million gross and S$92.2 million net to the company. After listing, JustCo will have 489,235,758 shares in issue, which at the offer price puts the market capitalisation just under S$460 million.

The register is heavily anchored. GIC holds 22.74% after listing, Frasers Property and the Charoen Sirivadhanabhakdi interests hold 17.63%, and founder Kong Wan Sing’s family vehicle holds 17.79%. The cornerstone investors, a group that includes JPMorgan Asset Management, Fullerton, Maybank Asset Management, Avanda and Amova, take another 15.19%. Hsieh Fu Hua, a familiar name in Singapore capital markets, chairs the board as lead independent director.

The money has a clear job. S$81.7 million of the gross proceeds is earmarked for expansion, fit-outs and capital expenditure, with S$56.8 million of that tied to 20 committed new centres. Another S$10.0 million is for working capital, and S$8.3 million covers the fees of the offering. In total, JustCo plans to open around 28 new centres in 2026.

A small float by design, not by accident

Notice what is missing from those numbers: any meaningful sale of existing shares. The 5.3 million over-allotment is just over 1% of the company, and it comes from the Kong family’s holding vehicle. GIC, Frasers, the Kong family and Pinetree are not using this listing to cash out. That leaves an unusually small free float of about 6.6%, rising to 7.6% if the over-allotment is fully taken up. A typical SGX Mainboard listing sells 15% to 25% of the company; JustCo sold the minimum needed to raise the capital it wanted, and not a share more.

Three things follow. The deal raised what was needed and no more, which is a capital-discipline signal in a market where IPOs are often sized to deliver an exit rather than to fund growth. The existing register is genuinely committed: GIC and Frasers came in between 2017 and 2019 and are choosing to mark their investment publicly rather than monetise it. And the tradable float will grow mechanically as lock-ups unwind. The standard SGX six-month moratorium releases the cornerstone tranche around the fourth quarter of 2026, taking effective float past 21%, with the controlling-shareholder shares coming off lock-up at twelve months. The post-listing share price in those early months will therefore partly reflect scarcity rather than fundamentals, which flatters it now and creates an overhang later, when supply normalises even if nothing about the business has changed.

The point underneath all of this is that the tight float is a design choice, not a forced outcome. JustCo could have sold more shares and produced a normal float, and it chose not to. That signals confidence in being able to come back to market later, and a reluctance to dilute further at what the existing register evidently sees as a still-early price.

The financial scoreboard

Revenue has compounded steadily, from US$113.8 million in FY2023 to US$128.2 million in FY2024 to US$144.2 million in FY2025, a little under 13% a year. The profit line is the part that needs care. JustCo lost US$12.5 million after tax in FY2023 and US$10.1 million in FY2024 before reporting a US$2.7 million profit in FY2025. That maiden profit, though, leans on a one-off. FY2025 other income included a US$3.7 million non-cash fair value gain on the remeasurement of JustCo’s pre-existing stake in its Japan operations, recognised when it bought out the rest of that business. Strip that gain out and FY2025 would have been a pre-tax loss of roughly US$1.8 million. The turn to profit is real on the reported line, but the underlying business has not quite crossed into the black yet.

The more useful trend is Cash EBITDA, the company’s measure of cash generated at centre level after actual rent is paid. It rose from US$3.4 million to US$6.2 million to US$13.5 million across the three years, and the margin widened from 3.0% to 9.4%. Occupancy improved from 78% to 84%, and the renewal rate climbed from 64.7% to 72.0%. The operating story is one of a business getting steadily more efficient as its centres mature.

The cash flow puzzle

One number in the scoreboard looks too good, and it is worth slowing down on. JustCo generated US$101.2 million of net cash from operating activities in FY2025. That is more than seven times its FY2025 Cash EBITDA of US$13.5 million, and around thirty-seven times its reported net profit. It is not a sign of a cash machine hiding inside the income statement. It is an accounting effect.

Under the lease accounting standard that applies here, the rent JustCo pays on its centres does not all run through operating cash flow. The interest portion does, but the much larger principal portion is recorded as a financing outflow. In FY2025 net cash used in financing was US$77.1 million, most of it lease repayments. So the US$101 million operating figure is, in plain terms, cash generated before paying most of the rent. The honest measure of what the business kept is further down: after rent, after capital expenditure, and after everything else, cash on the balance sheet rose by US$11.2 million. JustCo is cash generative. It is generative in the low tens of millions, not the hundred-million range the operating line first suggests.

A moat that is strongest when you need it least

A moat is whatever stops a competitor from copying a business and taking its customers. JustCo has one. The question for this offer is not whether it exists, but how well it holds when conditions turn, because the whole investment case rests on occupancy staying high and new centres filling up on schedule.

Start with what is genuinely defensible. JustCo is neither the biggest flexible-office operator in Asia nor the oldest. It competes against IWG, the listed owner of Regus and Spaces that has run this business since 1989, against the long-established premium operators The Executive Centre and Servcorp, and against a restructured WeWork. What JustCo has built instead is density in a handful of cities. The market study commissioned for the prospectus puts its share of flexible workspace stock at around 16% in Singapore, a comparable level in Bangkok, and higher in Taipei [1]. In those cities, a corporate real estate team drawing up a shortlist of options will almost always include JustCo. Being the default option in your core markets is a real advantage, and it is the strongest layer of the moat.

But notice what that advantage depends on. A network of workspace centres is only valuable to a member when the centres are full and active. This is what economists call a network effect: the product gets better for each customer as more customers use it. In a good year, full centres generate referrals, landlords compete to host JustCo, and the density looks like a fortress. In a bad year, the same network is a row of half-empty floors with the rent still due on every one of them. The moat, in other words, is pro-cyclical. It reinforces itself when times are good and erodes when times are hard. That is the opposite of what an investor wants from a moat, because the entire point of a moat is to protect a business when the cycle turns against it. JustCo’s is strongest exactly when it is needed least.

The management-contract model softens this, but only on one side. When a landlord funds the fit-out and shares the revenue, a weak year hurts JustCo less on those centres, because the pain is shared with the building owner. That protects the balance sheet. It does not make a single member more loyal, so it is not a demand-side moat.

And the demand side is where the moat is thinnest. JustCo’s members stay an average of about 15 months, so the moat has to be re-won, customer by customer, on a rolling basis: roughly 28% of the workstations due for renewal in 2025 were not renewed. The product itself is substitutable, because one operator’s private office differs from another’s mainly on location, price and fit-out quality, all of which a well-funded rival can match. Landlords who have watched the model work can choose to run flexible space themselves. And the city-level density, real as it is, sits inside a small niche. Flexible space is only about 6% of all office space in the region, so a 16% share of Singapore’s flexible market works out closer to 1% of the city’s total office stock. JustCo is a meaningful operator in a young, still-small slice of the property market, not an entrenched one in a large and mature market.

The WeWork question

The comparison is unavoidable, so we will take it head on. JustCo itself seems to know it: a sign in its centres reads “Let’s Make Work Better”, and the wordplay against the name of its largest cautionary tale is almost certainly deliberate. JustCo’s prospectus does not mention WeWork in its risk factors, but the structural feature that broke WeWork is present here too. JustCo signs leases with initial terms generally running three to ten years. Its members sign up for an average of about 15 months. That gap between long, fixed commitments on one side and short, cancellable revenue on the other is the central vulnerability of the leased-office model. It is why, at end-FY2025, JustCo carried US$402.2 million of lease liabilities against just US$40.4 million of total equity. When occupancy holds, this works. When occupancy falls, the rent does not.

What is genuinely different is almost everything else. WeWork at its 2019 IPO attempt carried around US$47 billion of lease commitments against roughly US$4 billion of rental income, was burning cash at scale, and had governance problems that became their own story. JustCo is a fraction of that size, grew at a measured pace, walked away from China and Indonesia rather than chase every flag on the map, and runs about three-quarters of its mature space under management contracts in which the landlord funds the fit-out and shares the risk. It is cash positive after everything. Its register is GIC and Frasers, not a single dominant venture backer. The honest answer is that JustCo is not WeWork. But it shares WeWork’s core structural risk, and an investor buying the IPO is buying that risk at a price that leaves little room for the occupancy cycle to disappoint.

What the market is asking you to pay

At S$0.94, the post-listing market capitalisation is just under S$460 million. Against FY2025 net profit after tax of US$2.7 million, about S$3.5 million at the rate the prospectus uses, that is a trailing price-to-earnings multiple of roughly 130 times. And because the maiden profit rests on a one-off gain, the underlying business produced no profit to multiply at all. On the company’s preferred measure, the offer values JustCo at around 27 times its FY2025 Cash EBITDA of US$13.5 million. There is no dividend policy, and none has ever been paid.

We are deliberately not putting a forward number on this article. Whether 130 times trailing earnings is the wrong price or simply an early price depends entirely on what FY2026 and FY2027 look like as 28 new centres open and season, and that forward build is a separate piece of work. What we will say plainly is what the offer price is, and what it is not. It is not a value entry point. It is a growth price, and it asks the buyer to underwrite the next two years of expansion going broadly to plan.

The bull, the bear, and the honest answer

The bull case is that JustCo is a real franchise at an inflection. Occupancy and renewal rates are both rising, the Cash EBITDA margin has tripled in three years, and the management-contract model lets the company keep growing without putting every fit-out dollar on its own balance sheet. The flexible-office market across Asia Pacific is still lightly penetrated relative to mature markets like central London, which leaves room to grow into [1]. And the quality of the register matters: GIC, Frasers and a serious cornerstone book do not anchor a business they expect to unravel.

The bear case is that the price gives you no margin for error. The maiden profit is flattered by a one-off, the structural lease-versus-membership mismatch is real and large, the free float is thin enough to make the early share price as much about scarcity as about fundamentals, there is no dividend to wait on, and the raise itself adds 28 centres of fresh lease liability and the associated drag before those centres mature. Every one of the bull points depends on the occupancy cycle staying friendly, and the moat that is supposed to hold occupancy up is, as we have seen, weakest precisely when the cycle turns against it.

The honest answer is that both cases are true at once, and the IPO price is what forces the choice. JustCo has built something durable enough that GIC and Frasers want to own it, and fragile enough, structurally, that the WeWork question is fair to ask. At nearly S$460 million on a business that has not yet made an underlying profit, the market is being asked to pay for the growth before it arrives. Whether that is a price worth paying is the question the offer puts to each investor, and it is not one we will answer for them.

Notes on data integrity

All financial figures in this article are drawn from the JustCo Holdings Limited Prospectus and the accompanying Product Highlights Sheet, both dated 15 May 2026. JustCo reports in US dollars; the offer is priced in Singapore dollars. Where we convert between the two, we use the rates the prospectus itself uses: approximately S$1.30 to US$1.00 for the FY2025 income statement, and S$1.2784 to US$1.00 as at the prospectus’s Latest Practicable Date. The trailing price-to-earnings multiple, the price-to-Cash EBITDA multiple, the post-listing market capitalisation and the underlying pre-tax loss excluding the Japan fair value gain are our own calculations from disclosed figures. “Cash EBITDA” is the company’s defined measure and is not a standard accounting metric; we use it as the company presents it. Flexible-office market penetration data is from the CBRE Independent Market Research Report commissioned for and reproduced in the prospectus. This is a focused first-look analysis of the offer, not a full research initiation, and it does not attempt a forward earnings estimate or a valuation target.

References

[1] CBRE Pte Ltd, “Market Due Diligence Report on Flexible Working Sector in Asia Pacific”, Independent Market Research Report reproduced as Appendix C in the JustCo Holdings Limited Prospectus dated 15 May 2026.

[2] JustCo Holdings Limited, “Prospectus dated 15 May 2026” and “Appendix 3 Product Highlights Sheet dated 15 May 2026”, lodged with and registered by the Monetary Authority of Singapore. Available via the SGX-ST website and the MAS OPERA portal.

[3] WeWork: comparative figures on its withdrawn September 2019 initial public offering and its lease commitments are drawn from contemporaneous public reporting; WeWork subsequently filed for Chapter 11 bankruptcy protection in November 2023.

IMPORTANT DISCLAIMERS

This article is published for informational and educational purposes only. It does not constitute financial or investment advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The author is not a licensed financial adviser under the Financial Advisers Act 2001 of Singapore. This content is exempt from the requirements of the Singapore Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication. This publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, readers should consult a licensed financial or investment adviser in their relevant jurisdiction. Past performance is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author may or may not hold positions in the securities discussed. No compensation has been received from any company mentioned in this article.

That is the figure to anchor on. The reported profit decelerated 51.4% in FY2025 because the FY2024 comparable was inflated by fair-value gains; the same arithmetic now runs in reverse in 1HFY2026. What investors are paying for is the cash-generative operating engine, and that engine grew 13.9%: a real number, and a deceleration from FY2025’s reported 62.6% jump in core profit. That FY2025 figure, though, needs a closer look of its own — we return to it below.

So the first read of these results is a fork. Headline strong, underlying decelerating. Where you stand depends on whether you think the underlying number is depressed by the IPO/listing transition (S$1.2 million of cost still in the bridge) and the early phase of a room-ramp drag, or whether 13.9% is the new run-rate for a business that has now reached the gross-margin ceiling at roughly 71%.

The second thing the results did was reframe the strategy. The press release stated the goal of 10,000 rooms by 2030, the first public articulation of an explicit target, and announced a portfolio sale of seven freehold hospitality and living assets at a combined indicative S$218.5 million. Cushman & Wakefield ran the expression-of-interest exercise, bids closed 13 April 2026, and negotiations are reportedly underway [1][2]. Buyers can take vacant possession or sign a leaseback at a 3.5% gross yield. The properties cluster in three districts: three on River Valley Road, three in Balestier, one at 99 Rangoon Road. Two of the seven currently operate under management contracts rather than full ownership.

The sale is the strategically loaded piece of news in this period. If it executes, Coliwoo monetises roughly half of its S$428.2 million investment-property book and redeploys proceeds into master leases, management contracts, and selective acquisitions where mispricing or repositioning upside is available. Asset-light, capital-efficient, scalable. That model is well-understood. The Assembly Place (SGX:TAP), the only other listed Singapore co-living operator, has always run it. Coliwoo is converging on TAP’s model rather than running parallel to it.

What the numbers actually say

Read more

Those headlines sit alongside something more market-visible. DBS Group Research’s Chee Zheng Feng published a “buy” call with a 52-cent target price on 7 May 2026, five trading days before the result landed [1]. Volume on the day of the DBS publication ran 5.7 million shares against a three-month average of roughly 600,000 [2]. By the time the half-year numbers were released on 12 May, the shares had moved from 39 cents at the time of our April article, to a pre-DBS close of 39.5 cents on 6 May, before settling at 41.5 cents on results day [3].

The instinct is to declare the thesis strengthened. On a closer read, that conclusion overstates what the result actually shows.

Read more

For most of the past decade, Sunright Limited’s share price moved like a SGX small-cap nobody cared about: a few cents either way, dividend zero or near-zero, occasional flickers of activity around the AGM and the half-year results. Then in late 2025 something changed. The share price was 15.3 cents at its 12-month low. By 13 March 2026, the day Sunright reported its 1HFY2026 turnaround, it had reached 32.5 cents. By late April 2026, the Singapore financial press was running columns on the rotational interest into Sunright, AEM Holdings and UMS Integration as the city’s “semiconductor value-chain” stocks found an audience. By 7 May 2026, the price was 89.5 cents and the market capitalisation had crossed S$110m. Return from the 12-month low: approximately +485%.

The rally is propelled by a real operating turnaround — net profit of S$1.4m in the first half of FY2026 against a S$4.6m loss in 1HFY2025 — and by a credible AI-data-centre narrative that Executive Chairman Samuel Lim has been articulating consistently in press releases and AGM presentations since at least 2024. But behind the headline lies an arithmetic question the holding-company structure makes uncomfortable: 87% of Sunright’s FY2025 revenue is generated by a separately-listed Malaysian subsidiary, and that subsidiary trades at 0.58x book value on its own exchange, a fraction of where the parent now trades on the SGX.

This is an article about that gap.

How Sunright was built

Sunright Limited was incorporated in Singapore in 1978 by Samuel Lim Syn Soo, a fifty-year veteran of the local semiconductor industry credited with three joint patents for testing of devices. Lim’s career through the 1970s ran across U.S. multinationals in Asia and the United States, on the engineering, manufacturing and marketing side of test-and-measurement businesses. He launched Sunright on the conviction that the reliability bottleneck in semiconductor manufacturing — the long overnight stress test that filtered field-failure devices out of every batch — was a service business that could be productised.

KESM Industries Berhad, established by Lim’s group in 1978 in Kepong, Selangor, had by 1983 relocated to Petaling Jaya. Lim then established KESP Sdn. Bhd. in the Bayan Lepas Free Industrial Zone in Penang to expand burn-in capacity into Malaysia’s emerging electronics-manufacturing hub. KESM Industries listed on the Main Board of Bursa Malaysia in 1994, structuring the parent–subsidiary relationship that defines Sunright’s accounting and economics today: Sunright owns 48.41% of KESM, but consolidates KESM as a subsidiary because Lim — Sunright’s Executive Chairman and CEO — also holds the same titles at KESM, and Sunright’s directors are duplicated on the KESM board. De facto control flows through governance, not equity.

Sunright entered FY2026 with 122,806,266 shares outstanding, a Singapore Mainboard listing, and almost five decades of operating history almost entirely in burn-in/test services rather than equipment.

What you are actually buying

The principal activities of Sunright Limited as the parent entity are described in the FY2025 annual report as “investment holding and provision of management services.” The operating business — burn-in and testing services to global semiconductor customers — sits inside the consolidated group, and the dominant operating entity within that group is KESM Industries Berhad and its Malaysian subsidiaries.

The numbers are decisive. In FY2025 (financial year ended 31 July 2025), Sunright’s group revenue was S$72.98m. KESM’s contribution to that group revenue was S$63.75m, or 87.4%. Sunright Singapore’s direct revenue contribution — equipment manufactured under the Sunright brand and sold to customers globally — was S$5.3m, or 7.3%. The remainder came from smaller subsidiaries in China and elsewhere, several of which (KEST Taiwan, KES Shanghai) were liquidated in FY2024–FY2025 as the China–US trade environment compressed China’s role in the group’s footprint.

Two facts about that 87% are worth dwelling on. First, KESM is consolidated as a subsidiary under SFRS(I), meaning every dollar of KESM revenue, every dollar of KESM operating cost, and every dollar of KESM net asset shows up in Sunright’s consolidated financial statements. Second, only 48.41% of KESM’s economic interest belongs to Sunright shareholders. The remaining 52% is held by Bursa Malaysia investors, including KESM minority shareholders who can buy KESM directly without the holding-company layer. This 52% economic interest is presented in Sunright’s balance sheet as “Non-controlling interests” and at 31 July 2025 stood at S$53.39m, against attributable equity of S$69.24m. Group equity totalled S$122.63m. Sunright shareholders own less than 60% of the consolidated equity they read about in the headline announcements.

The Singapore-incorporated parent (Sunright Limited as a standalone entity) reported total Company-level equity of S$29.2m at 31 January 2026 against total assets of S$33.7m. Those assets are dominated by S$17.6m of cash and short-term deposits, S$9.5m of trade and other receivables, and S$5.6m of investment in subsidiaries (at carrying value), with small balances of investment securities, prepayments and intra-group loans against S$4.5m of liabilities (S$3.3m of loans and S$1.2m of payables and tax). The parent entity is essentially a holding-and-treasury function. The operating business is downstream.

The industry behind the numbers

Burn-in and test services sit between wafer fabrication and final assembly. After a chip is packaged but before it ships, it goes through hours or days of temperature, voltage and signal stress to filter out infant-mortality failures — the small percentage of devices that would fail in a customer’s product within months of deployment. For automotive, industrial, military and AI/data-centre semiconductors where field failure is unacceptable, burn-in is non-negotiable. For consumer parts, it has historically been done in-house by IDMs or skipped on commodity grades.

The addressable market for outsourced burn-in is a sub-segment of the broader OSAT (outsourced semiconductor assembly and test) industry. Multiple research providers size the global OSAT market at USD 39–47bn in 2023–2025, growing to USD 58–73bn by 2030 at single-digit CAGR (Grand View Research, Next Move Strategy, Virtue Market Research). The wafer-level burn-in and reliability test sub-segment specifically (including equipment and services) is forecast to grow at 14.8% CAGR from USD 2.26bn in 2025 to USD 4.51bn by 2030 (Virtue Market Research). The fastest-growing slice of the test stack is the slice nearest to AI processor reliability requirements — exactly the workload Sunright/KESM and Aehr Test Systems both serve.

That is the context for the rally, and for management’s repeated framing in the FY2025 annual report and 1HFY2026 press release of AI/data-centre and automotive semiconductors as the two pillars of the next leg of growth. Worldwide semiconductor revenue was USD 793bn in 2025 (+21% YoY, per the 1HFY2026 outlook commentary), and the company quotes industry forecasts of USD ~1tn by 2030. Sunright and KESM both describe themselves in their corporate materials as the world’s largest independent burn-in and test service provider, a relative position within a niche rather than an absolute scale claim. KESM’s standalone revenue of MYR 210.5m in FY2025 (~USD 47m) is a single-digit-percent share of the global outsourced burn-in services market.

The Malaysian semiconductor cluster mapping (Inari Amertron, Globetronics, Unisem, Pentamaster, MPI, ViTrox, Carsem and the customer-side IDM footprint) and the Aehr Test Systems competitive read-across in detail are in the institutional-length version of this piece.

Moat, with caveats

Two moat characteristics defend Sunright/KESM. First, the engineering integration with customer chips: every burn-in fixture and test program is co-developed with the customer over months of qualification work, and the switching cost (repeating that qualification cycle with another vendor) is real. Second, the geographic placement of capacity: KESM’s Petaling Jaya and Penang plants sit close to the Malaysian and regional packaging operations of major IDMs and OSATs, allowing tight integration with assembly logistics. These are durable advantages within the existing customer base.

The financial track record is equivocal. Across FY2020–FY2025, group revenue ranged from S$73m to S$111m and the income statement oscillated between profit and loss without a clear secular trend. ROE was negative in three of six years. KESM standalone (RM210.5m revenue, RM8.2m loss in FY2025) shows the same volatility on its own scale. The S$67.6m of net cash at 1HFY2026 is a real strength, but it sits alongside the S$11.1m one-half-year capex pulse that signals the company is now reinvesting in capacity, which can either pay off (if AI utilisation arrives) or become depreciation drag (if it doesn’t). A moat that does not deliver consistent earnings needs explanation, and Sunright offers a cyclical one (demand swings, customer concentration, capacity utilisation). That explanation is honest. It is not a moat in the sustainable-economic-rent sense.

Financial Scoreboard

What the capital actually earns

Across FY2020–FY2025, Sunright’s six-year cumulative net loss attributable to owners was S$7.7m, against an opening attributable equity base of S$82.5m at FY2019 year-end. Average attributable equity over the period was approximately S$77m, implying a cumulative ROE of approximately negative 10%, or roughly negative 1.7% per annum on average. This is below the cost of equity by any reasonable measure.

Returns on invested capital tell a similar story. Property, plant and equipment averaged S$50m over the period and operating profit averaged near zero, implying ROIC indistinguishable from zero on the operating asset base. Interest income on the S$80–100m cash pile contributed S$1.3–2.6m annually, meaningful relative to operating profit and material to the resilience of the headline P&L during cyclical downturns. The capital that earned its keep was the Treasury portfolio, not the operating asset.

The corollary: if 1HFY2026’s S$11.1m capex inflection signals a sustained reinvestment cycle, that capital must earn a meaningful return on a S$50m PP&E base. Management’s working assumption is implicit in the H1 print: they are betting that AI-driven burn-in volumes will absorb the new capacity at higher utilisation than the FY2020–FY2025 average. The bet is not unreasonable. It is also not yet evidenced.

A second view comes from the labour cost line. Employee benefits expense as a percentage of revenue rose from 38.2% in FY2020 to 45.9% in FY2025 as revenue (down 34%) fell faster than headcount cost (down 21%). Burn-in testing is a services-and-people business: KESM has to keep paying its engineers and operators whether the test cells are running near full or only half full. When semiconductor demand is weak the fixed labour bill crushes margins (which is why FY2025 turned into a loss year); when factories ramp back up, revenue grows while headcount cost stays roughly flat, and the spare capacity drops straight to profit. That dynamic is the engine behind the 1HFY2026 turnaround. In 1HFY2026 the labour ratio compressed to 41.3% (employee expense −6% YoY against revenue +15%), the first material sign of the leverage running in the right direction. Whether the FY2025 45.9% reading was cyclical drag (under-utilisation) that compresses with revenue recovery, or structural drag (Malaysian wage inflation plus a skill-mix shift toward AI burn-in engineers) that persists, is the underwriting question Q3 and Q4 FY2026 will settle.

Dividends, and the asymmetry that hides inside them

Sunright paid no dividend across FY2020–FY2024. In FY2025 it declared a 0.2 cent final dividend (S$246k total payout), described in the FY2025 chairman’s statement as recognition of shareholder support during a loss year. At the 7 May 2026 share price, that implies a yield of 0.22%. Symbolic, not income.

Beneath the headline a more interesting cash flow runs. KESM Industries — the 48.41%-owned subsidiary — has paid a dividend in every one of the past five years (6 to 9 sen per share, source: KESM Industries Berhad Annual Report 2025 five-year summary). In FY2025, despite reporting a RM8.2m net loss, KESM declared 6 sen per share. Sunright’s FY2025 consolidated cash flow shows S$504k of “Dividends paid to non-controlling interests”: cash leaving the consolidated group to KESM’s Bursa minority shareholders during the financial year. The corollary cash inflow to Sunright (the parent’s share of KESM’s dividend, ~48.41%) is netted against intra-group transactions and is not separately disclosed. The structural feature: KESM’s dividend policy is set by the KESM board (chaired by Samuel Lim, who is also chair of Sunright), and KESM’s policy of paying dividends through cyclical loss years means cash is distributed to the 51.59% Bursa minority even when the consolidated group is in loss-making mode.

This is the dual-listing tax. It is not abusive. It is not unusual. But it is a recurring, structural cost of the holding-company arrangement that the headline group financials do not isolate. In plain terms: every time KESM declares a dividend, only 48.41% flows up to Sunright shareholders; the other 51.59% leaves the consolidated group entirely, paid to Bursa minorities. Sunright shareholders also receive a 0.22% yield from their own company, but that low number is a separate problem — Sunright sits on S$84m of cash and could pay much more. The leak is structural; the meagre yield is a board choice.

Growth drivers, and what would have to be true

Three growth drivers are explicitly invoked by management across the FY2025 annual report, the FY2025 AGM presentation (delivered 21 November 2025), and the 1HFY2026 commentary: AI/data centre, automotive semiconductors, and an “expanded portfolio” of wafer, package and module-level burn-in and reliability test solutions.

The AI/data-centre driver is credible at the demand-signal level. Aehr Test Systems’ record USD 41m order from a hyperscale AI customer in April 2026 confirms that AI processor manufacturers are spending materially on burn-in. That order was for package-level burn-in (PLBI) — the same architecture KESM operates in (Aehr competes in both wafer-level via FOX-XP and package-level via Sonoma; recent hyperscale wins are on the package side). Translation into Sunright/KESM revenue therefore depends on whether hyperscalers consolidate PLBI spend with turnkey equipment vendors (Aehr) or with third-party service capacity (KESM). The outcome is binary at the customer level and probabilistic at the portfolio level.

The automotive semiconductor driver is more familiar territory. KESM has supported automotive customers for decades. The forecast cited in KESM AR2025 (automotive semiconductor revenue USD 77bn in 2025 to USD 88bn by 2027) is a low-double-digit growth runway. If KESM holds its share, automotive can plausibly contribute single-digit-percent annual revenue growth.

The third driver — wafer, package and module level expansion — was disclosed in the KESM FY2025 chairman’s statement as a new offering for FY2026. The S$11.1m of 1HFY2026 capex (against S$2.7m a year ago) is the financial expression. By the time the FY2026 annual report is published in September 2026, the early customer adoption data will be in.

Risks, with numbers attached

Customer concentration. In FY2025, three customers accounted for S$48m of the S$73m group revenue (66%). The identity of these customers is not disclosed. Loss of any one of them would produce a step-change to group revenue of approximately S$10–20m, equivalent to 14–27% of FY2025 revenue.

Geographic concentration. FY2025 revenue: Malaysia 60% (billing geography), China 18%, US 8%, Singapore 7%, others 8%. Malaysian electronics-export policy and US tariff actions affect the KESM cost base directly.

Cycle risk. Revenue declined for three consecutive years from FY2022 (S$100.7m) to FY2025 (S$73.0m), a 28% peak-to-trough. The cycle bottom is now plausibly behind, but the FY2026 recovery is one half-year of data.

Texas litigation. Weatherford v. KES Systems, Inc. (filed May 2019, Midland County, Texas) remains active as of the FY2025 annual report. Sunright has made no provision; financial exposure is unquantified. EDGAR full-text search of Weatherford International plc 10-K filings 2019–2026 returned zero hits for “KES Systems”; the case is not separately disclosed in Weatherford’s SEC filings, which suggests the company considers it immaterial to the plaintiff’s USD 5bn-revenue scale. The fact that Weatherford does not surface KES Systems in its disclosures does not bound Sunright’s exposure; it merely indicates the absence of a public quantum signal.

Holding-company governance. Samuel Lim holds 54.94% of Sunright and is Executive Chairman and CEO of both Sunright and KESM; Kenneth Tan Teoh Khoon is Executive Director of both. Capital allocation sits with overlapping boards under a single controlling shareholder.

Currency. KESM’s MYR revenue translates into Sunright’s SGD reporting; FY2025 reported S$3.5m of FX translation gain in OCI. Generally a wash, but volatile period to period.

Deep dive: the holding-company arithmetic

The central thing to understand about Sunright is not in the consolidated statement of profit or loss. It is in the relationship between two stock prices.

At the close of 7 May 2026, Sunright was at S$0.895 per share, with 122.806m shares outstanding, for a market capitalisation of S$109.91m. KESM Industries was at MYR 4.56 per share, with 43.0145m shares outstanding, for a market capitalisation of MYR 196.15m. At the spot exchange rate of MYR/SGD 0.323 (Yahoo Finance, 7 May 2026), KESM’s market capitalisation translates to S$63.36m. Sunright owns 48.41% of KESM, so the market value of Sunright’s KESM stake is S$30.67m.

Sunright’s market capitalisation decomposes look-through. Group equity attributable to owners at 31 January 2026 was S$72.18m. Of that book, approximately S$50m is Sunright’s 48.41% share of KESM’s standalone book equity (KESM standalone equity at 31 July 2025: MYR 339.17m). The remaining ~S$22m sits at the Singapore parent and smaller non-KESM subsidiaries.

When the market values Sunright at S$109.91m and 48.41% of KESM at S$30.67m, it is implicitly valuing “Sunright ex-KESM” at S$79.24m against an accounting book of approximately S$22m. The result is two very different multiples on the same balance sheet:

• KESM stake: market value S$30.67m, consolidated book ~S$50m → 0.61x P/B

• Sunright ex-KESM (Singapore parent + non-KESM subs + treasury): implied market value S$79.24m, attributable book ~S$22m → 3.6x P/B

In plain terms: the market pays about 61 cents on the dollar for KESM’s share of the operating business (factories, equipment, working capital, cash), but roughly $3.60 per dollar for the Singapore holding shell that owns it. Same physical assets, valued differently depending on which exchange you look through. The two multiples sit on either side of the headline 1.52x P/Attributable NAV, and they do not move together.

If KESM rerated to 1.0x book over 18 months (MYR 7.89 per share, a +73% move from MYR 4.56), Sunright’s stake would rise to S$53.0m, an uplift of S$22.4m or 18.2 cents per Sunright share. That is the size of the convergence trade available to a Sunright shareholder if the Bursa view of KESM closes the gap to consolidated book.

The convergence trade requires more than waiting. KESM has traded below book for most of the past five years. Closing the gap requires sustained earnings improvement at KESM specifically, not at Sunright in aggregate. KESM’s standalone 1HFY2026 result (Bursa, 10 March 2026) was a modest revenue uplift to approximately RM108m, +4% YoY. If Q3 and Q4 FY2026 continue that direction, the gap narrows. If they don’t, Sunright’s 3.6x ex-KESM multiple gets very hard to justify on a Singapore parent that generated S$5.3m of FY2025 revenue and is loss-making at the entity level.

Management

Samuel Lim Syn Soo, Executive Chairman and CEO since founding in 1978, is 71 years old. The succession question is not formally addressed in the FY2025 annual report or in the 21 November 2025 AGM presentation. Kenneth Tan Teoh Khoon, age 68, has been Executive Director since 1992 and is the long-standing financial steward of the group; he sits on both the Sunright and KESM boards. Ms Lim Mee Ing, age 74, is a Non-Independent Non-Executive Director on the KESM board (since 1990) — surname coincidence aside, her presence is itself a governance flag for minority investors who care about director-related-party concentration. Daniel Soh is Sunright’s Lead Independent Director (also age 71). The board added Dr Babak Alizadeh Taheri, an independent director with technology and governance background, on 22 November 2024, consistent with SGX corporate governance code refresh requirements. No internal successor has been named publicly for either Lim’s role.

The capital allocation track record is mixed. Cash has been preserved (S$84m at FY2025 versus S$93m at FY2019), but capex was held below depreciation for most of the post-FY2020 period, implying capacity contraction in real terms. Dividend distribution has been near-zero. The S$11.1m H1 capex pulse is the most material pivot in five years. Management has not provided forward guidance.

The most material governance disclosure is the Lim dual role. Samuel Lim is Executive Chairman and CEO of Sunright (Singapore) and Executive Chairman and CEO of KESM Industries (Malaysia). The two roles cannot, in principle, be conflict-free at all times — KESM’s dividend policy, KESM’s capex priorities, and Sunright’s capital allocation between Singapore and Malaysia all involve choices between Sunright minority interests and KESM minority interests. Lim’s 54.94% stake in Sunright aligns him with Sunright shareholders; the KESM stake (held through Sunright) aligns him with KESM majority. The two minorities — Sunright SGX retail and KESM Bursa retail — receive whatever is left after both controlling stakes have voted. There is no public evidence of mismanagement, but the structural arrangement creates a permanent asymmetry that minority investors should price.

Valuation

Bull vs Bear

Bull case. The 1HFY2026 print is the first half-year in three years where revenue and operating direction agree. Sunright/KESM describe themselves as the largest independent package-level burn-in service operators, and the AI hyperscaler capex cycle that drove Aehr’s record USD 41m PLBI booking in April 2026 is direct demand validation for the same architecture KESM operates in. The S$11.1m of 1HFY2026 capex is leveraged exposure to AI-driven utilisation gains. The S$67.6m of net cash supports the downside. If KESM reports a strong 2HFY2026 and Bursa reflects the recovery, Sunright shareholders capture both the consolidated earnings recovery and a partial closure of the P/NAV gap. With FY2027 attributable equity of ~S$80m (flat NCI, S$10m cumulative profit accrual) and Sunright at 1.5x attributable NAV, the share price is S$0.98 — modest single-digit upside. At 2.0x attributable NAV, S$1.30, or ~46% upside. Either requires KESM execution.

Bear case. The S$0.895 share price already reflects two consecutive halves of operating recovery and an AI narrative. The 12-month low was S$0.153; almost the entire upside has been delivered in the seven months since October 2025. KESM’s Bursa share price has not moved with comparable amplitude. If hyperscaler PLBI volumes flow to integrated equipment vendors (Aehr) rather than third-party services (KESM), the S$11.1m capex underutilises and depreciation drag pulls ROIC back toward zero. A second half-year of sub-MYR 200m KESM revenue combined with any Texas litigation development would compress the multiple toward 1.0x attributable NAV (S$0.59), a 34% drawdown. The bear case is not catastrophic — net cash supports a floor — but the asymmetry of upside-already-banked versus downside-still-possible deserves underwriting at current prices.

What would break the thesis

The bull case fails on any of the following:

• KESM execution: two consecutive flat or negative-growth quarters in 2HFY2026 (Q3 announcement ~10 June 2026, Q4 ~25 September 2026).

• Competitive displacement: Aehr Test Systems wins additional package-level burn-in orders from hyperscale customers that are also customers of KESM.

• Capital allocation signal: KESM declares a total FY2026 dividend substantially above the 6 sen FY2025 level, signalling capital being returned rather than reinvested and contradicting the H1 capex narrative.

• Customer concentration: any one of the three customers contributing 66% of FY2025 revenue migrates volume to a competitor.

• Labour leverage: FY2026 full-year employee expense ratio above 44% (vs 41.3% in 1HFY2026, 45.9% in FY2025). A higher reading would signal the labour cost is structural rather than cyclical and would invalidate the operating-leverage component of the bull case.

The bear case fails (i.e. the bull case holds) if the FY2026 full-year results published in September 2026 show group revenue above S$90m and net profit attributable to owners above S$5m. That print would re-anchor the multi-year baseline.

Data points to monitor:

• KESM Bursa filings — Q3 FY2026 due ~10 June 2026, Q4 FY2026 due ~25 September 2026.

• Sunright FY2026 results announcement — ~late September 2026.

• Aehr Test Systems FY2027 quarterly bookings disclosures — NASDAQ filings.

• Customer concentration disclosure in the next Sunright annual report.

The Bottom Line

Sunright is a real operating business going through a real recovery, controlled by a real founder and supported by a real net cash position. None of those things are in question.

What is in question is whether the price the SGX is currently asking for that combination — 1.5x attributable book, 0.85x group book, on a stock that has rallied roughly 5x off its 12-month low — has overshot the operating evidence. The answer requires a view on KESM, not on Sunright. KESM’s own market — Bursa Malaysia — currently rates the operating business at 0.58x book, and that view has not materially changed during Sunright’s rally. The Sunright premium is therefore borrowed against an expected closure of the Singapore-Malaysia valuation gap. That closure is plausible. It is not yet evidenced.

A buyer at 89.5 cents is buying optionality on convergence, on AI-driven utilisation, and on a capex pulse delivering returns. A seller is taking the gain on the rally and acknowledging that the convergence trade has timing risk. Neither side is wrong. The article offers no recommendation, only the observation that the asymmetry between the two listings is the most important fact about the share price today, and that fact deserves to be owned as a position whether one is long, short, or absent.

The institutional-length version of this analysis — the historical and structural context, the industry context, the math behind every number, and the data points to monitor going forward — is available to Paid members. Read it here.

Data Integrity Notes

This article uses only company-filed data from SGX and Bursa Malaysia announcement systems and the FY2020–FY2025 annual reports of Sunright Limited and KESM Industries Berhad. Share price and market-capitalisation figures are from Yahoo Finance, retrieved 7 May 2026.

Known limitations: (1) Weatherford v. KES Systems, Inc. (Texas, filed May 2019) remains active. No provision; financial exposure is unquantified. EDGAR full-text search of Weatherford International plc 10-K filings 2019–2026 returned zero hits for “KES Systems”; no public quantum is assignable. (2) Sunright reports expenses by nature rather than function — gross profit is not separately disclosed and “Direct materials cost” is the closest proxy in the Financial Scoreboard. (3) Detailed KESM segment data was sourced from KESM’s own Bursa filings rather than Sunright’s summarised disclosures. (4) The FY2025 Sunright AR discloses three customers at 66% of revenue but does not name them; customer-level analysis is directional. (5) KESM's 1HFY2026 quarterly result (Bursa filing dated 10 March 2026) was available to us at draft date; the +4% YoY revenue trajectory and the loss-to-profit PBT swing were cited based on two third-party summaries. The primary Bursa filing was obtained post-publication (2026-05-11) and verified: all third-party-corroborated figures match the source filing exactly (revenue RM107.95m, PBT RM6.66m vs RM8.08m loss, cash RM195m, 6 sen interim dividend). No corrections required. (6) MYR/SGD spot rate of 0.323 is used throughout.

References

[1] Sunright Limited, Annual Report 2025 (SGX filing dated 26 September 2025).

[2] Sunright Limited, Annual Report 2024 (SGX filing dated 27 September 2024).

[3] Sunright Limited, Annual Report 2023, Annual Report 2022, Annual Report 2021, Annual Report 2020, Annual Report 2019 (SGX filings).

[4] Sunright Limited, Condensed Interim Financial Statements for the First Half Year ended 31 January 2026 (SGX filing dated 13 March 2026).

[5] Sunright Limited, Full-Year Results announcements FY2020–FY2025 (SGX filings).

[6] Sunright Limited, Press Release — 1HFY2026 (SGX filing dated 13 March 2026).

[7] KESM Industries Berhad, Annual Report 2025 (Bursa Malaysia filing dated October 2025).

[8] KESM Industries Berhad, Annual Reports 2020–2024 (Bursa Malaysia filings).

[9] KESM Industries Berhad, Quarterly Results Q2 FY2026 (Bursa Malaysia filing dated 10 March 2026).

[10] The Edge Singapore, “Sunright returns to profitability in 1HFY2026, with net profit of $1.4 mil” (13 March 2026). https://www.theedgesingapore.com/capital/results/sunright-returns-profitability-1hfy2026-net-profit-14-mil

[11] The Edge Singapore, “As interest moves to semiconductor value chain stocks, the STI continues consolidation” (24 April 2026). https://www.theedgesingapore.com/capital/right-timing/interest-moves-semiconductor-value-chain-stocks-sti-continues-consolidation

[12] Aehr Test Systems Inc, “Aehr Receives Record $41 Million Production Order from Lead Hyperscale AI Customer; Second-Half Bookings Exceed $92 Million” (April 2026). https://www.aehr.com/2026/04/aehr-receives-record-41-million-production-order-from-lead-hyperscale-ai-customer-second-half-bookings-exceed-92-million/

[13] Yahoo Finance, Sunright Limited (S71.SI) share-price and market data, retrieved 7 May 2026. https://finance.yahoo.com/quote/S71.SI/

[14] Yahoo Finance, KESM Industries Berhad (9334.KL) share-price and market data, retrieved 7 May 2026. https://finance.yahoo.com/quote/9334.KL/

[15] Grand View Research, “Outsourced Semiconductor Assembly And Test Services Market To Reach $67.92Bn By 2030” (press release). https://www.grandviewresearch.com/press-release/global-outsourced-semiconductor-assembly-test-services-market

[16] Virtue Market Research, “Wafer-Level Burn-In & Reliability Testing Market | Size, Overview, Trends, and Forecast | 2026–2030”. https://virtuemarketresearch.com/report/wafer-level-burn-in-reliabilit-testing-market

[17] Minichart, “KESM Industries Berhad Q2 2026 Financial Results: Revenue Growth, AI Chip Demand, and Profit Recovery” (10 March 2026). https://www.minichart.com.sg/2026/03/10/kesm-industries-berhad-q2-2026-financial-results-revenue-growth-ai-chip-demand-and-profit-recovery/

IMPORTANT DISCLAIMERS

This article is published for informational and educational purposes only. It does not constitute financial or investment advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The author is not a licensed financial adviser under the Financial Advisers Act 2001 of Singapore, nor a licensed adviser under the Capital Markets and Services Act 2007 of Malaysia. This content is exempt from the requirements of the Singapore Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication. This publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, readers should consult a licensed financial or investment adviser in their relevant jurisdiction. Past performance is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author may or may not hold positions in the securities discussed. No compensation has been received from any company mentioned in this article.

For most of the past decade, Sunright Limited’s share price moved like a SGX small-cap nobody cared about: a few cents either way, divid…

Read more

The company name itself tells part of the story. In Chinese characters, Sheng Siong is written 昇菘, where 昇 (sheng) carries the sense of “to rise” or “to prosper” in Mandarin, and 菘 (siong) is a classical name for the Chinese leafy-green vegetable family that includes bok choy and Chinese cabbage. It is a fitting label for a chain whose founding identity was anchored in fresh produce. Founders Lim Hock Eng, Lim Hock Chee and Lim Hock Leng started the business in 1985, after working in their family’s hog-rearing trade [13], and over forty years built it into a chain whose stated mission has not really shifted: deliver value-for-money daily essentials to heartland families, especially residents of HDB estates, with quality products at competitive prices.

What most people have not done is looked at the company itself as an investment. Sheng Siong Group Ltd. (Singapore Exchange ticker: OV8) is today the third-largest supermarket chain in Singapore, listed on the Singapore Exchange (SGX) Mainboard in August 2011. In its FY2025 financial year ended 31 December 2025, the Group generated S$1.57 billion in revenue and S$149.2 million in net profit, finished the year with S$435.5 million in cash and zero conventional debt, and paid 7.0 cents per share in dividends, a fresh record.

At the share price of roughly S$3.08 in late April 2026, the company carried a market capitalisation of approximately S$4.0 billion [1], placing it just inside Singapore’s mid-cap index neighbourhood. The numbers behind that headline are quietly extraordinary. The story behind those numbers, and whether that story is already fully discounted, is what this article tries to unpack.

A Forty-Year Journey: From Pork Stall to S$4 Billion Grocer

Sheng Siong’s origin is a textbook Singapore growth story. Brothers Lim Hock Eng, Lim Hock Chee and Lim Hock Leng worked in their family’s hog-rearing business before founding the chain in 1985 [13]. The early decades were unglamorous. The chain ground out store-by-store growth, leaning on direct sourcing relationships, value pricing, and a “wet-and-dry” format that combined live seafood, fresh produce and packaged groceries under one roof. It was the format Singaporean heartlanders had grown up with in traditional wet markets, simply put under the air conditioning of a supermarket anchored to a Housing and Development Board (HDB) estate.

The Initial Public Offering (IPO) on the SGX Mainboard in August 2011 marked the first inflection. With listing proceeds and operating cash flow, the Group built a purpose-built central headquarters and distribution centre at Mandai Link, which has anchored Singapore operations ever since. Online grocery followed in 2014, later rebranded as “Sheng Siong Online” in 2021, and a tentative move overseas opened a first store in Kunming, China in 2017.

The next inflection was COVID. Stockpiling drove revenue from S$991 million in FY2019 to S$1.39 billion in FY2020, and net profit jumped 84% to S$139 million in a single year. Investors who treated this as a new run-rate were modestly disappointed when revenue normalised slightly lower in FY2021 and FY2022. The retreat, however, was shallow: total revenue dipped only about 4% off the FY2020 peak, and profit dipped about 4% in FY2021 before re-stabilising. There has not been a year since the IPO when Sheng Siong failed to make money or skipped a dividend.

The most aggressive year in the Group’s listed history is the most recent one. In FY2025 the Group opened twelve new stores in Singapore, comfortably above the long-run guidance of three to five per year, and accepted an offer from JTC Corporation (the government-linked industrial real estate developer) to develop a new central distribution centre at Sungei Kadut. The new distribution centre is expected to be operational around 2029 or 2030, and is sized to support at least 120 stores. As part of the deal, the Group must sell or assign the existing Mandai Link property to a buyer approved by JTC Corporation, which triggered a S$2.2 million gain on lease modification recorded in the FY2025 results. In late 2024 the Group also acquired Jelita Property Pte Ltd for S$49 million, securing freehold investment property and a flagship store location. That was the only material corporate deal in years.

What Sheng Siong Actually Does

Sheng Siong reports as a single operating segment: supermarket retail of consumer goods. The simplicity is a feature of the thesis, not a bug. The Group makes its money in four reinforcing ways. The first is direct sourcing and house brands. As of the latest annual report, the Group carries 2,035 stock-keeping units (SKUs) across twenty-eight house brands, including Tasty Bites, Heritage Farm, HomeNiks, Phizz and Happy Family, which both expand gross margin and provide a defensive lever when consumers downtrade. The second is a heartland store rollout where most outlets sit in HDB estates whose rents are tendered through HDB and JTC Corporation processes, structurally cheaper than central business district or shopping mall locations. That said, the FY2025 openings of stores at Leisure Park Kallang and at The Cathay (the Group’s first Orchard Road outlet) demonstrate that the chain can also operate centrally when the rent maths works. The third is a centralised supply chain anchored by the Mandai Link distribution centre, soon to be replaced by Sungei Kadut. The fourth is a still-small but growing online and quick-commerce channel through Sheng Siong Online and the Sheng Siong app, supplemented in early 2025 by a quick-commerce partnership with Deliveroo.

Geographic exposure is overwhelmingly Singapore. The domestic market generated approximately 97.6% of FY2025 revenue, with six stores in Kunming, China contributing the remaining 2.4% and recording a small net deficit for the year amid intense local competition. A long-dormant Malaysian subsidiary remains inactive. The more revealing point is that the Group has not used this dormant subsidiary to make any move into Malaysia despite eight years of cross-border opportunity, even as the Group expanded steadily in Singapore over the same period. If the easiest adjacent market on Sheng Siong’s doorstep has not been pursued, the message about how rigorously the Group screens overseas opportunities is a clear one. The China presence, in turn, is best read as a small, low-capital test lab rather than a regional growth engine. For practical purposes, Sheng Siong is a pure-play Singapore consumer staple, with optional overseas upside that management has deliberately kept on a short leash.

Industry: A Defensive Triopoly Reshaped by Consolidation

Singapore’s grocery retail market is approximately US$36 billion in size and has historically been dominated by three players [3, 5]. The largest is NTUC FairPrice, the cooperative chain with over 370 outlets and a market share above 40%. The second, until very recently, was DFI Retail Group’s Singapore food business, the operator of Cold Storage, CS Fresh, Jason’s Deli and Giant. The third has been Sheng Siong, the heartland-value challenger. Below this top three sit smaller players such as Prime, Mustafa and Don Don Donki, which collectively occupy a single-digit share. The category itself is famously defensive: Singapore consumers buy groceries through inflation, recession, war and pandemic, with relatively low elasticity of demand.

Consolidation: DFI’s Exit and What It Means

The most significant change in the competitive landscape in years is happening right now. In March 2025, DFI Retail Group announced the divestment of its entire Singapore food business (48 Cold Storage, CS Fresh and Jason’s Deli stores, 41 Giant stores, and two distribution centres) to Macrovalue, a Malaysian-headquartered retail conglomerate, for an initial consideration of S$125 million [12]. The transaction was expected to close in the second half of 2025. DFI’s stated rationale was straightforward. In 2024, the food segment had a segment operating margin of just 1.8%, against 8.6% for its Health & Beauty (Guardian) business and 4.3% for Convenience (7-Eleven) [12]. The same Macrovalue group acquired DFI’s Malaysian food business in 2023, so the buyer is a known operator stepping into a familiar role rather than a financial sponsor with no retail track record.

For Sheng Siong, the implications run on two timeframes. In the short term, any ownership transition creates operational disruption, including staff turnover, supplier renegotiations, and customer churn during repositioning, and the most natural beneficiary of marginal customer outflow is the next-cheapest heartland alternative, which is Sheng Siong. In the medium term, the competitive picture depends on Macrovalue’s execution: a sharper, more focused regional owner could revitalise Cold Storage and Giant in ways that DFI did not, in which case the threat moves the other way. The transition also subtly recalibrates the league table. With Sheng Siong at eighty-seven Singapore stores and the former DFI portfolio at eighty-nine, what used to be a clear hierarchy is now a near-tie at the number-two spot by store count, and Sheng Siong already exceeds the former DFI Singapore food business in profitability by a wide margin.

Structural Tailwinds: Aging, Vouchers, Cost-of-Living

The macro backdrop in 2025 was supportive in a specific way. The Monetary Authority of Singapore (MAS) Core Inflation averaged 0.7% in 2025, moderating sharply from 2.8% in 2024, but consumers continued to skew towards value-driven shopping. That dynamic plays directly into Sheng Siong’s positioning. MAS now projects core inflation in a 1–2% range for 2026, slightly higher but still benign, while the Ministry of Trade and Industry (MTI) forecasts 2026 Gross Domestic Product growth in the 2.0–4.0% range [4].

Beyond the cyclical picture, three structural tailwinds matter more for the next decade than any single year’s GDP print. The first is Singapore’s aging population. The proportion of residents aged sixty-five and over is rising steadily and is projected to reach roughly one in four by 2030 [14], a demographic profile that broadly suits a chain of nearby, value-priced stores embedded in residential estates. The implication is two-sided. Demand for staple groceries becomes more stable and more recession-resistant, but the absolute growth rate of grocery spending per capita is unlikely to accelerate sharply because older households generally consume at lower volumes than younger families. Net-net the aging shift looks supportive for Sheng Siong’s positioning, even if it does not lift overall category growth on its own.

The second tailwind is government cost-of-living support. Budget 2026 voucher schemes, Community Development Council (CDC) vouchers redeemable at participating supermarkets, and the Progressive Wage Credit Scheme (PWCS) all act to channel discretionary spending into the supermarket channel and to underwrite consumer purchasing power in a way that disproportionately benefits value-positioned chains. The third tailwind is population growth and the HDB pipeline itself. Every new HDB estate is a tendered store opportunity, and the Singapore government’s ongoing residential build-out is the single largest organic source of new addressable square footage for Sheng Siong over the next decade.

Structural Headwinds and Slow-Burn Risks

The headwinds are tangible too. Singapore’s labour market is structurally tight, and aging works in the opposite direction here. A smaller working-age population means a tighter retail workforce. The Progressive Wage Model (PWM) for the retail sector is phasing in further wage increments, with Sheng Siong raising retail workers’ salaries again in September 2025 to comply with the PWM. The Beverage Container Return Scheme (BCRS) begins on 1 April 2026, adding incremental compliance complexity and modest cost pass-through.

Quick commerce and electronic grocery (RedMart, Grab, and the e-commerce build of FairPrice) is best understood as a slow-burn risk rather than an immediate disruption. Online does eat into small, frequent, dry-grocery purchases and is more relevant to younger consumers, but it is structurally weak in fresh produce (where customers still want to choose what they buy), expensive to run on a per-order basis given Singapore’s high last-mile costs, and disproportionately less relevant to the older heartland shopper who is overrepresented in Sheng Siong’s footfall. The likely path is gradual erosion at the margin rather than a step-change, and Sheng Siong’s online and app channels are themselves growing in absolute terms.

The Johor Bahru–Singapore Rapid Transit System (RTS) Link, scheduled to commence operations in late 2026 or early 2027, may divert some price-sensitive grocery spending across the Causeway. The impact is hard to size in advance, and management has acknowledged the uncertainty publicly. It is worth noting that grocery shopping is mostly a local, repeat-frequency activity, so cross-border shopping is unlikely to be daily behaviour even at the most price-sensitive end. There is also a possible offset on the labour side: easier cross-border movement could marginally ease the supply of retail workers, partially offsetting the wage-cost ratchet.

Cost pressure beyond labour is the final piece. Singapore imports a very high share of its food, which makes the supermarket channel structurally exposed to global commodity volatility and to currency translation, particularly against the US dollar for protein and grains and against regional currencies for fresh produce. Sheng Siong does not disclose a detailed foreign-exchange hedging policy, but the income statement does show meaningful unrealised exchange gains and losses on US-dollar-denominated fixed deposits in different years. Investors should treat input-cost and currency volatility as a normal feature of the business rather than a one-off risk.

The Moat: Cost, Convenience, Habit (and Where the Defences Thin)

Sheng Siong’s moat is not a single feature but a stack of overlapping advantages, most of which are anchored in consumer behaviour rather than in technology or ecosystem effects. Each one is individually shallow; layered together they are surprisingly durable.

The most foundational layer is cost leadership. Forty years of direct-sourcing relationships, a house-brand catalogue of 2,035 SKUs across twenty-eight brands, and a low-cost central distribution centre at Mandai Link give Sheng Siong a structural cost position that allows it to price below premium peers like Cold Storage and still expand gross margin. The proof is in the multi-year track record. Gross margin has climbed from 24.7% in FY2015 to 31.3% in FY2025 without any pricing-power moves that would have alienated value-seeking shoppers, and that path is the single hardest piece of the moat to replicate. Catching up requires either decades of supplier-relationship building or a willingness to subsidise pricing for a long period, neither of which is rational for a competitor with shareholders.

The second layer is location in the HDB heartlands. Most Sheng Siong outlets sit inside or beside HDB estates, embedded in the residential fabric of the city. In groceries, the rule of thumb is that the nearest acceptable option wins, because the basket is small, the trip frequency is high, and convenience compounds over many small purchases. HDB grocery slots are tendered competitively, but once secured a store anchors a community for years and is rarely displaced. Many Sheng Siong outlets have stood at the same address for over a decade, building footfall habits that are genuinely sticky. The recent FY2025 openings at Leisure Park Kallang and at The Cathay (the Group’s first Orchard Road store) demonstrate the chain can also operate centrally when the rent maths works, but the heart of the moat remains the heartland.

The third layer is fresh-food strength. Sheng Siong’s “wet-and-dry” format combines live seafood, fresh meat, fruits and vegetables under the same roof as packaged groceries. It is the format Singaporean shoppers grew up with in traditional wet markets, simply ported into air-conditioned stores anchored to HDB estates. Fresh-food shopping is the part of the grocery trip that is hardest for online players to displace, because customers want to see and choose what they buy, particularly for fish and produce. Pure-play online grocers like RedMart, and the e-commerce build of the FairPrice Group, have made meaningful inroads in dry packaged categories where the customer is comfortable trusting the picker, but fresh remains a category where physical store experience is genuinely preferred. The fresh-food layer is also a partial defence against premium grocers like Cold Storage, whose fresh selection is positioned at materially higher price points and whose customer base does not overlap with Sheng Siong’s heartland shoppers.

The fourth layer is operational excellence and inventory discipline. Sheng Siong’s negative-working-capital model is partly behavioural (high inventory turnover, disciplined replenishment, low spoilage) and partly structural, because the central distribution centre at Mandai Link is the single physical asset that lets all of these efficiencies compound. Each marginal improvement in inventory days, shrink rate or supplier terms flows directly to operating cash flow, because the company is not re-investing capital to grow at the same time. Free-cash-flow conversion above 90% in FY2025 is a downstream readout of this discipline rather than an accident of any single year. The new Sungei Kadut distribution centre, sized to support 120-plus stores and expected operational by 2029 or 2030, is a deliberate decision to lift this layer further over the long run, even though it will visibly compress reported free cash flow during the build period.

The fifth layer is the value positioning and habit moat. After four decades of consistent messaging, Sheng Siong’s mental shortcut among Singaporean consumers is “cheap and reliable.” That is a durable consumer asset that is hard to value precisely but easy to underestimate. Loyalty programmes from competitors (yuu Rewards Club at DFI Retail, covering Cold Storage and Giant, and LinkPoints at FairPrice) exist and have meaningful enrolment, but they have not noticeably disrupted Sheng Siong’s customer base. The reason is structural rather than tactical: the price gap on a weekly grocery basket is typically larger than the points value redeemable through any rewards programme, and convenience matters more than points to most heartland shoppers. The implicit habit of defaulting to Sheng Siong without re-evaluating each visit is the moat that consumer-staples investors recognise instinctively but that does not show up in any single financial metric.

Beneath these five consumer-facing layers, two further moats sit at the company level rather than the customer level. The first is founder-operator alignment, which is rare among SGX-listed mid-caps. All three Lim brothers remain on the board, with deemed beneficial interests of 44.5%, 44.8% and 46.4% respectively. CEO Lim Hock Chee is in his late sixties and still hands-on, and the second generation has been seeded into operating roles since 2024. Lin Ruiwen sits on the main board, while Lin Yuansheng, Lin Junlin and Lin Zikai serve as directors of the operating subsidiary Sheng Siong Supermarket Pte Ltd. The second is the balance-sheet moat: S$435 million in net cash representing roughly 10.9% of market capitalisation, and zero conventional debt, which give the Group countercyclical optionality that few global grocery peers can match.

Where the Moat Is Weaker

It is just as important to be clear about where the defences thin out. The first weak spot is technology and electronic commerce. Sheng Siong’s online and quick-commerce footprint remains modest, and the Deliveroo Singapore partnership launched in early 2025 hit an unforced setback when Deliveroo announced it would cease Singapore operations. Pure-play online grocers like RedMart, and FairPrice’s own e-commerce build, have invested more aggressively in the digital experience and in last-mile fulfilment. Sheng Siong’s app and online channels are growing, but they are following rather than leading.

The second weak spot, depending on how you read it, is overseas scalability, and this one deserves a more careful framing than a simple line. The advantages that work in HDB Singapore (heartland location, low-cost central distribution, deep local supplier relationships) do not travel well, and the six-store presence in Kunming reflects how hard it is to replicate the formula in unfamiliar real-estate, supply-chain and consumer-behaviour environments. The important nuance is that this is largely a deliberate strategic discipline rather than a managerial inability. Management’s stated approach is to expand overseas only where the Group can credibly replicate its edge, and so far it has assessed that neither Malaysia nor most of China clears that bar. Malaysia, in particular, is the strongest signal. A dormant subsidiary is sitting one Causeway away from the Singapore base, and management has actively declined to revive it because the supply chain is more complex and the cost advantage that anchors the Singapore model is absent in the Malaysian retail market. The trade-off is that Sheng Siong is, by its own choice, capping its addressable market at Singapore plus a small China test lab. The growth ceiling is real even if the discipline is laudable, which is precisely the tension this article keeps coming back to.

The third weak spot is switching costs. There are essentially none. Customers can walk into any other supermarket without friction, and any sustained price war from a deeper-pocketed competitor would force Sheng Siong either to follow it down or watch traffic erode. So far the value gap has been wide enough, and competitor margins thin enough, to insulate the chain from this scenario, but it is a permanent rather than a one-off vulnerability.

Stepping back, the durability ranking matters more than the count. The cost-leadership and value-positioning layers are the most defensible, because both compound through repeat consumer behaviour rather than through capital expenditure. The fresh-food and location layers are nearly as durable but are exposed to slow shifts in consumer preference (more delivery, and from late 2026 more cross-border shopping via the RTS Link to Johor) and in real-estate cycles (HDB tender renewals). The operational-excellence layer is durable and self-reinforcing, but the new distribution centre capex cycle will narrow its visible benefit during the build period. The founder-operator and balance-sheet moats are the ones that change most over the next five to ten years, because family succession will be tested and net cash will fall as Sungei Kadut is funded. None of this is flashy. It is built on cost, convenience and consumer habit, not on technology, network effects or ecosystems. Whether that combination is enough at the price the market is asking today is the question the rest of this article tries to address.

Ten-Year Financial Scoreboard

A few features stand out in the long-run track record. Revenue compounded at roughly 7.5% per year from FY2015 to FY2025; even stripping out the COVID bump, the underlying compound annual growth rate (CAGR) is around 6.5%, which is solid for a low-growth category. Net profit compounded faster, at approximately 10.1% per year, and the gap between revenue and profit growth is the single most important number on the page. It is a direct readout of management’s “sales-mix optimisation plus house brands plus direct sourcing” thesis: gross margin expanded from 24.7% in FY2015 to 31.3% in FY2025, six full percentage points over a decade. Earnings per share more than doubled from 3.78 cents to 9.94 cents, despite zero share issuance. The share count has been a flat 1,503,537,000 since the IPO. Dividends per share doubled from roughly 3.5 cents to 7.0 cents, and the payout ratio held remarkably steady at around 70% across the cycle.

The balance sheet has fattened in step with profits. Cash has grown from S$87 million at end-FY2018 to S$435 million at end-FY2025, accumulated despite paying out roughly S$96 million per year in dividends. Equity has nearly doubled to S$591 million. The lease liability number on the balance sheet looks worse than it really is. It is almost entirely operating leases on store space that previously did not appear on the balance sheet (Singapore Financial Reporting Standards 16 took effect from 2019), and is offset on the asset side by right-of-use assets of similar magnitude. Net asset value per share has compounded from 19.4 cents at end-FY2018 to 39.1 cents at end-FY2025, doubling in seven years.

Returns on Capital: Best in Class

Return on Equity (ROE) has been above 25% in eight of the last ten years, peaking near 40% during COVID and settling around 26–27% in FY2024 and FY2025. Return on Invested Capital (ROIC) is structurally a few percentage points lower because of the lease-liability denominator, but still above 19% in FY2025. For context, the Group was awarded “Highest Weighted ROE Over Three Years” in the Consumer Defensive industry by The Edge Billion Dollar Club for the third consecutive year [11].

The quality of those returns matters as much as their level. Revenue is paid in cash at the till; working capital is structurally negative, since suppliers fund inventory; capital expenditure requirements are modest in steady state; and incremental gross profit drops nearly intact to operating cash flow. The picture is one of a business that does not need to be re-capitalised to grow, which is why the dividends have been paid every year without strain.

In FY2025 the Group generated S$236.6 million in operating cash flow against capital expenditure of just S$20.9 million. That is a free cash flow conversion ratio above 90%, and a free cash flow figure that comfortably covers the dividend with room to spare. The new Sungei Kadut distribution centre will eventually pull this conversion ratio down for several years, but the trough of free cash flow cover should still leave the dividend intact under management’s communicated plan.

Eleven Years of Dividends: Never Cut, Raised Again

Sheng Siong has paid an interim and a final dividend every year since the IPO, almost always inside a self-imposed 70% payout-ratio policy. The FY2025 final dividend of 3.80 cents per share, up from 3.20 cents the year before, brings total FY2025 dividends to 7.0 cents, a fresh record, payable on 15 May 2026 subject to Annual General Meeting (AGM) approval on 29 April 2026. At the April 2026 share price of S$3.08, the trailing yield is roughly 2.27% [1]. Consensus expectations for FY2026 imply a forward dividend per share around 8.0 cents [2], which would lift the forward yield closer to 2.6%. Modest in absolute terms, but the yield sits on top of organic earnings growth. The total-return profile is closer to a “dividend grower” than a “dividend stalwart”, and the payout has never been funded out of incremental debt.

Growth Drivers Over the Next Three to Five Years

The most visible growth driver is the store rollout. Management opened twelve stores in FY2025 against long-run guidance of three to five per year, and the pipeline includes a secured site at Blk 120 Canberra Crescent, a new store at 11 Rivervale Crescent expected to open in 3Q 2026, and five further tender results pending. The new distribution centre is sized to support at least 120 stores, and the Group’s stated growth aspiration is to add three new stores per year for ten to fifteen years, implying a network of around 117 to 132 stores by the late 2030s. That is roughly 3–5% network growth per year on top of comparable-store growth, which was +1.4% in FY2025.

The second driver is continued sales-mix and house-brand expansion. Gross margin expanded another 80 basis points in FY2025 to 31.3%, and each 100 basis points of additional gross margin is worth roughly S$15.7 million in pre-tax profit at current revenue.

The third is the new Sungei Kadut distribution centre, which is sized to support 120-plus stores and will lift productivity and supply-chain leverage when it comes online around 2029 or 2030. The trade-off is that meaningful capital expenditure must be funded in the late 2020s, and the Mandai Link disposal that anchors the JTC Corporation deal will be timed against this.

A fourth driver, more speculative, is online and quick commerce. Singapore consumers have shifted towards electronic commerce more slowly than peers in larger Asian markets, but the trend is unmistakable. The Deliveroo Singapore partnership launched in early 2025 hit a setback when Deliveroo announced it would cease Singapore operations, but management has stated it will continue to explore alternative quick-commerce partners and to develop the Sheng Siong app organically.

A fifth, almost optional, driver is China, but the right framing is closer to a test lab than to a growth engine. Six Kunming stores generated 2.4% of FY2025 revenue and a small net deficit, and the capital deployed there is small in the context of the Group’s S$1 billion-plus asset base. Management’s tone is unmistakably cautious, framed as “prudent and measured” expansion, and the explicit objective for FY2026 is to improve the performance of existing stores rather than to add new ones. The role of the China subsidiary in the investment thesis is therefore as cheap optionality. If Kunming eventually breaks even and the unit economics travel, that may, in time, support a more confident regional expansion. If it does not, the sums involved are small enough that the downside is contained, and management has shown both the willingness and the discipline to keep it that way.

Major Risks and the Bear Case

Six risks are worth sizing carefully, listed below in rough order of how likely they are to drive the share price over the next three years:

1. Valuation richness. At S$3.08 the stock trades at roughly 31x trailing earnings and 7.9x book [1]. That is a clear premium to DFI Retail Group at approximately 25x trailing earnings [8], and a wider premium to most US grocery comparables that trade in the 17–20x range. The premium reflects quality, balance sheet, and earnings predictability, but it leaves limited margin for execution slip-ups, and any half-year result that disappoints the consensus could compress the multiple meaningfully.

2. Margin ceiling. Six points of gross-margin expansion in a decade is rare, and the next 100 basis points will almost certainly be harder to extract than the last. If sales-mix improvement plateaus while wage costs keep ratcheting through Progressive Wage Model and Beverage Container Return Scheme compliance, gross margin could stall or modestly compress. Combined selling, distribution and administrative expenses grew about 12.5% in FY2025, faster than revenue growth of 9.9%. A pattern that, sustained, would erode operating margin even if gross margin holds.

3. Capex cycle. The Sungei Kadut distribution centre project plus continuing store openings means capital expenditure will step up materially from the recent S$20 million-per-year run-rate. Management has not disclosed a precise total budget, but a multi-year project of this scale and capacity will plausibly run into the hundreds of millions of Singapore dollars. Net cash is likely to fall meaningfully through the build period, although the exact trough depends on the project schedule and on Mandai Link disposal proceeds.

4. China underperformance. Six stores, eight years after entering Kunming in 2017, with the China subsidiary still loss-making in FY2025. Continued small deficit accumulation is a manageable distraction. An attempt to scale China meaningfully without first proving unit economics in Kunming would be a step-change in capital-allocation discipline that would have to be re-underwritten.

5. Founder transition. All three founder brothers are now in their late sixties or seventies. Management succession to the second generation is being telegraphed publicly (Lin Ruiwen on the main board, three other family members in operating director roles since 2024), but the handover has not yet been stress-tested.

6. Free-float and liquidity. The Lim family plus Sheng Siong Holdings own approximately 53% directly, with deemed interests pushing combined family control closer to 62%. Public free float is approximately 46.7%, but daily trading volume is modest by institutional standards, which partly explains why disclosed institutional holdings are unusually thin for a company of this market capitalisation.

A Closer Look at Sungei Kadut: Forced Re-Tooling, Not Free Choice

The most controversial item on the risk list deserves its own treatment, because the natural question for any investor is whether the new Sungei Kadut distribution centre is a sign of management over-confidence or a necessary defence of the cost-leadership moat against a freshly-owned Cold Storage and Giant under Macrovalue. The honest answer is neither, because the binary misses a frame that the FY2025 disclosure makes explicit: this is partly a forced re-tooling.

The over-confidence reading would say that the multi-year capital outlay runs to many multiples of the recent capex run-rate, and that filling distribution capacity sized for 120-plus stores requires a continuation of the very aggressive FY2025 opening pace of twelve stores rather than the long-run guidance of three to five. If store growth normalises, the new distribution centre is structurally over-built for at least a decade.

The moat-defence reading would say that Singapore’s structural labour squeeze (Progressive Wage Model wage increments, an aging working-age population) makes labour-intensive distribution more expensive year by year, and that a more automated centre is partly an insurance policy on wage inflation. Macrovalue is a focused regional operator with a track record of running DFI’s Malaysian food business since 2023, and it would be naive to assume Cold Storage and Giant’s supply chain will be left untouched over 2026 to 2028. Investing in distribution productivity during the window when the rival is still in ownership transition, rather than after it has fully revitalised, is sensible timing even if the absolute number is large.

What the binary misses is that this was not a free strategic choice. JTC Corporation offered the Sungei Kadut parcel conditional on the Group selling or assigning the existing Mandai Link property to a JTC-approved buyer by December 2031. The Group did not initiate the move; JTC did, by tendering a parcel that happens to fit Sheng Siong’s long-run capacity needs. Once that is understood, the question changes from “should the Group spend this much on an upgraded distribution centre?” to “was JTC’s conditional offer good enough to accept, given that staying at Mandai Link past 2031 was not really an option?” The S$2.2 million gain on lease modification booked in FY2025 is the early accounting signal that the swap is at least neutral on book terms.

The honest view, then, is closer to necessary forward-defence than to over-confidence. Strategic direction looks right, the timing relative to Macrovalue is sensible, and the productivity case against wage inflation is real. Execution risk is the hard part. Delivering a project of this scale to budget and on schedule, in Singapore’s tight construction labour market, with a four-to-five-year build window, is where this part of the thesis gets tested. If Sungei Kadut comes in on planned cost and on schedule, the moat-defence reading wins. If it slips materially in cost or to a 2031 delivery, the over-confidence reading wins retrospectively. For the next two to three years, project budget and schedule disclosures matter more than any single quarter’s same-store sales.

Management Quality and Capital Allocation

The promoter family has run this business for over four decades. Executive Chairman Lim Hock Eng was conferred the Pingat Bakti Masyarakat (Public Service Medal) in 2016 and the Bintang Bakti Masyarakat (Public Service Star) in 2022 for community contributions. CEO Lim Hock Chee currently chairs the Marsiling Citizens’ Consultative Committee and was appointed Co-Chairman of the Unit Pricing Industry Workgroup in 2026. The capital-allocation track record has been consistent and conservative across the listed history.

There has been no equity raise since the IPO. The share count has been flat at 1,503,537,000 since 2011, meaning every cent of earnings-per-share growth has come from earnings expansion rather than financial engineering. Mergers and acquisitions activity has been deliberate and infrequent. The Jelita Property acquisition in late 2024 for S$49 million is the only notable corporate deal in years, paid for entirely from operating cash flow, and the deal anchored a flagship store as well as freehold investment property. The dividend policy has been roughly 70% of profits returned every year; the payout ratio has only deviated meaningfully in early IPO years when it ran higher. The China experiment has been disciplined, with six stores in nine years, no hurried roll-out, and no announced intention to accelerate. The board has nine members, five of them independent and three of them female (above the Group’s 30% diversity target). The Audit and Risk Committee is chaired by Tan Huay Lim, a former audit and banking partner of KPMG Singapore with 23 years at the firm.

Related-party transactions, formally known under SGX listing rules as Interested Person Transactions (IPTs), are present but well-disclosed, and small in absolute size relative to the income statement. The largest aggregate IPT in FY2025 was S$3.1 million in rent payable to E Land Properties Pte Ltd (a Lim-family vehicle) for three operating-space leases. Investors should monitor this line item, but it is at a scale that is hard to consider abusive given the visibility of disclosure.

The shareholder register itself tells a clear story. Sheng Siong Holdings Pte Ltd, the family vehicle, holds 29.85%. The three Lim brothers hold a further 22.59% directly in their own names. Citibank Nominees Singapore Pte Ltd, at 8.37%, is the largest custodian-account block, followed by DBS Nominees, DBSN Services, Raffles, HSBC, OCBC and UOB nominees in descending size. Beneath the nominee blocks the register thins out quickly. Position numbers fifteen and sixteen, Lin Yuanfeng and Tan Peck Hiang, hold 0.67% each, with Tan Peck Hiang a spouse of Lim Hock Leng.

Valuation: What the Market Is Paying For

Three framings help decompose the S$3.08 price. The first is the Price-to-Earnings (P/E) multiple. At roughly 31x trailing on FY2025 earnings per share of 9.94 cents [1], the stock is at a clear premium to DFI Retail Group at roughly 25x [8]. DFI is bigger and more geographically diversified, but has structurally lower returns. Globally, Sheng Siong sits between the elevated multiples paid for Costco (above forty times trailing earnings on most data providers in 2025–26) and the more grounded multiples on Walmart and Kroger, which trade in the high-twenties to mid-thirties and the low-to-mid-teens respectively, depending on the data provider and the period [15]. The premium versus the average grocer is real, and reflects the market’s view that Sheng Siong is closer to the Costco end of the spectrum on returns and durability if not on scale.

The second framing is Enterprise Value (EV) divided by Earnings before Interest, Taxes, Depreciation and Amortisation (EBITDA). FY2025 EBITDA, taking operating profit of S$176 million and adding back depreciation of property, plant and equipment plus right-of-use assets, was approximately S$240 million. Net of the S$435 million cash position and ignoring lease liabilities, that produces an EV/EBITDA ratio in the order of 14–15x. Treating capitalised lease liabilities as debt would push the ratio slightly higher. Either way, the cash pile takes some of the sting out of the headline P/E, but Sheng Siong still trades at a premium to most regional grocery peers on this measure.

The third framing is Price-to-Book (P/B). At a market price of S$3.08 and book value of 39.1 cents per share, the stock trades at roughly 7.9x book. That looks demanding in isolation but it is consistent with a 26% return on equity. A return-decomposition lens is in some ways cleaner than a multiples lens. At a 26% ROE and a 70% payout ratio, the implied internal compounding rate of book equity is around 8% per year, and the dividend yield adds another roughly 2.3%. That implies a base-case total-return expectation of around 10–11% per year, before any change in valuation multiple, which value-conscious investors would describe as priced for delivery, not for upside surprise.

A simple discounted-cash-flow framing reaches a similar conclusion. At a 9% cost of equity and a 3.0–3.5% terminal growth rate, the current share price implies roughly 5–6% real revenue growth and stable margins for the next decade. That is plausible. The company’s targeted Singapore store count (eighty-seven to 120 by 2030) alone supports approximately 4% revenue growth, before any margin gain. But it is not heroically conservative either. The valuation is a price for execution. If the execution comes through, the stock pays you in dividends and modest multiple support. If it slips, the de-rating could be sharp.

A Note on the “Parent Company” Question

A few readers will ask how Sheng Siong’s valuation relates to its parent company. The structural answer is that there is no listed parent. The largest shareholder, Sheng Siong Holdings Pte Ltd (often referred to as SS Holdings), is a private investment vehicle owned approximately one-third each by the three Lim brothers. SS Holdings exists primarily to consolidate the family’s stake; its only material asset is shares in the listed company. There is therefore no listed-parent discount to monetise, of the kind that historically existed for, say, Jardine Strategic versus Jardine Matheson. For minority investors, the listed share price is the parent-company price. The controlling family takes its economics primarily through Sheng Siong Group dividends rather than through a separately valued holding company, which is unusually clean by Southeast Asian conglomerate standards.

Recent News and Catalysts

The Group released full-year FY2025 results on 27 February 2026, with revenue of S$1.57 billion (up 9.9%), net profit of S$149.2 million (up 8.5%), and a final dividend lifted from 3.20 cents to 3.80 cents per share. On 23 April 2026, management published responses to questions submitted ahead of the AGM, addressing topics including the Sungei Kadut distribution centre, China losses, the labour-cost outlook and the Group’s quick-commerce strategy. The AGM is scheduled for 29 April 2026, with the re-election of CEO Lim Hock Chee and Independent Director Ko Chuan Aun on the slate.

The most material industry-level catalyst is unfolding outside Sheng Siong’s own operations. DFI Retail Group’s divestment of its Singapore food business (Cold Storage, CS Fresh, Jason’s Deli and Giant) to Macrovalue for S$125 million was announced in March 2025 and was expected to close in the second half of 2025 [12]. The transition will play out through 2026 and 2027, and Sheng Siong is the most natural beneficiary of any short-term operational dislocation at the rebranded competitor stores. Investors should monitor Sheng Siong’s half-year comparable-store sales for any visible step-up in 2026 attributable to this transition.

Looking forward, the major dates and catalysts to watch are:

• 1 April 2026. Beverage Container Return Scheme implementation begins, adding small operational complexity that supermarkets will absorb across their stores.

• 29 April 2026. AGM and final dividend approval.

• 15 May 2026. Final dividend payment date.

• 3Q 2026. New store at 11 Rivervale Crescent expected to open.

• Late 2026 / early 2027. Johor Bahru–Singapore RTS Link scheduled commencement, with potential cross-border shopping diversion that is genuinely difficult to model in advance [10].

• 2026–2027. DFI / Macrovalue transition plays out at competing Cold Storage and Giant stores.

• 2029–2030. New Sungei Kadut distribution centre operational. The biggest single multi-year catalyst from within Sheng Siong’s own control, and also the multi-year capital-expenditure peak.

Top Institutional Holders: A Note on the Free Float

A point of distinction worth flagging is that Sheng Siong does not show up as a top holding in the major institutional Form 13F filings disclosed to the US Securities and Exchange Commission (SEC) [9]. The disclosed top holders below the Lim family are mostly Singapore-based nominee accounts: Citibank Nominees (8.37%), DBS Nominees (4.43%), DBSN Services (4.20%), Raffles Nominees (2.55%), HSBC Singapore Nominees (2.29%), OCBC Securities (1.38%) and UOB Nominees (1.34%). These obscure the underlying beneficial owners. Smaller nominee blocks include Moomoo Financial Singapore (0.89%), BNP Paribas (0.68%), iFAST Financial (0.67%) and Phillip Securities (0.66%). The free float, while officially 46.7%, is functionally dominated by Singapore-domiciled retail and high-net-worth investors holding via local custodians rather than by international long-only institutions. This shareholding structure has a real consequence: institutional analyst coverage is thin, and price discovery often runs through retail flows. That is both a liquidity risk and, occasionally, a source of mispricing for patient investors.

Bull vs Bear

The Bull Case

The bull case for Sheng Siong rests on five reinforcing observations:

• It is the largest pure-play Singapore-grocery operator on the SGX, in a defensive category, with no listed Singapore competitor of comparable quality.

• The store rollout pipeline has accelerated rather than slowed (twelve openings in FY2025 versus the long-run guidance of three to five), with the new distribution centre sized to support a network of at least 120 stores in the medium term.

• The S$435 million net cash position, plus a lease-funded operating model, gives the company unusual balance-sheet flexibility to fund the new distribution centre, ride out a recession, and continue raising the dividend.

• An interim and final dividend has been paid every year since the IPO, and the FY2025 final has been raised again, providing a yield baseline on top of organic earnings growth.

• ROE above 25% and ROIC near 20% are best-in-class among listed Southeast Asian grocers, with founder-led ownership aligning insiders and minority shareholders.

The thread running through these is that the gross-margin expansion engine (sales-mix optimisation plus house brands plus direct sourcing) has been quietly running for more than a decade with no signs of stalling. An illustrative bull scenario, not a price target, is that mid-single-digit revenue growth combined with continued modest margin expansion drives earnings per share to around 12 cents within three years. Sustained at the current ~31x multiple, that scenario implies a stock price meaningfully higher than today.

The Bear Case

The bear case begins with the multiple. At roughly 31x trailing earnings, Sheng Siong trades at a premium to DFI Retail (about 25x) and well above global grocery averages of 17–20x [8]. There is limited margin for error built into the price. The new distribution centre capex cycle (estimated at S$200 million-plus over multiple years) will halve the net cash buffer over 2027–2030 and depress free-cash-flow cover during that period. House-brand and sales-mix gross-margin gains may be approaching a structural ceiling, and any compression here would compound with the wage-cost ratchet from the Progressive Wage Model and Beverage Container Return Scheme. Quick-commerce execution remains an open question after the Deliveroo Singapore exit. China stores are still loss-making and represent an ongoing capital sink unless management demonstrates unit economics work. Founder ownership of 60-plus per cent on a deemed-interest basis is a corporate-governance double-edged sword: alignment, yes, but also a low free float that limits institutional absorption capacity. Finally, the company has never operated through a genuinely deep Singapore consumer recession as a listed entity; COVID was a stockpiling-driven supply-side shock, not a demand-side contraction. An illustrative bear scenario is that a 100–200 basis point gross-margin compression, combined with capital expenditure that runs above expectations, drives earnings per share lower for two consecutive years. Under those conditions a multiple compression to the low-twenties range is plausible, with corresponding share-price downside.

A Variant View: Why Margin Durability Is the Single Question

Strip away the competing scenarios, the macro context, and the management appraisal, and the investment case at S$3.08 ultimately rests on one variable: whether the gross-margin expansion engine that has added more than six percentage points to gross margin over the past decade can continue to grind higher from here. House brands, direct sourcing and sales-mix optimisation have done the heavy lifting for ten years. The market is implicitly underwriting a continuation of that engine, and at roughly 31x trailing earnings, that expectation is not unreasonable. It does, however, leave limited room for deviation.

The variant bullish reading is that the market is underestimating how much margin-expansion runway is still left. House-brand penetration in Sheng Siong’s portfolio, although growing steadily through 2,035 SKUs across twenty-eight brands, is still structurally lower than at the most penetrated global grocers, where private-label products account for a substantially higher share of total sales. Incremental house-brand and sales-mix gains, layered onto a S$1.57 billion revenue base, can still translate into meaningful profit growth. In this framing, Sheng Siong is less a traditional grocer and more a capital-light consumer compounder still early in its margin journey, and the current multiple is, if anything, a reasonable price for an underappreciated runway.

The variant bearish reading is that the easy gains have already been harvested. The next 100 basis points of gross margin will be harder to extract than the last, because the obvious sales-mix shifts and the lowest-hanging house-brand categories have already been worked. At the same time, wage inflation under the Progressive Wage Model, Beverage Container Return Scheme compliance costs, and a competitive landscape under reshuffled DFI ownership may offset further mix improvements, placing a soft ceiling on operating margin precisely as the Group enters a heavier capital-expenditure cycle for Sungei Kadut. In that scenario, earnings growth slows while the valuation multiple stays elevated, a combination that rarely sustains for long.

Positioning: When Does This Setup Work?

At current levels, the investment case is less about multiple expansion and more about execution. If the Group delivers continued store rollouts at 4–5% per year, stable or slightly expanding gross margins, and disciplined capital deployment through the Sungei Kadut cycle, then mid-single-digit earnings growth combined with a 2–3% dividend yield can support a low double-digit total return profile, with little contribution from any change in valuation multiple. The margin for error, however, is narrow. Any evidence of gross-margin compression, negative comparable-store sales, or capital-expenditure overruns would likely re-rate the stock to a lower multiple.

In practical terms, this is the kind of stock that tends to become more attractive during periods of operational noise, when short-term pressures temporarily obscure what is otherwise a stable long-term profile. Buying high-quality compounders during their less interesting quarters has historically been a more reliable path than buying them after a string of clean results.

A Single-Variable Decision Framework

If the investment thesis can be reduced to a single question, that question is margin durability. If you believe Sheng Siong can continue to extract incremental gross margin through sales mix, scale and sourcing advantages over the next five to ten years, then the current valuation is defensible as a fair price for a high-quality consumer compounder. If you believe gross margin is near a structural ceiling, then the stock is pricing in a level of future profitability that will be difficult to exceed and easy to disappoint. At S$3.08, the market is not obviously wrong, but it is also not leaving much room for it to be.

What Would Break the Thesis

If you own Sheng Siong, or are thinking about it, the leading indicators to watch are concrete and few. Five matter most:

1. Half-year gross-profit margin. A drop below 30% in any half-year would suggest either a competitive pricing reset, a US-dollar-driven raw-material shock, or a labour-cost step that cannot be passed on.

2. Comparable-store sales growth. Comparable stores grew 1.4% in FY2025. A persistent negative number in subsequent half-years would indicate either heightened competition (most plausibly NTUC FairPrice undercutting) or genuine consumer-demand erosion.

3. Sungei Kadut distribution centre capex schedule. If the budget materially exceeds expectations or delivery slips beyond 2030, free-cash-flow cover and dividend cover thin out.

4. China profit and loss trajectory. A larger China net deficit, or any decision to expand China meaningfully, would mark a step-change in capital-allocation discipline that would have to be re-priced.

5. Ownership transition. A material change in the Lim family’s deemed interest, or the resignation of any of the three brothers without a clear handover, would force a re-pricing of the management premium currently embedded in the stock.

The Bottom Line

Sheng Siong remains one of the cleanest consumer-staples businesses on the SGX. High returns on capital, strong free-cash-flow generation, eleven straight years of dividends, and a balance sheet that provides both resilience and optionality. None of that has changed in the last three years, the last five years, or the last decade. What has changed is not the business, but the price.

From here, returns are less likely to be driven by multiple re-rating and more by the company’s ability to keep executing the same model that has delivered for four decades. The bull case is execution-led: keep doing what the family has been doing for forty years, just with more stores, a bigger distribution centre, and a slowly-modernising omnichannel. The bear case is ceiling-led: the company is great, but is now perhaps priced as if it were even greater, and the deliberate decision to cap regional ambition means the upside on revenue growth is anchored to Singapore’s HDB pipeline rather than to a multi-country roll-out story.

For investors, the question therefore shifts from “Is this a good business?”, which it clearly is, to “How much of that goodness is already reflected in the price?” Watching the half-year gross-profit margin, comparable-store growth and the Sungei Kadut capex schedule will tell you which scenario is unfolding well before the multiple does.

References

Market Data Sources

1. Yahoo Finance, Growbeansprout, TradingView (sg.finance.yahoo.com/quote/OV8.SI; growbeansprout.com/quote/OV8.SI; tradingview.com/symbols/SGX-OV8). Share price (S$3.08 as at 20 April 2026), 52-week high (S$3.25 on 9 April 2026), market capitalisation (approximately S$3.97–4.01 billion), trailing P/E and dividend yield references. Accessed April 2026.

2. Stock Analysis (stockanalysis.com/quote/sgx/OV8) and consensus dividend forecast data. FY2025 yield of approximately 2.27% on a 7.0¢ dividend; FY2026 consensus dividend per share of approximately 8.0 cents; consensus target price of approximately S$3.04. Accessed April 2026.

3. Mordor Intelligence. Singapore retail/supermarket industry market size of approximately US$36.25 billion in 2024. (mordorintelligence.com/industry-reports/retail-industry-in-singapore)

4. Singapore Ministry of Trade and Industry (MTI). 2026 GDP growth forecast range of 2.0–4.0%. Referenced via the Group’s FY2025 results announcement and supporting MTI press releases.

5. Gourmet Pro. Singapore supermarket landscape and the FairPrice / DFI / Sheng Siong triopoly composition. (gourmetpro.co/blog/biggest-supermarkets-singapore)

6. Monetary Authority of Singapore (MAS). Singapore Core Inflation: 2.8% in 2024, 0.7% average in 2025, projected 1–2% in 2026. Referenced via the Group’s Chairman’s Statement (FY2025 Annual Report) and supporting MAS publications.

7. Singapore Department of Statistics / National Population and Talent Division. Population and HDB housing background context referenced for the heartland-store-rollout thesis.

Industry and Peer Comparison Sources

8. Stock Analysis, Stockopedia, Simply Wall St. DFI Retail Group (SGX: D01) peer multiples; DFI trailing P/E of approximately 20–25x as referenced in published valuation pages, and analyst consensus target ranges. Accessed April 2026. (stockopedia.com/share-prices/dfi-retail-group-SGX:D01; simplywall.st/stock/sgx/d01)

9. Fintel.io and Yahoo Finance. Third-party institutional ownership analysis for Sheng Siong, indicating no disclosed Form 13F-filing institutional holders above the substantial-shareholder threshold; ownership functionally dominated by retail and Singapore-domiciled custodial accounts. Accessed April 2026. (fintel.io/so/sg/ov8)

10. Johor-Singapore Special Economic Zone (JS-SEZ) and Land Transport Authority Singapore. Johor Bahru–Singapore RTS Link scheduled commencement late 2026 / early 2027; cross-border consumer flow context cited in the Group’s FY2025 commentary as well as supporting public infrastructure briefings.

Other Public References

11. The Edge Billion Dollar Club. “Highest Weighted ROE Over Three Years (Consumer Defensive Industry)” awarded to Sheng Siong for the third consecutive year, as cited in the FY2025 Chairman’s Statement.

12. DFI Retail Group / Macrovalue transaction announcements (March 2025). DFI Retail Group’s divestment of its Singapore food business (Cold Storage, CS Fresh, Jason’s Deli and Giant; 89 stores plus two distribution centres) to Macrovalue for S$125 million, expected to close in the second half of 2025. Source of: deal price, store count, segment operating margin context (food 1.8% versus Health & Beauty 8.6% and Convenience 4.3% in FY2024), and the prior 2023 Macrovalue acquisition of DFI’s Malaysian food business. (Coverage referenced via DBS Insights, The Smart Investor, Dr Wealth, theedgemalaysia.com, theonlinecitizen.com.) Accessed April 2026.

13. Sheng Siong Group Ltd FY2025 Annual Report, Board of Directors profiles. Source of: founders’ employment in their family’s hog-rearing business prior to founding the Group; the Group’s establishment in 1985; Lim brothers’ service as directors of Sheng Siong Supermarket Pte Ltd since 1983 (Lim Hock Eng and Lim Hock Chee) and 1994 (Lim Hock Leng).

14. Singapore Department of Statistics, Population in Brief 2024 / National Population and Talent Division. Projection that residents aged 65 and over will reach approximately 24% of total resident population by 2030, up from 18.4% in 2023.

15. Yahoo Finance, stockanalysis.com, Bloomberg consensus pages for COST, WMT and KR. Indicative Price-to-Earnings reference points for Costco Wholesale Corp., Walmart Inc. and Kroger Co. as at April 2026. Multiples vary across data providers and reporting periods; the article uses approximate ranges only as cross-references.

Notes on Data Integrity

• Historical financial figures from FY2015 through FY2024 are sourced from Sheng Siong Group’s published Annual Reports for those years. FY2025 figures are sourced from the SGX Results Announcement dated 27 February 2026 (”SSG-Results-Announcement-2HFY2025”). Where the FY2024 comparative differs slightly between the FY2024 and FY2025 filings, this article uses the figures as restated in the most recent FY2025 announcement.

• Estimates of free cash flow, ROIC, and EBITDA are author-derived from disclosed P&L, balance-sheet and cash-flow line items. Pre-2018 operating cash flow and capex figures used in the cash-flow chart are approximations based on the closest disclosed proxies in earlier annual reports.

• The Sungei Kadut distribution centre capital-expenditure figure has not been disclosed in primary filings as a single committed budget. References to “hundreds of millions of Singapore dollars” or to a “multi-year project” reflect indicative project-scale estimates only. Investors should rely on the Group’s own subsequent disclosures for the actual budget and schedule.

• Peer P/E multiples for global grocers (Costco, Walmart, Kroger) are indicative reference points sourced from third-party data providers (see reference 15) and vary by source and reporting period. They are intended only as illustrative cross-checks against Sheng Siong’s multiple, not as authoritative comparables.

• The illustrative bull and bear scenarios are editorial in nature and are not derived from a formal discounted-cash-flow or earnings model.

All financial data drawn from Sheng Siong Group SGX filings (FY2014–FY2025) and Annual Reports unless otherwise indicated. Market data references are as at April 2026.

IMPORTANT DISCLAIMERS

General Disclaimer: This article is published for informational and educational purposes only. It does not constitute financial advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The views expressed are based on publicly available data from Sheng Siong Group Ltd’ SGX filings and publicly accessible market data, and may not reflect the most current developments.

Not Licensed Financial Advice: The author is not a licensed financial adviser, and this publication is not issued by a holder of a Capital Markets Services Licence under the Securities and Futures Act 2001 of Singapore. This content does not fall within the definition of “financial advisory service” under the Financial Advisers Act 2001 of Singapore. Readers in Singapore should note that this content is exempt from the requirements of the Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication.

MAS Compliance Notice: In accordance with the Monetary Authority of Singapore’s guidelines, this publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, you should consult a licensed financial adviser who can provide advice tailored to your personal circumstances. Past performance of any security discussed herein is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author may or may not hold positions in the securities discussed. No compensation has been received from any company mentioned in this article.

Q&M Dental Group has been listed on the SGX Mainboard since 2009. In that time, it has grown from a small chain into the largest private dental operator in Singapore, survived a pandemic that nearly doubled its PATMI from FY2019 to FY2021, and is now attempting to become a regional dental platform across Asia-Pacific. The question for investors is whether the stock at S$0.60 (up 114% from its 52-week low [1]) reflects the company as it is today, or the company it’s trying to become.

The Company: What Q&M Actually Does

Q&M Dental Group (全民牙科集团) was established around 1996 by Dr Ng Chin Siau — the company describes 2026 as its “30th year.” The name tells the story: “全民” (Quan Min) means “for all the people,” and from day one, Q&M was positioned as mass-market dental care, not premium boutique dentistry. Dr Ng started with a single clinic and built it into Singapore’s dominant private dental chain through relentless acquisition of small practices and organic clinic openings. The corporate entity was incorporated in 2008 and listed on the SGX Mainboard in November 2009.

As at 31 December 2025, the Group operates 110 dental outlets and 5 medical clinics in Singapore, 37 dental clinics in Malaysia, and, through its newly consolidated subsidiary Aoxin Q&M, 7 dental polyclinics and 7 dental hospitals in China, supported by 4 dental laboratories and 2 dental equipment and supplies distribution companies. That’s approximately 161 dental clinic-equivalent outlets across three countries, plus ancillary facilities, served by about 270 dentists seeing roughly 42,000 patient visits per month in Singapore alone.

Beyond clinics, Q&M runs a dental college (the first private postgraduate dental diploma programme in Singapore), a dental AI technology subsidiary (EM2AI), and dental equipment distribution businesses in Singapore and Malaysia.

Revenue is heavily concentrated in Singapore (84% of FY2025 revenue), with Malaysia contributing 6% and China (now consolidated for the first time) adding 9%. This geographic split is about to change dramatically if the company’s acquisition plans materialise.

A Brief History: The Ups and Downs

2009–2016: The Growth Machine. Listed on the SGX in November 2009, Q&M expanded aggressively through clinic acquisitions. Revenue grew from roughly S$60 million to S$155 million. A valuable stake in Aidite Technology (a Chinese dental supplies manufacturer) generated significant associate income, and FY2016 PATMI hit S$28.3 million, though much of it came from one-off disposal gains.

2017–2019: Restructuring. Q&M spun off its China operations as Aoxin Q&M, disposed of its Aidite stake, and repaid its first S$60 million Medium Term Note. Stripping out one-offs, core dental profit was roughly S$13 million per year. Revenue grew modestly to S$128 million by FY2019.

2020–2021: The COVID Windfall. Q&M pivoted into COVID-19 PCR testing, boosting medical lab segment revenue from near-zero to S$45.4 million. Total revenue hit S$205.6 million, PATMI reached S$30.5 million, and the company paid S$0.04/share in dividends. This was the peak. The testing revenue was ephemeral.

2022–2023: The Hangover. Testing revenue evaporated, PATMI fell to S$11.3–11.5 million as lab impairments and Aoxin losses dragged on results. But the core dental business proved its resilience: core healthcare EBITDA was stable at S$37–40 million throughout.

2024–2025: The M&A Pivot. Core dental profit recovered to S$26.1 million (FY2024, restated) and then S$30.4 million (FY2025) — a 16% year-on-year jump. Meanwhile, Q&M consolidated Aoxin Q&M as a subsidiary, raised S$130 million through Medium Term Notes at 3.95%, and signed non-binding MOUs to acquire dental groups in Australia (AUD 144.5M), Thailand (30+ clinics), and China. Reported PATMI fell to S$9.3 million due to one-off consolidation losses and MTN interest costs — but the core business has never been stronger.

Financial Performance: What the Numbers Tell Us

The most important insight from the financials is that Q&M’s core dental business has been remarkably stable and quietly growing, even as the headline numbers have been volatile.

Revenue. Core dental revenue has grown at a roughly 5% CAGR over the past five years, from S$126 million in FY2020 to S$195 million in FY2025. The jump in FY2025 includes approximately S$18 million from the Aoxin consolidation. Stripping that out, organic core dental revenue growth was still solid at approximately 3–4%.

Profitability. The reported PATMI line is noisy, distorted by COVID testing profits in FY2020–21, lab impairments in FY2022–23, and consolidation losses in FY2025. The cleaner metric is core dental profit after tax, which has grown from S$17.1 million in FY2022 to S$30.4 million in FY2025, a 78% increase over three years. This is the trend that matters.

Margins. Core dental segment results (before corporate costs and finance charges) were S$55.4 million on S$195 million revenue in FY2025, implying a segment margin of roughly 28%. Employee costs are the largest expense at S$115 million (58% of revenue), followed by lease-related depreciation at S$13.8 million (7%).

Cash Flow. Operating cash flow has been consistently strong: S$33–50 million annually. FY2025 saw S$36.7 million, sufficient to cover capex of S$4.8 million and dividend payments. The S$130 million MTN issuance in July 2025 transformed the cash position from S$34 million to S$117 million.

Balance Sheet: From Conservative to Leveraged

The balance sheet has undergone a significant shift. Prior to FY2025, Q&M maintained a relatively conservative balance sheet with net debt of S$39–46 million and a debt-to-equity ratio of 0.68–0.83x. The S$130 million MTN issuance changed this materially.

As at 31 December 2025, total borrowings (including finance leases) stood at S$143.4 million against cash of S$117.1 million, giving a net debt of just S$26.3 million. However, this is somewhat misleading: the cash is earmarked for acquisitions. If the Australian deal (AUD 144.5M ≈ S$130M) closes, the cash will be substantially deployed, and net debt could rise to S$100M+ depending on the financing mix.

Goodwill increased from S$52.4 million to S$75.2 million following the Aoxin consolidation. This will grow further if the M&A pipeline closes. NAV per share is S$0.1105 (equity attributable to owners of the parent divided by shares outstanding), meaning the stock trades at approximately 5.4x book value on a per-share basis.

The Clinic Network: Scale as Moat

Q&M’s network of 110 dental outlets in Singapore represents the single largest private dental chain on the island. For context, Singapore has approximately 1,400 licensed dental clinics [8]; Q&M operates roughly 8% of them. The next largest chain is significantly smaller.

This scale provides several advantages. First, it gives Q&M bargaining power with landlords and suppliers. Second, it enables a training and talent pipeline through the Q&M College, where the company can recruit, train, and rotate dentists across its network, which is difficult for smaller players to replicate. Third, the CHAS (Community Health Assist Scheme) subsidy framework favours larger chains that can absorb the administrative burden of subsidy claims and fee benchmark compliance.

The enhanced CHAS subsidies effective from October 2025, covering additional restorative procedures and expanding coverage to 1.7 million cardholders [6], are a structural tailwind. Q&M’s clinics are CHAS-accredited, and management noted a roughly 3% revenue boost from the subsidy enhancements in H2 2025. The upcoming Flexi-MediSave expansion (mid-2026) allowing seniors to use S$400/year for dental work at CHAS clinics should provide further support [6].

The Johor-Singapore Special Economic Zone: Threat and Opportunity

The most disruptive near-term development for Singapore’s dental market may not come from competitors or regulation. It may come from infrastructure. The Johor Bahru–Singapore Rapid Transit System (RTS) Link, scheduled to open in December 2026, will connect Bukit Chagar in Johor to Woodlands North in Singapore with a design capacity of 10,000 passengers per hour [11]. Combined with the broader Johor-Singapore Special Economic Zone (JS-SEZ) framework, this creates a step-change in cross-border accessibility.

The implications for dental care are significant. Routine dental procedures in Johor cost 40–70% less than in Singapore. A scaling and polishing that costs S$100–180 in a Singapore private clinic runs RM80–150 (S$25–45) across the Causeway. With the RTS Link reducing crossing time to minutes rather than the current hour-plus queue at the land checkpoints, the calculus for price-sensitive Singaporean patients shifts dramatically. This is particularly relevant for elective and cosmetic procedures — crowns, veneers, implants, where the price differential runs into thousands of dollars.

Q&M is uniquely positioned on both sides of this equation. It operates 37 clinics across Malaysia — with locations in Kuala Lumpur, Selangor, Negeri Sembilan, Malacca, and Johor, more than any other Singapore-listed dental chain. If patient flow moves south, Q&M captures some of that demand in its Malaysian clinics rather than losing it entirely. However, the risk to Singapore same-store revenue is real: Q&M’s 110 Singapore outlets generate 84% of group revenue, and any meaningful patient outflow would hit the highest-margin part of the business.

Management has acknowledged the JS-SEZ in the AR2025 Operations Review, noting that Q&M continues “to explore opportunities to grow our dental business, particularly within the Johor–Singapore Special Economic Zone, with the upcoming Rapid Transit System expected to enhance connectivity and support growth in Johor.” Notably, management frames the RTS Link as a growth opportunity for its Malaysian clinics rather than a cannibalization risk to Singapore — investors should weigh whether this framing adequately addresses the downside scenario. H2 2026 same-store revenue trends will be the first real data point once the RTS Link comes online.

Singapore’s Demographic Tailwind: Ageing by the Numbers

While the JS-SEZ creates near-term uncertainty, Singapore’s demographic trajectory is an unambiguous structural tailwind for dental care demand. By 2030, 24% of Singapore’s resident population will be aged 65 or older, up from 18.4% in 2023 [5]. This is one of the fastest ageing populations in the world.

The dental implications are acute. Among Singaporeans aged 65 and above, approximately 69% wear dentures and dental disease prevalence is significantly higher than in younger cohorts [7]. Periodontal disease, tooth loss, and the need for prosthetic and restorative work all increase sharply with age. The Ministry of Health’s expansion of CHAS subsidies and the Flexi-MediSave dental benefit are direct policy responses to this demographic reality [6].

For Q&M, this means the addressable patient base for its highest-frequency services (dentures, crowns, extractions, periodontal treatment) is growing structurally, and government subsidies are reducing the out-of-pocket barrier. The company’s HDB heartland clinic locations are precisely where Singapore’s elderly population is concentrated.

The M&A Bet: Going Regional

The most significant strategic shift in Q&M’s 30-year history is happening right now. The company has simultaneously announced three major international expansion initiatives:

Australia (AUD 144.5 million). In March 2026, Q&M signed a non-binding MOU to acquire a leading Australian dental group operating 40+ clinics across NSW, VIC, QLD, TAS, and ACT with approximately 120 dentists. The purchase includes a profit guarantee of 5–8 years. To understand the significance of this deal, consider the market Q&M is entering: Australia’s dental industry is worth approximately A$13 billion annually and growing at roughly 3% per year [10], with no single dominant national chain. The market has been undergoing PE-driven consolidation — 1300 Smiles was acquired by BUPA in 2021, Abano Healthcare (NZ-listed, with Australian operations) was taken private by Adams & Co, and several mid-tier chains have attracted private equity interest. Q&M is entering this consolidation wave as a listed strategic buyer with a dental operating playbook, which differentiates it from pure financial buyers. The AUD 144.5 million price tag, however, makes this Q&M’s largest-ever acquisition by a wide margin and represents a market-entry bet where the company has zero operating history.

Thailand (30+ clinics). In October 2025, Q&M signed a non-binding MOU to acquire a Thai dental group focused on cosmetic and aesthetic dentistry, also with a profit guarantee.

China (via Aoxin Q&M). With Aoxin now a subsidiary, Q&M is deploying capital through it to acquire dental chains in China beyond Aoxin’s existing northeastern base. Two MOUs have been signed totalling approximately RMB 420 million (S$77M), targeting clinics in southern China.

The strategy is a “partnership-driven acquisition model” where founders receive a mix of cash and Q&M equity, aligning incentives. If all three deals close, Q&M could grow from approximately 161 dental outlets to potentially 300+ within two years, with a medium-term target of 300–400 clinics.

The risk is obvious: three major cross-border acquisitions simultaneously, funded partly by debt, in markets the company has limited experience operating in (Australia and Thailand are entirely new). Integration risk, currency risk, and execution risk are all elevated. This is what makes Q&M a coin flip: the upside from successful execution is transformative, but the company is attempting it all at once with no margin for error.

Competitive Advantages and Their Durability

Q&M’s moat rests on four pillars.

Network density in Singapore. With 110 outlets, Q&M has the largest private dental footprint. This is difficult to replicate because good clinic locations (typically in HDB heartlands and shopping centres) are scarce, and the company has 30 years of landlord relationships. Durability: strong in Singapore, not yet established regionally.

Talent pipeline and the dentist shortage. The Q&M College of Dentistry, now EduTrust-certified for four years, provides a training advantage. The company employs 270 dentists and can offer them a career progression path across its network. This matters more than it might appear: Singapore faces a genuine supply constraint in dental professionals. The country’s only domestic dental school (NUS Faculty of Dentistry) graduates approximately 50–60 dentists per year [9], and foreign-trained dentists must pass a rigorous licensing examination. The total number of registered dentists in Singapore is roughly 2,600 [8], serving a population of 5.9 million. This supply bottleneck is Q&M’s single biggest constraint on organic growth (you cannot open new clinics without dentists), but it is simultaneously a structural moat: any competitor looking to build a rival chain faces the same limited talent pool and the same multi-year lead time to train and credential new practitioners. Durability: strong — the licensing regime and limited training capacity are structural, not easily disrupted.

CHAS accreditation and government relationships. As the largest CHAS-accredited dental chain, Q&M benefits disproportionately from subsidy enhancements. The upcoming requirement for non-accredited clinics to be offboarded by December 2026 further entrenches incumbents [6]. Durability: strong, but dependent on government policy.

Founder leadership. Dr Ng Chin Siau controls approximately 56% of shares through Quan Min Holdings and has been CEO since founding the company. This provides strategic continuity but creates key-man risk. Durability: inherently fragile.

Valuation: What You Pay vs. What You Get

Q&M’s valuation is complicated by the noisy earnings picture. The metric that matters most here is the normalised P/E, because reported earnings are so distorted by one-offs that trailing multiples are meaningless, and EV/EBITDA doesn’t capture the finance cost burden from the new S$130 million debt.

Trailing P/E: 61x [1]. This is based on FY2025 reported PATMI of S$9.3 million, which is distorted by a S$4.2 million loss on the deemed disposal and consolidation of Aoxin Q&M and EM2AI, S$2.4 million MTN interest, and PSP-related expenses. This is not a meaningful number.

Normalised P/E: 22–27x. Using adjusted PATMI of S$17 million (excluding one-offs), the P/E is approximately 33x. Using core dental profit of S$30.4 million and attributing it more generously, the multiple drops further. Morningstar calculates a normalised P/E of 22.4x [2].

EV/EBITDA: 15.9x [1]. EBITDA was S$37.8 million in FY2025. At an enterprise value of S$671 million [1], this is roughly in line with IHH Healthcare but significantly above Raffles Medical.

P/B: 5.4x — NAV per share is S$0.1105 (based on equity attributable to parent of S$104.4 million divided by approximately 947 million shares). At S$0.60, the stock trades at a substantial premium to book. Third-party data providers report P/B ratios in the range of 4.2–5.4x depending on whether total equity (including minority interests) or parent-only equity is used. Either way, the premium reflects the market’s view that Q&M’s intangible assets (brand, network, relationships) are worth significantly more than their accounting value.

Dividend Yield: 1.4% [2]. At S$0.0082 per share, the yield is modest. However, management has historically been flexible with dividends, paying 4 cents in FY2021 (7% yield at the time) and as low as 0.69 cents in FY2023.

Relationship with Aoxin Q&M (SGX: 1D4). Aoxin’s market cap is just S$26 million [3] despite operating 24 facilities in China. Q&M’s 52.65% stake is worth roughly S$13.5 million at market, a tiny fraction of Q&M’s S$568 million market cap [1]. If Aoxin’s China expansion succeeds, there could be significant value embedded in this subsidiary. If it fails, the write-downs would be manageable relative to Q&M’s overall business.

Dividend History: Feast and Famine

Q&M’s dividend track record is lumpy. During the COVID windfall years (FY2020–21), the company paid out S$0.03 and S$0.04 per share, extraordinary payouts funded by extraordinary testing profits. Since then, dividends have normalised to S$0.0069–S$0.011 per share, with payout ratios of 57–83%.

In FY2025, the payout ratio was 83% of reported earnings but only about 46% of core dental profit, suggesting the current S$0.0082 per share dividend is sustainable even without M&A-driven earnings growth.

For yield-focused investors, Q&M is not the right vehicle at current prices. The 1.4% yield is below the SGX healthcare average. The investment case here is about capital appreciation from the M&A-driven growth thesis, not income.

Key Growth Drivers (2026–2030)

1. Australian dental market entry. If the AUD 144.5M acquisition closes, Q&M immediately gains scale in a large, fragmented, and high-margin developed market. Australia’s dental industry is approximately A$13 billion [10], with no single dominant chain. The profit guarantee de-risks the near-term earnings impact.

2. Enhanced CHAS subsidies and Flexi-MediSave. The expansion of government dental subsidies is a multi-year tailwind for Singapore revenue. Q&M is the largest beneficiary by virtue of its network size. The Flexi-MediSave expansion in mid-2026 will further boost demand at CHAS clinics.

3. China expansion via Aoxin. Aoxin’s move into southern China through acquisitions diversifies away from its northeastern base. China’s dental market is growing rapidly. Private dental chains are consolidating in Tier 1–2 cities, and Q&M has a platform to participate.

4. Thailand entry. Cosmetic and aesthetic dentistry in Thailand is a growing niche, driven by both domestic demand and medical tourism. The 30-clinic acquisition would provide immediate market presence.

5. Technology and EM2AI. Q&M’s investment in dental technology through its subsidiary EM2AI deserves more attention than it typically receives. EM2AI is developing AI-assisted dental imaging and treatment planning tools — essentially using machine learning to analyse dental X-rays, detect pathologies, and recommend treatment options. The technology is still in its early commercial stages, and Q&M has not disclosed standalone revenue or profitability for EM2AI. What is clear from the annual reports is that EM2AI is being positioned as both an internal efficiency tool (improving diagnostic speed and consistency across 270 dentists) and a potential external licensing play. If the technology proves clinically robust, it could be deployed across the entire expanded clinic network post-acquisition — creating operating leverage that is distinct from simply adding more clinics. For now, EM2AI remains more of an R&D cost centre than an earnings contributor, but it is the kind of optionality that could differentiate Q&M from pure brick-and-mortar dental chains in 3–5 years.

Macro Environment: Headwinds the Market Isn’t Discussing

No analysis of Q&M is complete without acknowledging the macro backdrop. The US–China trade war has intensified through 2025–2026, with US tariffs of 10–26% now applied across ASEAN imports. Singapore’s Ministry of Trade and Industry (MTI) has upgraded its 2026 GDP growth forecast to 2.0–4.0% [4], after the economy expanded 5.0% in 2025, and business confidence surveys show softening consumer sentiment.

Dental care occupies an unusual position in a downturn. Basic dental services (check-ups, fillings, extractions) are relatively recession-resilient; toothache doesn’t wait for an economic recovery. However, elective and cosmetic procedures (orthodontics, veneers, implants, whitening) are highly deferrable and carry the highest margins. If consumer confidence weakens, these procedures are among the first discretionary healthcare expenses to be postponed. Q&M does not break out its revenue between basic and elective procedures, which makes it difficult to model the sensitivity. As a rough guide, dental industry surveys suggest that elective and cosmetic work typically accounts for 25–35% of private dental revenue in developed Asian markets (an estimate, not a verified Q&M-specific figure).

The tariff environment [12] also creates indirect risk for Q&M’s China operations. Aoxin Q&M’s patient base in northeastern China is concentrated in provinces with heavy manufacturing exposure. A trade-war-induced slowdown in Chinese industrial activity could depress dental demand in precisely the regions where Aoxin operates.

More broadly, if Singapore's growth disappoints the upgraded forecast — not the base case, but tariff uncertainty makes it possible — Q&M’s fixed-cost base (clinic leases, salaried dentists, equipment depreciation) means operating leverage works in reverse. A 5–10% decline in same-store revenue would flow through to a disproportionately larger decline in operating profit, given that employee costs alone account for 58% of revenue. The company — listed in November 2009, after the Global Financial Crisis — has never stress-tested its clinic economics through a genuine consumer recession as a public company. COVID was a supply-side demand shock with a massive government spending offset, not a consumer spending contraction.

Major Risks and Bear Case

Execution risk on concurrent M&A. Three major cross-border acquisitions simultaneously is ambitious for a company of Q&M’s size. Each market has different regulatory, cultural, and operational challenges. The management team’s experience is overwhelmingly in Singapore and Malaysia.

Leverage risk. The S$130 million MTN at 3.95% adds approximately S$5.1 million in annual interest expense. If the Australian deal is partly debt-funded, leverage could increase further. In a rising-rate environment, this is a drag on earnings.

Key-man risk. Dr Ng Chin Siau is the founder, CEO, and controlling shareholder. The company’s strategic direction, acquisition strategy, and talent relationships are heavily concentrated in one individual. There is no disclosed succession plan.

Integration risk. Dental practices are relationship-driven businesses. When you acquire a clinic, the dentist might leave, and take the patients with them. Profit guarantees provide protection but only for 5–8 years.

Aoxin Q&M drag. The China operations through Aoxin have been loss-making at the associate level for several years. Now that Aoxin is consolidated, these losses flow through Q&M’s P&L. If the China expansion fails, impairment charges could be significant (goodwill from Aoxin is already S$22+ million).

Currency and interest rate risk. Q&M’s regional expansion introduces multi-currency exposure that the company has not historically managed. Revenue will soon be earned in SGD, MYR, RMB, and AUD — each with different drivers and volatility profiles. The Australian dollar has weakened against the SGD in recent quarters, meaning AUD-denominated earnings will translate into fewer Singapore dollars. The RMB faces structural pressure from the US–China trade war [12]. On the financing side, the S$130 million MTN at 3.95% fixed rate is well-structured, but any additional debt to fund the Australian acquisition may carry a higher coupon in the current rate environment. Total finance costs rose from S$5.4 million in FY2024 to S$6.4 million in FY2025 — and will rise further if the M&A pipeline is partly debt-funded.

Regulatory risk. Changes to CHAS subsidies, dental licensing regulations, or foreign ownership rules in target markets could impact growth plans.

Management Quality and Capital Allocation

Dr Ng Chin Siau has led Q&M from one clinic to over 160 dental outlets over 30 years, an impressive track record of organic and acquisitive growth. The management team is small and lean, with CFO Ng Sook Hwa (since 2002, CFO since 2022) and COO Dr Ang Ee Peng Raymond providing continuity.

The board has been strengthened with the appointment of independent chairman Ted Tan (former Deputy CEO of Enterprise Singapore) and Professor Chew Chong Yin (former Dean, NUS Faculty of Dentistry). These appointments bring M&A expertise and dental industry credibility.

Capital allocation has been mixed. The COVID-era dividends (S$0.04/share declared for FY2021) were generous. Cash dividends paid to equity owners totalled S$48.8 million during calendar year 2021 (this figure includes both FY2020 final dividends and FY2021 interim dividends paid during that year), a level of distribution that proved unsustainable as testing profits evaporated. Share buybacks have been more disciplined, with the company repurchasing shares at prices below current levels.

The S$130 million MTN issuance was well-timed (3.95% fixed rate), and the recent allocation of up to 90 million shares for buyback provides flexibility.

Insider buying by Quan Min Holdings (Dr Ng’s vehicle) in April 2026, totalling approximately S$4.6 million, is a positive signal.

One underappreciated aspect of Q&M’s corporate profile is its community dental programme. The company operates a free dental clinic providing pro bono dental care to low-income patients, one of very few listed healthcare companies in Singapore to run a sustained charitable healthcare service rather than writing a cheque to a foundation. For ESG-focused investors increasingly screening healthcare companies on social impact metrics, this is a tangible differentiator. It also speaks to the company’s social licence to operate as the largest private dental chain in a market where dental care affordability is a growing policy concern.

Who Owns Q&M: The Shareholder Register

Understanding who owns Q&M is critical to understanding how this stock trades, and what happens if things go wrong.

As at 1 April 2026, the top 20 registered shareholders hold 82.6% of shares outstanding [14]. Only 33.9% of issued shares are in public hands. The register is dominated by three distinct groups:

The Founder Block (55.8%). Dr Ng Chin Siau’s control over Q&M flows primarily through Quan Min Holdings Pte Ltd, which holds 528.3 million shares — 236.7 million registered under its own name (25.0%) and 291.6 million held via various nominees (30.8%), totalling 55.79% of shares outstanding [14]. Dr Ng holds 49.80% of Quan Min Holdings directly and is deemed interested in a further 121,200 shares held by his spouse, giving him a total deemed interest of 55.80% [14]. He also holds 6.6 million shares (0.70%) in his own name. Two other entities with the Quan Min name — Quan Min Plus (1.82%) and Quan Min Plus 2 (0.79%) — appear in the top 20 register, but the AR2025 does not list them as giving Dr Ng any deemed interest; their beneficial ownership is not disclosed [14]. Taking only the disclosed interests, Dr Ng’s effective voting power is approximately 56.5% — an outright majority. He can pass or block any ordinary resolution unilaterally. For investors, this means governance is effectively a one-man show: whatever Dr Ng wants to do, including the current triple-acquisition strategy, will happen unless it requires a supermajority vote. The recent April 2026 purchases by Quan Min Holdings (approximately S$4.6 million in open-market buying) reinforce that the founder is putting personal capital behind the M&A thesis at current prices.

The Tsao Family / OCTAVE Block (6.8%). IMC Dynamic Investments holds 64.1 million shares (6.77%), making it the only other substantial shareholder besides Dr Ng [14]. IMC Dynamic is wholly owned by IMC Heritas Investments, which is in turn wholly owned by Tsao Pao Chee Group [14], a multi-generational Singaporean family conglomerate (the family describes itself as fourth-generation [15]) with interests spanning shipping, real estate, and healthcare-focused impact investing through its OCTAVE Capital arm. This is not a passive index fund parking capital. It is a strategic family office with a stated focus on healthcare investments across Asia [15]. Their presence at 6.8% as at April 2026 suggests alignment with Q&M’s regional healthcare expansion thesis. SGX substantial shareholder disclosure rules require notification when crossing the 5% threshold, so we know IMC Dynamic has remained above 5% continuously — but movements within that band are not publicly disclosed, and we cannot confirm the exact size of their position at any earlier point.

Nominee, Brokerage, and Individual Accounts. The remaining top 20 shareholders fall into two categories. The first is custodian and brokerage accounts — OCBC Securities (8.7%), Raffles Nominees (8.6%), Phillip Securities (7.2%), KGI Securities (6.5%), Sing Investments & Finance Nominees (5.0%), DBS Nominees (3.8%), and several smaller custodians including Citibank, HSBC, Maybank, UOB, Moomoo, and iFAST nominees [14]. These accounts collectively hold a large share of the register, but without beneficial ownership disclosure it is impossible to determine how much of this block is institutional versus high-net-worth retail. No single institutional fund has disclosed a substantial (5%+) position in Q&M. Among US-registered funds, SEC filings show Dimensional Fund Advisors (DFA) holding Q&M through its small-cap international index funds [16] — a passive, systematic allocation rather than a conviction bet. Non-US institutional holders would not appear in SEC filings and could hold positions through the nominee accounts above. The second category is named individuals: Chan Pui Kee (1.55%) and Lai Ming Chun (1.38%) are the largest individual holders outside the Ng family [14]. Their relationship to the company, if any, is not disclosed in the AR2025.

What This Means for the Investment Thesis. The shareholder structure has three important implications.

First, liquidity is thin. With approximately 56% locked up by the founder and 6.8% by a strategic family office, only about a third of shares trade freely. This amplifies price moves in both directions, partly explaining the 114% rally from the 52-week low. It also means any attempt to build or exit a meaningful position will move the price.

Second, institutional underownership is both a risk and an opportunity. Third-party ownership analyses estimate institutional ownership at less than 5% [16], meaning Q&M lacks the analyst coverage and fund flows that typically support valuation re-ratings. However, if the M&A strategy executes well and the company’s market cap grows into the S$800M–1B range, it could cross the threshold for inclusion in more small-cap indices and attract passive fund inflows — a catalyst that is entirely absent today.

Third, minority shareholder protection is a legitimate concern. With 55.8% control through Quan Min Holdings alone, Dr Ng has the votes to approve related-party transactions, share issuances, and strategic pivots without minority consent. The partnership-driven acquisition model — where founders of acquired businesses receive Q&M equity — means dilution is a structural feature of the growth strategy, not a one-off event. The board’s independent directors (Ted Tan, Prof Chew Chong Yin) provide some governance guardrails, but the power asymmetry is stark. Investors buying at S$0.60 are essentially betting on Dr Ng’s judgment and integrity with limited structural protections beyond SGX listing rules. The coin flip, ultimately, lands on one man’s ability to execute.

Bull vs Bear Investment Thesis

The Bull Case

Q&M is at an inflection point. The core Singapore dental business is growing steadily, generating S$30+ million in annual profit with strong operating cash flow. The enhanced CHAS subsidies provide a structural tailwind. The S$130 million war chest enables transformative M&A. If the Australian, Thai, and Chinese acquisitions all close with profit guarantees, FY2027–28 earnings could step-change higher. The profit guarantees alone suggest EPS could more than double from FY2025 levels. The stock trades at a normalised P/E of 22–27x, which is reasonable for a healthcare company with multi-year growth visibility. The founder’s 56% stake and recent insider buying provide alignment. Illustrative scenario (not a price target): S$0.65–0.75, implying 10–25% upside from S$0.60.

The Bear Case

The stock has already run 114% from its 52-week low [1], and much of the M&A optionality is priced in. Three concurrent cross-border acquisitions by a management team with limited international experience is high-risk. The S$143 million in debt creates earnings drag through S$6.4 million in annual finance costs. Aoxin Q&M has been a persistent drag on earnings and is now fully consolidated. If any major deal falls through or integration stumbles, the stock could de-rate quickly. The trailing P/E of 61x leaves no margin for disappointment. Key-man risk is unmitigated.

Consider a simple stress scenario: if a macro downturn drives a 5–10% decline in same-store revenue across Singapore — not implausible if the JS-SEZ diverts patients to Johor while a tariff-induced slowdown dampens elective procedure demand — the impact on profitability is amplified by Q&M’s fixed-cost structure. Employee costs (S$115 million) and lease depreciation (S$13.8 million) are largely fixed in the near term. A 7% revenue decline (roughly S$14 million) would fall almost entirely to the bottom line, potentially halving core dental operating profit. The company has never been tested through a genuine consumer recession as a listed entity — and it would enter one at higher leverage than at any previous point in its history.

Illustrative scenario (not a price target): S$0.40–0.50, implying 15–33% downside from S$0.60.

What Could Break the Thesis

For bulls: If the Australian deal falls through (it’s a non-binding MOU), the growth narrative collapses. If integration of Aoxin leads to sustained losses that offset Singapore profits, the quality of the business deteriorates. A sharp deterioration in Singapore dental demand (recession, regulatory change) would undermine the base business.

For bears: If all three acquisitions close on favourable terms with strong profit guarantees, the earnings step-change could be dramatic enough to justify current valuations. A re-rating to peer multiples (IHH at 37x, Raffles at 20x) on higher earnings would drive significant upside.

The Bottom Line

At S$0.60, you are not buying a dental business. You are underwriting one man’s ability to simultaneously execute three cross-border acquisitions — in Australia, Thailand, and China — while managing S$143 million in debt, a thin public float, and a core Singapore business that has never been tested through a consumer recession.

The data says the core business deserves its premium: 5–7% revenue growth, 28% segment margins, S$35–40 million in annual operating cash flow, and a founder with 30 years of compounding behind him. But it also says Q&M has zero operating history in any of its target markets, and the entire M&A pipeline rests on non-binding MOUs.

That’s the coin flip. The fundamentals are real. The ambition is extraordinary. And the gap between the two is where the risk lives.

References

Market Data Sources

1. Stock Analysis (stockanalysis.com) — Q&M share price (S$0.60), market cap (S$568M), trailing P/E (61x), EV/EBITDA (15.94x), enterprise value (S$671M), shares outstanding (~947M), 52-week low (S$0.245–0.25), 52-week price change (+114%). Data as at 20 April 2026.

2. Morningstar — Normalised P/E (22.42x), dividend yield range (1.37–2.12%). Accessed April 2026.

3. Yahoo Finance / MarketScreener — Aoxin Q&M (SGX: 1D4) share price (S$0.194), market cap (~S$25.6M). Accessed April 2026.

Industry and Macro Data Sources

4. Singapore Ministry of Trade and Industry (MTI) — 2026 GDP growth forecast upgraded to 2.0–4.0%; 2025 full-year GDP growth of 5.0%. MTI press release, 10 February 2026. https://www.mti.gov.sg/newsroom/mti-upgrades-2026-gdp-growth-forecast-to--2-0-to-4-0-per-cent-/

5. National Population and Talent Division, Singapore — Population projections: 24% of residents aged 65+ by 2030, up from 18.4% in 2023. https://www.population.gov.sg/our-population/population-trends/longevity/

6. Ministry of Health, Singapore / CHAS.sg — Enhanced CHAS dental subsidies effective 1 October 2025; Flexi-MediSave expansion for seniors (S$400/year) effective mid-2026; non-accredited clinic offboarding by 31 December 2026; 1.7 million CHAS cardholders. https://www.moh.gov.sg/newsroom/enhanced-financing-support-for-chas-dental-procedures-and-financial-governance-of-chas-clinics/

7. MOH Singapore — Oral health survey data: approximately 69% denture prevalence among Singaporeans aged 65+. (Note: exact survey year varies by source; figure is from publicly available MOH oral health statistics.) https://www.ndcs.com.sg/news/patient-care/closing-the-gap-in-elderly-oral-healthcare-in-singapore-with-smartrpd

8. Singapore Dental Council (SDC) — Approximate number of registered dentists in Singapore (~2,600). Registry data accessed via public sources. https://data.gov.sg/datasets/d_6c8cf7ce0c6830608637418fcd0979a7/view

9. NUS Faculty of Dentistry — Approximate annual graduate output of 50–60 dentists. Based on publicly available faculty information. https://sgschoolkaki.com/statistics/university-graduates/dentistry

10. IBISWorld — Australian dental services industry: approximately A$13 billion market size, ~3% annual growth. Industry report data. https://www.aihw.gov.au/reports/dental-oral-health/oral-health-and-dental-care-in-australia/contents/costs

11. JB-SG RTS Link project authority — RTS Link design capacity of 10,000 passengers per hour; scheduled opening December 2026; connecting Bukit Chagar (Johor) to Woodlands North (Singapore). https://www.lta.gov.sg/content/ltagov/en/upcoming_projects/rail_expansion/JB-Singapore_RTS_link.html

12. US Trade Representative / Singapore government sources — US tariffs of 10–26% on ASEAN goods, referenced in the context of the 2025–2026 trade environment. https://www.aseanbriefing.com/news/u-s-tariffs-in-asia-2025-a-regional-investment-map/

13. Ken Research — Singapore dental services market revenue estimate (~USD 2.4 billion in 2026). https://www.kenresearch.com/industry-reports/singapore-dental-services-market

14. Q&M Dental Group — Statistics of Shareholdings as at 1 April 2026 (AR2025, pp.128–129). Source of: top 20 registered shareholders, substantial shareholders list, public float (33.93%), Quan Min Holdings total stake (55.79% including nominees), Dr Ng Chin Siau’s deemed interest (55.80%), IMC Dynamic Investments (6.77%), Tsao Pao Chee Group corporate chain, Quan Min Plus (1.82%), Quan Min Plus 2 (0.79%), and named individual shareholders.

15. Tsao Pao Chee Group / OCTAVE Capital — corporate website (tsaopaochee.com) and OCTAVE Capital website (octavecapital.co). Source of: Tsao family generational history (”fourth-generation”), OCTAVE Capital’s healthcare investment focus across Asia, and IMC Group corporate structure.

16. Fintel / Simply Wall St / Yahoo Finance — Institutional ownership estimates for Q&M Dental (<5% institutional), Dimensional Fund Advisors (DFA) holdings via small-cap international index funds. Accessed April 2026. Note: these are third-party estimates based on disclosed filings; actual institutional ownership may differ as non-US funds and nominee-held positions are not fully captured.

Notes on Data Integrity

• FY2024 figures throughout this article use the restated numbers as reported in the FY2025 filing (Note 18), which differ from the originally published FY2024 figures. Where relevant, this is noted in the text.

• Dental price comparisons between Singapore and Johor (scaling: S$100–180 vs RM80–150) are indicative ranges based on publicly available clinic fee schedules and are not sourced from a single authoritative database.

• The estimate that elective/cosmetic work accounts for 25–35% of private dental revenue is an industry-level approximation, not a Q&M-specific disclosure.

• Bull and bear illustrative scenarios are editorial in nature and are not derived from a formal discounted cash flow or earnings model.

All financial data sourced from Q&M Dental Group SGX filings (FY2015–FY2025) and Annual Reports. Market data as at 20 April 2026.

IMPORTANT DISCLAIMERS

General Disclaimer: This article is published for informational and educational purposes only. It does not constitute financial advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The views expressed are based on publicly available data from Q & M Dental Group (Singapore) Limited’ SGX filings and publicly accessible market data, and may not reflect the most current developments.

Not Licensed Financial Advice: The author is not a licensed financial adviser, and this publication is not issued by a holder of a Capital Markets Services Licence under the Securities and Futures Act 2001 of Singapore. This content does not fall within the definition of “financial advisory service” under the Financial Advisers Act 2001 of Singapore. Readers in Singapore should note that this content is exempt from the requirements of the Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication.

MAS Compliance Notice: In accordance with the Monetary Authority of Singapore’s guidelines, this publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, you should consult a licensed financial adviser who can provide advice tailored to your personal circumstances. Past performance of any security discussed herein is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author may or may not hold positions in the securities discussed. No compensation has been received from any company mentioned in this article.

And yet, at a trailing P/E of 7.2x and a market cap of just S$215 million, the stock trades as if none of this matters.

This piece is a deep dive into Hafary: its history, business model, financials, competitive advantages, and the strategic pivot that could change the investment case entirely.

A Brief History: From Tile Trader to Integrated Platform

Hafary was founded in 1980 by Low Kok Ann, who started as a small tile trader in Singapore. The business grew steadily through the construction booms of the 1990s and 2000s, eventually listing on the SGX Catalist board in 2010.

For most of its history, Hafary operated a simple but effective model: source tiles and surfacing materials from Europe (mainly Italy and Spain) and Asia, then distribute them through showrooms to retail customers and through project teams to developers and contractors. Two segments, General (retail) and Project (developers), accounted for virtually all revenue.

The company weathered several downturns. Revenue peaked at S$120 million in FY2018 before declining through FY2019–2020, hit by a softening construction cycle and then the COVID-19 circuit breaker, which shut showrooms and halted construction sites for months. FY2020 was the trough: revenue fell 22% to S$84 million, and PATMI dropped 48% to S$5.3 million.

What happened next was remarkable. From that FY2020 low, Hafary’s revenue has grown more than threefold to S$287 million in FY2025. The recovery was driven by three forces: a rebound in Singapore’s construction and renovation activity, geographic expansion into Malaysia and export markets, and, most importantly, the launch of a manufacturing segment that did not exist before FY2023.

Business Model: Three Segments, One Ecosystem

Hafary today operates across three segments.

General (49.7% of FY2025 revenue, S$142.7M): This is the retail-facing arm. Homeowners, interior designers, architects, and renovation contractors purchase tiles, natural stone, wood flooring, countertops, and sanitary ware from Hafary’s showrooms. The company operates multiple showrooms in Singapore (including the flagship Hafary House at 161 Lavender Street) and one in Petaling Jaya, Malaysia. This segment has been the steady base of the business for decades.

Project (28.3%, S$81.2M): Hafary supplies surfacing materials for public sector projects (HDB flats, government buildings, hospitals) and private developments (condominiums, commercial buildings, hotels). Customers include architecture firms, property developers, and construction companies. This segment is more lumpy and contract-driven, but benefits from long-term government infrastructure spending.

Manufacturing (22.0%, S$63.1M): This is the newest and fastest-growing segment. Since commencing ceramic tile production at two facilities in Kluang, Johor in June 2023, manufacturing revenue has surged from S$5.4 million in FY2023 to S$46.5 million in FY2024 and S$63.1 million in FY2025 (a 35.6% year-on-year increase). The segment serves Malaysian and international markets, with the US emerging as a significant export destination (S$35.7 million in FY2025 revenue).

Geographic exposure has diversified meaningfully. Singapore remains the anchor market at S$171.4 million (59.7% of revenue), but Malaysia contributes S$54.5 million (19.0%), the US S$35.7 million (12.4%), and the remaining 8.9% (S$25.5 million) is spread across 12 other countries.

A broader international footprint than the headline numbers suggest. What the geographic revenue table does not fully convey is the network of dedicated entities Hafary has seeded across Asia. In China, the group operates through three distinct vehicles: Foshan Hafary Trading Co. (a wholly owned export agent that widens procurement), Guangdong ITA Element Building Materials Co. (designing and producing glazed porcelain tiles), and the newly acquired MML Shanghai Trading Co. (which contributed to project revenue growth in FY2025). Combined China revenue reached S$8.5 million in FY2025. Indonesia generated S$7.8 million, making it the fourth-largest market by revenue, ahead of China, and yet rarely discussed. In Vietnam, Hafary’s associate, Viet Ceramics International Joint Stock Company, was the group’s first foray into overseas tile retailing. It is carried at S$18.7 million on the balance sheet and contributed S$1.3 million in share of profit in FY2025, making it a quietly profitable investment despite the weakening Vietnamese Dong. In Myanmar, a joint venture (Hafary Myanmar Company Limited) contributed S$0.8 million in share of profit on S$2.1 million in revenue, a solid margin for an early-stage market entry. Smaller but growing presences in Taiwan (S$3.2 million), Thailand (S$835K), Cambodia (S$679K), the Philippines (S$570K), and Australia (S$356K) round out an ASEAN-wide distribution network that is still in its early stages but clearly by design, not by accident.

The strategic logic is clear: each entity serves a different function (sourcing, manufacturing, distribution, or retail) and together they form a regional platform that gives Hafary multiple levers for growth beyond its dominant Singapore base.

But has the international expansion actually delivered? A track record assessment.

Hafary has been promising overseas expansion since at least AR2014, when the corporate profile noted it would “continue to explore overseas opportunities.” Tracking the annual reports year by year reveals a mixed but instructive record.

Vietnam: the longest-running bet (10+ years). Viet Ceramics International (VCI) was described as Hafary’s “first foray into the overseas tile retailing market” as early as the AR2014. By AR2015, it was a clear success: profit contribution of S$2.1 million, five showrooms across Vietnam (including new openings in Ho Chi Minh City’s Phu My Hung district in February 2015 and Hanoi in March 2016), and an Outdoor Sales Department - all credited to Vietnam’s 6.68% GDP growth. By AR2020, COVID had cut VCI’s profit contribution 55.7% to S$1.8 million, down from S$4.0 million in FY2019. By FY2025, the profit share had shrunk further to S$1.3 million, and the carrying value of the associate dropped by S$1.7 million due to the weakening Vietnamese Dong. Vietnam was supposed to be the proof of concept for overseas retail expansion, and it has been consistently profitable, but after more than a decade, it has never scaled beyond a modest profit contributor, and returns are trending in the wrong direction.

China: patient, multi-layered build-out. In AR2014, China was just Foshan Hafary Trading, an export agent. By AR2015, Hafary had completed the refurbishment of a 441,000 square-foot warehouse in Gaoming, Guangzhou, positioned as a logistics hub near a port for quick inventory shipping, with unused space leased for rental income. A pragmatic, low-risk move. By AR2020, a new entity had appeared: Guangdong ITA Element Building Materials Co., which moved Hafary from trading into actual glazed porcelain tile production in China. By FY2025, a third entity, MML Shanghai Trading, acquired from MMSB for S$2.8 million, expanded the project sales base, and combined China revenue reached S$8.5 million. China has been the most disciplined international expansion: each step was functional (sourcing → logistics → production → sales), each was relatively low-cost, and none was oversold in the annual reports. It has quietly become a meaningful market.

Myanmar: the risk that hasn’t killed the venture yet. Hafary Myanmar Company Limited entered a market with high construction growth and low competition. By AR2020, the CEO’s Statement acknowledged the elephant in the room: “With the recent developments in Myanmar arising from the military coup bringing uncertainty and unrest to the country, the performance of Hafary Myanmar may be affected in the next financial year.” That warning was prescient - but remarkably, the JV survived. By FY2025, it was generating S$2.1 million in revenue and S$0.8 million in profit share. The margins suggest it has carved out a viable niche, but the political risk remains existential and largely uncontrollable.

Malaysia: the slow-burn Hap Seng promise that eventually delivered. The AR2015 set expectations clearly: “The business combination between the Company and HSCB is expected to create strong synergistic benefits, as Hafary’s business as a downstream player is complementary to HSCB’s existing involvement in the building materials upstream market segment.” By AR2020, five years after the deal, the synergies had barely materialised. Hafary Trading Sdn Bhd was only incorporated in September 2020 as a wholly owned subsidiary “to capture any potential trading and distribution opportunities in future.” It took until June 2023, eight years after the Hap Seng deal closed, for the manufacturing segment to commence production at the Kluang facilities. But once it did, the results came fast: manufacturing revenue reached S$63.1 million by FY2025, Malaysia became the second-largest market at S$54.5 million, and the US emerged as an entirely new S$35.7 million export market - none of which was even hinted at in earlier annual reports. The Hap Seng synergy promise was real, but it required far more patience than the original framing suggested.

The US: the unannounced success. Not mentioned in any annual report prior to the manufacturing launch, the US went from zero to S$35.7 million in revenue by FY2025, driven entirely by manufactured tile exports from Malaysia. This is perhaps the strongest evidence that the manufacturing pivot has strategic merit. It unlocked a market that the distribution business alone could never have reached.

The scorecard: Malaysia and the US are unambiguous wins, albeit ones that took eight years to materialise. China has been a patient, disciplined build with solid progress. Vietnam has been consistently profitable but is stagnating and exposed to currency risk. Myanmar is profitable against the odds but remains a wild card. The pattern that emerges is that Hafary’s international expansion works best when it is connected to the Hap Seng manufacturing infrastructure (Malaysia, US, China via MML Shanghai) and is more fragile when it depends on standalone retail operations in developing markets (Vietnam, Myanmar). This distinction matters for how investors should weigh the international growth optionality in the bull case.

Industry Overview: Riding Singapore’s Construction Supercycle

The timing of Hafary’s expansion coincides with what analysts describe as a multi-year construction supercycle in Singapore.¹ BCA’s January 2026 release projects construction demand of S$43–46 billion in 2026,² while Hafary’s Chairman’s Statement cites a BCA forecast range of S$47–53 billion³ - the difference likely reflecting the inclusion of different project categories. Either way, the pipeline is substantial, supported by mega-projects including Changi Airport Terminal 5, the Tuas Megaport expansion, Marina Bay Sands IR2, and the ongoing HDB BTO programme.⁴

Singapore’s construction market is valued at approximately USD 25 billion (2025), projected to reach USD 34 billion by 2031 at a 5.4% CAGR.⁵ Medium-term annual demand is forecast at S$39–46 billion per year through 2030.²

For a company that supplies the finishing materials for virtually every type of construction project, this pipeline represents years of sustained downstream demand.

Competitive Advantages and Moat

Hafary’s moat rests on several interlocking advantages.

Market dominance in Singapore tiles. An estimated 50–60% share of the general consumer tile market. This was built over more than four decades through showroom network effects, supplier relationships, and brand recognition among renovation contractors and interior designers (the key decision-influencers in tile purchases).

Entrenched supplier relationships. Hafary is the exclusive Singapore distributor for Antolini, the Italian premium natural stone brand, according to the company. Decades of sourcing relationships with European and Asian manufacturers give the company access to products and pricing that new entrants cannot easily replicate.

Vertical integration via manufacturing, enabled by Hap Seng. The Kluang, Johor manufacturing facilities are strategically significant. They reduce dependence on third-party imports, improve gross margins on manufactured products, enable export to markets like the US (where S$35.7 million in revenue was generated in FY2025), and give Hafary control over quality and lead times. But this capability did not arise organically, it was made possible by Hap Seng’s 2015 acquisition and the subsequent integration with Malaysian Mosaics (MMSB), which brought six decades of ceramic manufacturing expertise and three existing Johor production facilities. Hafary’s manufacturing moat is inseparable from the Hap Seng relationship.

Property asset base. Hafary owns significant real estate: the 161 Lavender Street conservation shophouse block (acquired for S$71.3 million, now operating as Hafary House) and the World Furnishing Hub at 18 Sungei Kadut Street 2 (independently valued at S$72 million). These assets provide operating utility and represent embedded value on the balance sheet.

Durability of the moat: The distribution network and brand are durable; tiles are a fragmented, relationship-driven market, and switching costs for contractors are real (familiarity with product range, credit terms, delivery reliability). The manufacturing moat is earlier-stage and still needs to prove sustained profitability. The Hap Seng relationship is both an enabler and a dependency: it accelerates growth but concentrates strategic risk in a single controlling shareholder.

Financial Performance: A Decade in Numbers

The 10-year financial trajectory tells a clear story: steady pre-COVID growth, a pandemic dip, and then an explosive post-2020 recovery.

Revenue grew from S$109.6 million in FY2016 to S$287.0 million in FY2025, a 2.6x increase, representing an 11.3% CAGR. The manufacturing segment, which did not exist before FY2023, accounted for S$63.1 million of FY2025 revenue.

EBITDA expanded from S$16.5 million to S$70.9 million over the same period, with EBITDA margins improving from 15.1% to 24.7%. The margin improvement is notable: it suggests the business has operating leverage, and that the manufacturing segment (despite still being in ramp-up) has not diluted group profitability.

PATMI peaked at S$39.1 million in FY2023, driven by strong distribution margins and the initial ramp of manufacturing. FY2024 included a one-off gain of S$3.7 million on disposal of an investment property. FY2024 saw a normalisation to S$27.6 million before recovering to S$29.9 million in FY2025.

ROE has been consistently strong, averaging over 20% in recent years. FY2022 and FY2023 saw extraordinary ROE of 35% and 37% respectively, driven by profit growth on a still-modest equity base. FY2025 ROE of 21.7% remains well above cost of equity.

Balance sheet and leverage: Total assets have grown to S$509.8 million, driven by property acquisitions (161 Lavender Street, Sungei Kadut) and manufacturing capex. Net debt peaked at S$275.6 million in FY2024 and has since declined to S$255.1 million in FY2025. The net debt-to-equity ratio has improved from 2.7x in FY2022 to 1.7x in FY2025, still elevated but trending in the right direction. Interest cover stands at a comfortable 6.6x.

Operating cash flow was strong in FY2025 at S$57.9 million (vs S$22.6 million in FY2024), reflecting improved working capital management and higher profits.

Dividends have been consistently paid and growing. DPS increased from 1.0 cent in FY2016 to 2.75 cents in FY2025, with the current yield at approximately 5.5%. The payout ratio has moderated from over 50% in earlier years to around 40% in FY2025, suggesting room for further increases as earnings grow.

Key Growth Drivers (Next 3–5 Years)

1. Manufacturing segment reaching profitability. The segment has grown from zero to S$63 million in revenue in just over two years but is still moving towards breakeven at the operating level. Analysts expect breakeven by FY2026. If manufacturing achieves a 10–15% operating margin at scale, it could add S$6–10 million in incremental profit to the group.

2. Singapore construction supercycle. With S$43–53 billion in annual construction demand projected by BCA through 2030, Hafary’s core distribution business has a multi-year tailwind. Terminal 5, Tuas Port, MBS IR2, and ongoing HDB BTO provide sustained downstream demand for tiles and surfacing materials.

3. US and international export growth. US revenue grew from near zero to S$35.7 million in FY2025, driven by manufactured tile exports from Malaysia. If US construction demand holds and Hafary expands its distribution network, this could become a meaningful profit contributor.

4. Malaysia as a dual platform. Malaysia serves both as a market (S$54.5 million in revenue) and a manufacturing base. Growth in Malaysian construction (forecast 6.1% in 2026) supports both sides.

5. ASEAN and China network maturing into profit contributors. The web of associates, JVs, and subsidiaries across Asia is no longer just a seeding exercise, it is generating real returns. The Vietnam associate contributed S$1.3 million in profit share, the Myanmar JV contributed S$0.8 million, and Indonesia is already a S$7.8 million revenue market. China revenue reached S$8.5 million with the MML Shanghai acquisition expanding the project sales base. If even a few of these markets scale to S$15–20 million in revenue each over the next 3–5 years, the group’s revenue base diversifies meaningfully beyond its Singapore-Malaysia-US core, reducing concentration risk and opening new profit pools.

6. Property asset monetisation. The 161 Lavender Street and Sungei Kadut properties (combined ~S$143 million in acquisition/valuation) are carried at cost on the balance sheet. Any revaluation, partial divestment, or yield enhancement from Hafary House operations could unlock value.

Major Risks and Bear Case Scenarios

Leverage remains elevated. Net debt of S$255 million against shareholders’ equity of S$146 million (1.7x) is manageable but leaves limited room for error. A significant downturn in construction activity or a rise in interest rates could squeeze cash flows. Borrowing rates currently range from 1.5% to 5.4%.

Manufacturing execution risk. The segment is not yet profitable at the operating level. If production quality issues arise, demand softens, or US trade policy changes (tariffs on Malaysian exports), the manufacturing bet could become a drag on returns.

Customer and revenue concentration in Singapore. Despite geographic diversification, Singapore still accounts for 60% of revenue. A sharp construction downturn in Singapore would hit the core business hard.

Inventory and working capital intensity. Inventories stood at S$124 million at FY2025 year-end (266 days of turnover). This is characteristic of the business but ties up significant capital and creates impairment risk if demand weakens.

Key man risk. Founder-CEO Low Kok Ann has led the business since 1980. Succession planning and management depth beyond the founding family are important considerations.

Thin trading liquidity. Average daily volume of ~20,860 shares means institutional investors may struggle to build or exit positions. This limits the re-rating potential in the near term.

Management Quality and Capital Allocation

Understanding Hafary’s management requires understanding the 2015 ownership transition because it fundamentally reshaped who runs the company and why.

Before 2015: a family business. Low Kok Ann founded Hafary in 1980 and built it into Singapore’s leading tile distributor over three decades. By 2014, the Low family collectively controlled about 54% of the company: Low Kok Ann held 15.85%, his son Low See Ching (then CEO) held ~28.7% through direct and nominee accounts, and daughter Dr Low Bee Lan Audrey held 9.58%. Property developer Ching Chiat Kwong (co-founder of Oxley Holdings) held ~19%. It was, in every sense, a founder-led, family-run business.

The 2015 Hap Seng deal: trading control for scale. On 31 December 2014, Malaysia-listed Hap Seng Consolidated Berhad announced a voluntary partial cash offer to acquire 51% of Hafary at S$0.24 per share, a total consideration of S$52.5 million. The Low family and Ching Chiat Kwong gave irrevocable undertakings to accept, collectively selling down their stakes to make room for Hap Seng’s 51% block. The deal closed in early 2015. Low See Ching had already stepped down as CEO and been redesignated as Non-Independent Non-Executive Director in January 2014, with his father Low Kok Ann taking over as CEO.

The logic was strategic. Hap Seng’s building materials arm, anchored by Malaysian Mosaics Sdn Bhd (MMSB), a tile manufacturer since 1964, was upstream (manufacturing). Hafary was downstream (distribution) with dominant Singapore market share. The combination created an integrated building materials platform. The Low family gave up majority control but retained significant skin in the game and kept operational leadership. They traded control for access to Hap Seng’s manufacturing infrastructure, capital, and regional network.

Today: a dual-power structure. The company is effectively co-governed by two forces. Hap Seng holds 50.82% and provides two board seats (Datuk Edward Lee Ming Foo and Cheah Yee Leng, both appointed March 2015), manufacturing know-how through MMSB, corporate management services, and access to regional networks. The Low family holds ~39.1% combined (Low Kok Ann 8.56%, Low See Ching 25.44%, Low Bee Lan Audrey 5.14%) and provides the operational leadership; Low Kok Ann remains CEO, with a seasoned operational team built over decades in the tile industry.

This is not a typical parent-subsidiary relationship where the controlling shareholder dictates strategy. The founder is still CEO, his family still holds 39% and is deeply embedded in operations. But Hap Seng’s majority stake means they have the votes on any matter that goes to shareholders. The alignment has worked well so far, revenue has tripled and the manufacturing segment would not exist without it, but it is an unusual governance structure that depends on continued alignment between the Lau family (Hap Seng’s ultimate controllers) and the Low family.

Capital allocation has been aggressive but largely sound. The 161 Lavender Street acquisition (S$71.3 million) was a bold move that gave Hafary both a flagship showroom and a heritage property asset. The manufacturing push into Malaysia required significant capex but is now generating S$63 million in revenue and approaching breakeven. Dividend policy has been consistent: the company has paid dividends every year through the cycle, including during COVID, and has progressively increased DPS from 1.0 cent to 2.75 cents.

Recent governance improvements include the appointment of two new independent directors in July 2024 and a new CFO, strengthening the independent voice on a seven-member board that otherwise has two Hap Seng representatives and two Low family-linked directors.

The Hap Seng Connection: Parent Company, Partner, and Platform

Hap Seng Consolidated Berhad (Bursa: 3034) is a Malaysian conglomerate with a market cap of approximately RM 7.3 billion (~S$2.1 billion), operating across six segments: automotive (one of Southeast Asia’s largest Mercedes-Benz dealers), property development, plantations (oil palm), credit financing, trading (fertilizers and agro-chemicals), and building materials. Per public market data, it reported revenue of RM 5.63 billion and net profit of RM 650 million in FY2024.

The building materials connection runs deep. Hap Seng’s building materials arm includes Malaysian Mosaics Sdn Bhd (”MMSB”), one of Malaysia’s oldest ceramic tile manufacturers, founded in 1964, with products sold in over 50 countries under the MML brand. MMSB operates three production facilities in Johor, the same state where Hafary’s own manufacturing operations are based. This is not a coincidence. Notably, Hap Seng recently reorganised its ceramic tiles business under MMSB to the Building Materials Division under Hafary Holdings, a signal that Hafary is becoming the group’s primary building materials platform rather than just a subsidiary. Hafary’s rapid scaling of its manufacturing segment, from zero to S$63 million in revenue in just over two years, would have been far more difficult without access to MMSB’s six decades of production know-how, established facilities, and distribution infrastructure.

The interested person transaction disclosures reveal the breadth of commercial dealings between the two groups:

Total interested person transactions with the Hap Seng group amounted to S$7.5 million in FY2025 (down from S$20.1 million in FY2024, when tile purchases from MMSB were significantly higher at S$12.3 million). The FY2025 figures include a notable one-off: the S$2.8 million acquisition of MML Shanghai Trading Co., Ltd. from MMSB, which expanded Hafary’s project revenue base in China.

Beyond the Hap Seng relationship, there is also a secondary network of interested person transactions linked to director Low See Ching, including rental income from The Assembly Place Holdings (S$207K), property management fees to TAP Co-livings (S$336K), and the earlier S$4.5 million acquisition of the remaining 19% stake in World Furnishing Hub from Low See Ching in FY2024.

Governance considerations. With 50.82% control and only 10.04% of shares in public hands, minority shareholders have limited influence over strategic decisions. The interested person transactions, while disclosed and conducted under shareholders’ mandate, require ongoing scrutiny to ensure arm’s-length pricing. The presence of two Hap Seng representatives on a seven-member board concentrates influence. Investors should satisfy themselves that the governance framework, including the three independent directors and the Audit Committee’s oversight of IPTs, provides adequate safeguards.

An Alternative Route: Hap Seng vs Hafary as an Investment

An investor interested in Hafary’s building materials story might reasonably ask: should I buy the subsidiary directly, or buy the parent at a conglomerate discount?

The numbers reveal a clear trade-off. Hap Seng trades at 0.92x book value, a discount to its RM 3.19 NTA per share, with lower leverage (0.37x net debt/equity vs Hafary’s 1.7x) and a higher dividend yield (~6.8% vs ~5.5%). It is a more conservative, diversified holding. But its ROE is a modest 8.2%, its earnings have been declining (PATMI fell from RM 951 million in FY2022 to RM 650 million in FY2024), and its revenue has contracted for two consecutive years.

Hafary, by contrast, is a higher-octane bet: 21.7% ROE, 11.3% revenue CAGR over the past decade, and a clear growth trajectory from its manufacturing expansion. But it comes with higher leverage and a much thinner public float.

The critical exposure question: Hap Seng’s 50.82% stake in Hafary is worth approximately S$109 million (RM 371 million) at current market prices, just 5.1% of Hap Seng’s RM 7.3 billion market cap. Buying Hap Seng gives you a small slice of Hafary diluted across Mercedes-Benz dealerships, palm oil plantations, property development, and fertilizer trading. Buying Hafary gives you 100% pure-play building materials exposure to Singapore’s construction supercycle.

Neither is inherently better, they just serve different investment objectives. Hap Seng suits an investor seeking a diversified, income-generating Malaysian conglomerate trading below book value. Hafary suits an investor with conviction in the Singapore construction cycle and Hafary’s manufacturing pivot, willing to accept higher leverage and lower liquidity for concentrated upside.

Valuation

At S$0.50 per share, Hafary trades at 7.2x trailing P/E, approximately 6.6x EV/EBITDA (based on enterprise value of ~S$470 million and EBITDA of S$70.9 million), and 1.5x P/B (based on NAV of 33.9 cents per share). Dividend yield is approximately 5.5%.

These multiples are low relative to the broader Singapore construction sector. The discount likely reflects Hafary’s small-cap status, thin liquidity, the still-unproven manufacturing segment, and elevated leverage.

NAV perspective: NAV per share of 33.9 cents likely understates intrinsic value because key properties (161 Lavender Street, Sungei Kadut) are carried at historical cost. An independent valuation of the Sungei Kadut property alone was S$72 million, suggesting meaningful embedded value not reflected in the book.

Earnings perspective: At current earnings levels, the multiple is undemanding. Investors should consider whether the manufacturing segment’s path to profitability and the construction supercycle justify a higher or lower multiple, and form their own view accordingly.

Recent Developments and Catalysts

The twelve months to April 2026 have been eventful and the market has started to take notice. Hafary’s share price has risen approximately 49% over the past year, from a 52-week low of S$0.32 to trade around S$0.50, though it remains well below the 52-week high of S$0.60.

FY2025 results (released February 2026) delivered across every metric that matters. Revenue grew 9.1% to S$287 million. Gross margins expanded from 40.3% to 41.1%, indicating that the revenue mix is improving, not just growing. Operating cash flow more than doubled, from S$22.6 million to S$57.9 million, the strongest in recent memory. Net debt declined by S$20.5 million to S$255.1 million, and finance costs fell 12% to S$10.7 million as bank loan interest rates eased. The balance sheet, which had been a persistent concern, is healing.

Hafary House officially opened in January 2025, a 10,000 square-foot luxury flagship showroom at 161 Lavender Street, following a S$3 million refurbishment of the conservation shophouse block. This is more than a showroom upgrade. It positions the Hafary brand in the premium residential segment, targeting GCB owners, high-end renovation projects, and architectural firms, a market where margins are higher and brand differentiation matters more. The ground floor houses F&B and commercial tenants, while upper floors are managed as co-living spaces by The Assembly Place, generating rental income from the property.

Hap Seng reorganised its ceramic tiles business under Hafary. In a structural move that signals Hafary’s growing importance within the group, Hap Seng transferred the Building Materials Division, including MMSB’s operations, to sit under Hafary Holdings rather than as a separate Hap Seng division. This consolidation positions Hafary as the group’s primary building materials platform across the region, not merely a downstream distributor. It also suggests Hap Seng views Hafary’s management as capable of running a larger, more integrated operation.

MML Shanghai was acquired and consolidated from January 2025, expanding Hafary’s project revenue base in China. The S$2.8 million acquisition from MMSB brought a ready-made sales entity that contributed to the 2.2% project segment revenue growth in FY2025, a modest start, but it establishes Hafary’s direct presence in China’s project market for the first time.

Board and management refreshment. Two new independent directors were appointed in July 2024: Darrell Lim (who also sits on the board of BRC Asia Limited (SGX: BEC), Singapore’s largest steel reinforcement supplier) and Lim Wah Fong (with over 20 years of capital markets experience as a research analyst and senior portfolio manager). A new CFO was also appointed. These moves strengthen the independent voice on a seven-member board and bring capital markets expertise at a time when the company could benefit from improved investor communication and coverage.

Macro tailwinds for SGX small/mid-caps. The Straits Times Index broke historical highs and crossed 5,000 during 2025, and as noted in Hafary’s own Chairman’s Statement, “capital market stakeholders are predicting further upside by the end of 2026.” The ongoing MAS EQDP capital injection programme and SGX’s Value Unlock initiative are channelling institutional attention towards under-covered small and mid-cap stocks, exactly the category Hafary falls into, with its S$215 million market cap, 10% public float, and minimal analyst coverage.

Bull vs Bear Investment Thesis

The Bull Case: Hafary is a dominant market leader in an essential, non-discretionary construction material, trading at undemanding multiples relative to peers. The manufacturing segment is inflecting towards profitability, which could add S$6–10 million in incremental profit. Singapore’s multi-year construction supercycle provides a long runway for the core distribution business. US export growth adds a new dimension. The breadth of the international network, profitable associates in Vietnam, a producing JV in Myanmar, established revenue streams in Indonesia (S$7.8 million), China (S$8.5 million), and a dozen other markets, means the company has multiple optionalities beyond its Singapore core. If even two or three of these markets scale meaningfully, the revenue base diversifies in ways the current valuation does not reflect. Property assets are undervalued on the balance sheet. Consistent dividend payments provide a meaningful yield while investors wait.

The Bear Case: Leverage is elevated and leaves limited cushion for a downturn. Manufacturing is unproven at scale and may struggle to achieve sustainable margins, particularly if US tariff policy shifts. Singapore construction demand could soften if mega-projects face delays or if the economy slows. The international expansion, while promising, also introduces execution complexity: managing subsidiaries, associates, and JVs across 15 countries requires management bandwidth and exposes the group to currency risk (the Vietnamese Dong weakened materially in FY2025, reducing the carrying value of the Vietnam associate by S$1.7 million), political risk (Myanmar remains unstable), and the challenge of maintaining quality and brand consistency across fragmented markets. Inventory of S$124 million represents significant impairment risk. Thin liquidity (10% public float, ~20,860 shares daily volume) means the stock could be volatile. CEO Low Kok Ann has led the business since 1980, succession planning is a genuine concern given the dual-power structure between the Hap Seng and Low families. The alignment between the Lau family (Hap Seng’s controllers) and the Low family has worked well so far, but any divergence in strategic priorities could create governance friction. And for investors used to more liquid, widely-held stocks, the concentrated ownership structure may be a structural deterrent.

Key Factors That Could Break the Thesis

On the bull side, watch for: manufacturing segment turning profitable (analysts expect breakeven by FY2026), sustained revenue growth above S$300 million, net debt-to-equity declining below 1.5x, Indonesia or China revenue crossing S$15 million (signalling a third pillar market is maturing), any property revaluation or strategic asset move, and increased analyst coverage or institutional interest.

On the bear side, watch for: construction demand falling below BCA forecasts, manufacturing margins remaining negative beyond the expected FY2026 breakeven, a spike in interest rates increasing finance costs materially (currently S$10.7 million), impairment charges on inventory or receivables, write-downs of international associates or JVs (particularly if Myanmar deteriorates or the Vietnam Dong continues weakening), and any regulatory or trade policy changes affecting Malaysian exports to the US.

Summary

Hafary Holdings has evolved from a single-product tile trader into a S$287 million revenue platform spanning distribution, project supply, and manufacturing across multiple geographies. The company’s 50–60% share of Singapore’s general consumer tile market, built over more than four decades, is a genuine competitive advantage, and one that is difficult to replicate.

The 2015 Hap Seng acquisition was the pivotal inflection point. It transformed a family-run distributor into the building materials arm of a RM 7.3 billion Malaysian conglomerate, giving Hafary access to manufacturing infrastructure, regional networks, and capital that it could not have built alone. The Low family’s decision to trade majority control for scale has, by the numbers, paid off handsomely: revenue has tripled, a new manufacturing segment has emerged, and the company is now exporting tiles to the US. But it also created an unusual governance structure, the original founder still running day-to-day operations, a Malaysian conglomerate holding 50.82%, and a public float of just 10%, that investors need to understand and be comfortable with.

The financial track record is strong: revenue has grown at an 11.3% CAGR over the past decade, EBITDA margins have expanded from 15% to nearly 25%, and ROE has consistently exceeded 20% in recent years. Dividends have been paid every year through the cycle, including during COVID.

The key question facing the business is whether the manufacturing segment, still approaching breakeven, can deliver on its promise of margin expansion and export-driven growth. If it does, Hafary’s earnings power steps up meaningfully. If it doesn’t, the company remains a well-run distributor with elevated leverage from its aggressive expansion phase.

On the macro side, Singapore’s multi-year construction supercycle provides a supportive backdrop, but this is not a risk-free tailwind: project delays, interest rate movements, and trade policy shifts all matter for a company with S$255 million in net debt.

For those considering the building materials theme but preferring a different risk profile, the parent company Hap Seng Consolidated offers a diversified alternative at 0.92x book value with lower leverage and a higher dividend yield, though with only ~5% exposure to Hafary’s story.

References

All financial data sourced from Hafary Holdings annual reports (FY2010–FY2025) and SGX announcements. Market data from public sources as of April 2026

¹ DBS Group Research, "From Backlog to Breakout," March 2026, https://www.dbs.com.sg/sme/aics/templatedata/article/generic/data/en/GR/032026/260302_insights_sg_construction.xml

² BCA Media Release, 22 January 2026, "Steady Construction Demand in 2026," https://www1.bca.gov.sg/resources/newsroom/steady-construction-demand-in-2026-as-singapore-steps-up-support-for-built-environment-firms-through-collaboration-and-innovation/

³ Hafary Holdings AR2025, Chairman and CEO Statement, p.14, citing BCA-REDAS Built Environment and Real Estate Prospects Seminar 2026.

⁴ Hafary Holdings AR2025, Chairman and CEO Statement, p.14.

⁵ Mordor Intelligence, "Singapore Construction Industry Report," https://www.mordorintelligence.com/industry-reports/singapore-construction-market; also cited in GlobeNewsWire, 23 February 2026.

IMPORTANT DISCLAIMERS

General Disclaimer: This article is published for informational and educational purposes only. It does not constitute financial advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The views expressed are based on publicly available data from Hafari Holdings’ SGX filings and publicly accessible market data, and may not reflect the most current developments.

Not Licensed Financial Advice: The author is not a licensed financial adviser, and this publication is not issued by a holder of a Capital Markets Services Licence under the Securities and Futures Act 2001 of Singapore. This content does not fall within the definition of “financial advisory service” under the Financial Advisers Act 2001 of Singapore. Readers in Singapore should note that this content is exempt from the requirements of the Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication.

MAS Compliance Notice: In accordance with the Monetary Authority of Singapore’s guidelines, this publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, you should consult a licensed financial adviser who can provide advice tailored to your personal circumstances. Past performance of any security discussed herein is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author may or may not hold positions in the securities discussed. No compensation has been received from any company mentioned in this article.

The disconnect between operational performance and share price warrants closer examination. This report walks through the full picture.

The Business: How Coliwoo Makes Money

Coliwoo acquires or leases old, underutilised buildings across Singapore, converts them into co-living spaces, and operates them. The business model combines value-add real estate repositioning with a hospitality operations platform. As of the IPO prospectus, the portfolio spanned 25 properties and 2,933 rooms across three tiers. With the completion of the S$101M Changi Business Park acquisition in Q1 FY2026, the portfolio has grown to approximately 3,200 rooms.

Leased properties (~71% of FY2024 revenue, 1,855 rooms at IPO): Coliwoo signs master leases with building owners, pays fixed rent, and captures the spread between rent cost and tenant revenue. The largest single property is 2 Mount Elizabeth Link in Orchard (411 rooms). This is the core of the business — capital-light, scalable, but exposed to lease renewal risk.

Owned properties (~26% of FY2024 revenue, 670 rooms at IPO): Higher capital intensity, better long-term economics. Includes properties across River Valley, Balestier, Beach Road, and Arab Street. Owned property occupancy improved from 73% in FY2022 to 95.5% in 1H2025.

Managed properties (~3% of FY2024 revenue, 408 rooms): Pure fee income. Includes two MOHH contracts for healthcare worker housing and — notably — two properties owned by CEO Kelvin Lim’s personal entities (classified as Interested Person Transactions).

The dual hotel/residential licensing model is worth noting. Some properties hold hotel licenses (allowing 1-night stays), while others operate under residential co-living rules (3-month minimum). This flexibility allows Coliwoo to fill short-stay gaps with tourist traffic during low seasons.

The Numbers: Strong, But Read the Fine Print

*) FY2025 revenue decline partly due to non-recurrence of one-time retrofitting income; owned rental income +23.9%
**) Reported PATMI distorted by fair value swings on investment properties

A note on accounting basis: Coliwoo’s prospectus presents FY2022-FY2024 financials on a pre-SFRS(I)16 basis, while the FY2025 annual report uses SFRS(I)16. This matters — SFRS(I)16 capitalises leases, which changes revenue recognition and margin calculations. Revenue figures and margins may not be directly comparable across periods without adjustment.

On a pre-SFRS(I)16 basis (prospectus data), revenue grew from S$19.8M in FY2022 to S$52.2M in FY2024. FY2025 revenue on an SFRS(I)16 basis was S$46.7M, though the decline partly reflects the non-recurrence of one-time retrofitting income — owned rental income actually rose 23.9%.

The metric that matters is core PATMI. Reported net profit is unreliable for Coliwoo because fair value swings on investment properties create wild distortions (S$14.9M gain in FY2024, S$7.4M loss in FY2025). Strip those out, along with IPO costs and share of associate/JV results, and the picture becomes clearer. On this core basis, management reported that FY2025 core PATMI surged 62.6% year-on-year to approximately S$22.9M. The three-year trajectory from S$7.0M (FY2022 adjusted, pre-SFRS(I)16 basis) to S$22.9M represents a 48% CAGR — though comparing across accounting bases requires caution.

Gross margins have been in the 60-75% range on a pre-SFRS(I)16 basis (74.7% in FY2022, 54.6% in FY2023, 60.2% in FY2024) and reached 70.8% in 1H2025. The FY2023 dip reflects the rapid scaling of new leased properties before they reached full occupancy. Operating cash flow jumped from S$15.4M to S$24.8M in FY2025. Working capital dynamics are favourable: tenants prepay (2-4 day receivables), while Coliwoo stretches payables to 19-25 days.

The portfolio composition has shifted over time. Leased properties accounted for roughly 80% of rooms in FY2022 but have declined to about 63% as of the IPO prospectus date, as owned and managed properties grew as a share of the total. Management has diversified away from pure leased concentration — owned properties provide better long-term economics, while managed properties offer capital-light fee income.

The Moat Question: What’s Defensible?

This is where most analysis of Coliwoo falls short. An honest assessment: the moat is moderate, not structural.

What IS defensible: LHN Group sponsorship is the strongest factor. LHN retains a 65% stake, provides deal pipeline, operational expertise in space optimisation, and balance sheet backing. LHN has delivered strong total shareholder returns (397% over 5 years per one December 2025 report, though an earlier February 2024 measurement put it at 161%). The combination of 25+ properties, established brand (55K+ social media followers, multiple awards), and dual licensing flexibility creates real operational advantages.

What ISN’T defensible: The regulatory moat is almost non-existent. A URA change-of-use approval through the fast-track “deemed authorised” route costs S$150 and can be instant; the standard route costs S$500 and takes about 10 working days. Any operator with capital can enter Singapore’s co-living market. The technology “platform” is operational tooling, not defensible IP.

The competitive reality: The Assembly Place (TAP.SI, listed on Catalist in January 2026) now operates more rooms — 3,422 keys across approximately 100 assets — compared to Coliwoo’s 2,933 at IPO (now approximately 3,200). Habyt has $120M in venture funding. The top 5 operators control 65% of the market, and the sector is consolidating.

Management: What the Record Shows (And Doesn’t)

Kelvin Lim founded Coliwoo in 2018 within LHN Limited, secured a Mainboard listing, and attracted cornerstone investors including Maybank AM, UOB AM, and Value Partners. The execution track record is strong. In seven years, the business grew from zero to over 3,000 rooms.

However, several aspects warrant scrutiny. The prospectus — all 800 pages of it — does not disclose Kelvin Lim’s age, education, or prior career history beyond his role at LHN. That is unusual for a Mainboard listing. He serves as Executive Chairman AND CEO, concentrating significant authority. Two managed properties are owned by his personal entities (Interested Person Transactions, though small at 57 rooms).

The parent company picture is also worth noting. LHN’s ROE is 7.9% — weak for a real estate operator. Consensus expects LHN’s EPS to decline 8.5% in FY2025. Coliwoo contributes 56% of LHN’s 1H2025 pre-tax profit — a substantial dependency. If Coliwoo’s growth slows, LHN’s financials deteriorate, which could reduce the parent’s capacity to support expansion.

Recent capital allocation has been aggressive but strategic: a S$43.9M sale-leaseback (capital recycling), S$40M JV acquisition, and the S$101M Changi Business Park deal. The 40% dividend payout policy balances returns with reinvestment. The question is whether these investments generate returns that justify the capital deployed — something that will only become clear in 12-18 months.

Occupancy: The Headline Number Needs Context

The 96.8% portfolio-level occupancy (as of 1H2025) is strong. The Q1 FY2026 business update reported 96.5% as of January 31, 2026.

Breaking it down by property type, the data available from the prospectus shows: Owned properties improved from 73.0% in FY2022 to 95.5% in 1H2025 — strong execution on a previously underperforming segment. Leased properties were at 97.3% in FY2022 and 96.6% in 1H2025. Managed properties run at 98.7%, largely driven by MOHH healthcare contracts with guaranteed demand. (Note: Intermediate-year occupancy breakdowns by property type are not fully disclosed in the prospectus or annual report.)

The risk is that 96.8% occupancy leaves almost no room for improvement — it can really only go sideways or down. As Coliwoo targets adding 800-1,000 rooms annually, maintaining near-full occupancy during ramp-up periods for new properties will be a challenge worth monitoring.

Valuation: Context Matters More Than Headline Multiples

At S$0.50 per share (480.8M shares outstanding):

• Market cap: ~S$240M

• P/E on FY2025 core PATMI (~S$22.9M): ~10.5x

• Price/Book: ~1.87x (equity S$128.1M)

• Dividend yield: ~3.5% (based on 40% payout policy)

• EV/EBITDA: ~16x

The 10.5x P/E is not obviously cheap for a Singapore-listed small-cap property operator with moderate competitive moats. Both Coliwoo and Assembly Place trade below their IPO prices — the market has repriced co-living sector expectations.

A directional fair value estimate, assuming 20% core PATMI growth for 3 years followed by 10% for 2 years, a terminal growth rate of 3%, and a 10% discount rate, points to approximately S$0.55-0.60 per share. This is a rough estimate, not a rigorous DCF model, and the result is sensitive to growth assumptions. The 10-20% potential upside provides a thin margin of safety, given execution uncertainties.

The January 2026 analyst target of S$0.74 (from a single visible coverage initiation) implies roughly 48% upside from today’s price. With limited analyst coverage and the target predating several months of trading, it should be treated as one data point rather than an anchor.

Key Catalysts to Monitor

Bullish triggers: Changi Business Park occupancy ramp (250+ rooms), FY2026 core PATMI exceeding S$28M (confirming growth trajectory), any concrete regional expansion deal, continued MSCI-driven institutional interest.

Bearish triggers: Occupancy falling below 90%, non-renewal of 2 Mount Elizabeth Link lease (411 rooms = ~13% of expanded portfolio), LHN financial deterioration, or management turnover.

Assessment

Coliwoo is a well-run business in a growing market with real operational strengths. The 96.8% occupancy, strong gross margins, and 48% core PATMI CAGR over three years are notable.

But “good business” and “good investment at this price” are different questions. The moat is moderate, the competitive position is being challenged by The Assembly Place and well-funded private operators, the parent company shows earnings weakness, and the margin of safety at S$0.50 appears thin.

The bull case rests on: the 48% core PATMI CAGR continuing, Changi Business Park ramping successfully, MSCI inclusion driving institutional demand, and LHN’s deal pipeline delivering accretive acquisitions. If FY2026 core PATMI exceeds S$28M, the growth thesis strengthens considerably.

The bear case rests on: moderate moats in a consolidating market, Assembly Place’s larger portfolio, LHN’s declining earnings trajectory, and the risk that near-full occupancy cannot be sustained as the portfolio expands rapidly. Both co-living IPOs trading below issue price suggests the market is pricing in risks the bulls may be underweighting.

The co-living sector in Singapore has structural tailwinds — urbanisation, expatriate demand, housing affordability constraints. The question for Coliwoo specifically is whether operational advantages can compound into durable competitive advantages before well-funded competitors close the gap. The next 12 months will be telling.

Data sources: Coliwoo FY2025 audited annual report (PwC), IPO Prospectus dated 28 October 2025 (registered with MAS), Q1 FY2026 business update, SGX corporate announcements, market data as of April 2026. Financial figures prior to FY2025 are on a pre-SFRS(I)16 basis unless otherwise noted.

IMPORTANT DISCLAIMERS

General Disclaimer: This article is published for informational and educational purposes only. It does not constitute financial advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The views expressed are based on publicly available data from Coliwoo Holdings Ltd’s SGX filings and publicly accessible market data, and may not reflect the most current developments.

Not Licensed Financial Advice: The author is not a licensed financial adviser, and this publication is not issued by a holder of a Capital Markets Services Licence under the Securities and Futures Act 2001 of Singapore. This content does not fall within the definition of “financial advisory service” under the Financial Advisers Act 2001 of Singapore. Readers in Singapore should note that this content is exempt from the requirements of the Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication.

MAS Compliance Notice: In accordance with the Monetary Authority of Singapore’s guidelines, this publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, you should consult a licensed financial adviser who can provide advice tailored to your personal circumstances. Past performance of any security discussed herein is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author may or may not hold positions in the securities discussed. No compensation has been received from any company mentioned in this article.

Here’s what caught my attention: the company just posted record revenue of S$163.5 million in FY2025, growing 14% year-on-year. Net profit hit S$19.2 million. And yet the market values the entire company at around S$183 million, less than half the S$322 million of net assets sitting on its balance sheet.

Let’s unpack why.

What Does Tiong Woon Actually Do?

Tiong Woon is an integrated heavy lift and haulage specialist. If you need to lift 3,600 tonnes of refinery equipment in India using a pair of ultra-heavy crawlers, or hoist a beam launcher frame onto the Pan-Island Expressway, these are the people you call.

The company operates through three segments, though one overwhelmingly dominates:

Heavy Lift and Haulage (98% of FY2025 revenue, S$159.9M): This is the core business: project planning and engineering, heavy lift execution using mobile, crawler, and tower cranes, heavy haulage with modular transporters and prime movers, rigging, jacking and skidding services, and barge transportation for oversized cargo. Revenue grew 15% from S$139.4M in FY2024 to S$159.9M in FY2025.

Marine Transportation (~1%): Sea transportation using tugs and barges. A small segment but one that has been recovering: fleet utilisation improved to 35% in FY2022 after bottoming at 31% in FY2021.

Trading (~1%): Authorised dealer for XCMG products in Southeast Asia and KATO crawler cranes in ASEAN, plus parts distribution and after-sales services. Strategically useful as it supports the core heavy lift business.

The fleet is massive: 600+ cranes and heavy lifting assets, with capacities up to 2,200 tonnes. In FY2025 the company added an XCMG XGC12000 (800T) crawler crane, further strengthening its ultra-heavy lift capabilities. Plus 359 transportation assets, prime movers, low beds, trailers, and marine vessels. The company owns yards and offices across 12+ countries.

Geographically, Singapore is the dominant market at 73% of FY2025 revenue (S$119.1M). India and Thailand each contributed 7% (S$11.9M each). The balance is spread across Indonesia, Brunei, the Middle East, and other regional markets. Singapore’s share has been fairly stable in the 73–78% range over recent years.

The Numbers: A Decade of Turnaround

The financial story is one of dramatic recovery and, more recently, acceleration

The downturn years (FY2016–FY2018)

In FY2016–2017, Tiong Woon posted combined losses of nearly S$20 million. The oil and gas downturn hammered demand for heavy lift services. To make matters worse, the company took massive trade receivable impairments: S$9.8M in FY2016 and S$5.9M in FY2017, largely related to a long-outstanding receivable from Saudi Arabia that was eventually fully written off.

Revenue fell from S$139.4M in FY2016 to just S$97.7M in FY2018, the trough year. But even at the bottom, operating cash flow remained positive at S$23.9M, the underlying business was still generating cash despite the reported losses. This is an important nuance: the losses were driven more by impairments and below-the-line items than by operational cash burn.

The recovery (FY2019–FY2022)

FY2019 marked the inflection point. Revenue climbed back to S$117.2M and the company returned to profitability, albeit modestly (PATMI of S$2.9M, EPS of 1.27 cents). FY2020 saw revenue grow to S$124.7M despite the COVID-19 disruption, the company was able to continue operating in essential services sectors (oil and gas, marine, logistics) even during the Circuit Breaker.

Margins began expanding meaningfully. Gross profit margin improved from 26% in FY2018 to 35% in FY2020 and 40% in FY2022, driven by better pricing, improved fleet utilisation, and a focus on higher-value projects. The Heavy Lift and Haulage segment specifically saw margin improvement as the company invested in fleet management and cost control.

The acceleration (FY2023–FY2025)

The past three years represent the strongest financial performance in the company’s history:

• FY2023: Revenue S$135.8M (+11% YoY), PATMI S$15.7M (+38%), gross margin 39.9%

• FY2024: Revenue S$143.1M (+5%), PATMI S$18.2M (+16%), gross margin 41.2% (peak)

• FY2025: Revenue S$163.5M (+14%), PATMI S$19.2M (+6%), gross margin 37.6%

A few things stand out from the numbers:

Margin trajectory: Gross margins expanded from 23% in FY2016 to a peak of 41.2% in FY2024. FY2025 saw a pullback to 37.6%, which the annual report attributes to project sales mix and higher indirect manpower costs. The 14% revenue growth only translated to 4% gross profit growth (S$59.0M to S$61.4M), which tells us the incremental revenue came at lower margins than the existing base.

Is this a temporary blip or the beginning of margin normalisation? The answer likely depends on fleet utilisation trends. Utilisation dipped slightly from 56% in FY2024 to 54% in FY2025, even as the fleet expanded from 543 to 600+ units. That 2-percentage-point decline, combined with higher overhead from a larger fleet, explains most of the margin compression.

Other operating expenses have been growing: S$36.8M in FY2025 vs S$34.3M in FY2024 and S$25.8M in FY2021. This line includes staff costs, which have risen as the company scaled up to 1,223+ employees. These costs are somewhat sticky, they don’t shrink quickly if demand softens.

Impairment losses have shrunk dramatically, from S$3.7M in FY2020 to S$0.9M in FY2025. The company has clearly cleaned up its receivables book.

Finance costs remain moderate at S$4.2M in FY2025, though they’ve been creeping up from S$2.8M in FY2022 as borrowings increased for the FY2025 capex cycle.

EPS has grown from a loss of 4.16 cents in FY2016 to a positive 8.29 cents in FY2025, a complete transformation. The 7-year EPS CAGR from FY2018’s 0.51 cents to FY2025’s 8.29 cents is approximately 49%, though this is from a depressed base.

Balance Sheet: The Hidden Strength

Here’s where it gets really interesting for value-oriented investors.

Asset composition

Total assets grew from S$413M in FY2018 to S$532M in FY2025. The balance sheet is dominated by Property, Plant and Equipment at S$387M. That’s cranes, heavy lifting equipment, yards, and other physical assets. PPE alone exceeds the entire market capitalisation (S$183M) by more than 2x.

Right-of-use assets add another S$11.7M, and cash and bank deposits stand at S$64.5M (down from S$81.1M in FY2024, reflecting the heavy capex year). Trade receivables of S$59.0M are up from S$53.0M in FY2024, consistent with the revenue growth.

Deleveraging story

The most impressive balance sheet trend is the deleveraging. Net gearing has declined from 0.48x in FY2016 to just 0.15x in FY2025. Here’s how that played out:

Total borrowings fell from S$136M in FY2016 to a trough of S$92.8M in FY2024, while net assets grew from S$255M to S$309M over the same period. In FY2025, borrowings increased to S$111.8M to fund the major fleet expansion (S$45.2M capex), but net gearing of 0.15x is still very conservative for an asset-intensive business.

The company’s borrowings are split between current (S$21.6M) and non-current (S$90.2M). The non-current portion increased significantly in FY2025, suggesting the fleet investments are being financed with long-term facilities, a sensible match of asset life to financing tenor.

Net assets

Net assets have grown steadily from S$247.6M in FY2017 to S$322.3M in FY2025, translating to NAV per share of S$1.39. This compares to a current share price in the S$0.60–0.81 range, meaning the stock trades at 0.43x–0.58x book value.

Now, specialised heavy lift equipment may not be worth full book value in a distressed sale. Cranes and modular transporters are expensive to transport and maintain, and buyer pools are limited. But the equipment is productive and generating returns, not sitting idle. And the consistent cash generation (see next section) validates the earning power of these assets.

Cash Flow: The Real Test

One of the most important tests for an asset-heavy business: does it actually generate cash? Or do the depreciation charges mask a business that’s barely earning its cost of capital?

Operating cash flow

Operating cash flow has been consistently positive for the entire 10-year period, even during the loss years. OCF ranged from S$23.9M (FY2018, the trough) to S$54.5M (FY2020). FY2025 saw strong OCF of S$51.4M, up 30% from FY2024’s S$39.5M, driven by higher earnings and working capital improvements.

A key metric: depreciation consistently runs at S$30–35M per year (S$34.8M in FY2025, comprising S$33.9M on PPE and S$0.9M on right-of-use assets). The fact that OCF of S$51.4M comfortably exceeds depreciation means the business is generating real economic profit, not just accounting profit.

Capital expenditure cycles

Capex has been highly variable, ranging from just S$3.6M in FY2023 to S$45.2M in FY2025. This reflects the lumpy nature of fleet investment. Cranes are expensive assets purchased when specific growth opportunities justify them.

The FY2025 capex of S$45.2M is the highest in the company’s recent history and represents a major growth bet. The annual report highlights the addition of the XGC12000 (800T crawler crane) as a strategic investment to expand ultra-heavy lift capabilities. This is equipment that positions the company to compete for the largest projects in the region, the kind that previously would have gone to international players like Mammoet or Sarens.

The company partially offset the capex through disposal proceeds of S$8.8M (selling underutilised older equipment), bringing net investment to approximately S$36.4M.

Free cash flow

Free cash flow (OCF minus capex) has been positive in 9 of the 10 years, with only FY2025 essentially breakeven at S$6.2M due to the heavy investment year. The cumulative FCF over the 10-year period is approximately S$204M, which is remarkable for a company with a current market cap of S$183M, investors are essentially buying the entire company for less than one decade of free cash flow.

Dividend payments

Dividends paid have grown from zero (FY2018–2019) to S$3.5M in FY2025. Even at the current payout level, dividends represent less than 7% of OCF, leaving substantial capacity for further increases or investment.

Dividends: Small but Growing Fast

Tiong Woon suspended dividends during the downturn years (FY2018–2019) but has reinstated and progressively increased them:

• FY2020: 0.30 cents

• FY2021: 0.40 cents (0.30 regular + 0.10 special)

• FY2022: 0.50 cents (0.35 + 0.15 special)

• FY2023: 1.00 cent (0.40 + 0.60 special)

• FY2024: 1.50 cents (0.60 + 0.90 special)

• FY2025: 1.75 cents (final only, subject to AGM approval)

That’s nearly a 6x increase in six years, from 0.30 cents to 1.75 cents. At a current price of S$0.76 (midpoint), the trailing yield is approximately 2.3%.

The payout ratio remains conservative at roughly 19% of earnings. With EPS of 8.29 cents and DPS of 1.75 cents, the company is retaining over 80% of earnings for reinvestment. There’s substantial room to grow the dividend further without straining the balance sheet.

The progressive introduction of special dividends alongside regular dividends is a positive signal. It suggests management is willing to return capital to shareholders when results are strong, while maintaining flexibility by not locking in unsustainably high regular dividends

.Competitive Position and Industry Context

Tiong Woon’s competitive positioning is strengthened by several factors:

Fleet scale: With 600+ cranes ranging from small mobile units to 2,200T capacity crawlers, the company can handle projects of virtually any scale. This breadth matters because customers increasingly prefer one-stop solutions rather than engaging multiple contractors.

Track record: Decades in the business, with the kind of safety and execution record that gets you invited to bid on complex projects. Recent showcase projects include the PIE Beam Launcher Frame installation (using a 900T mobile crane and 10-axle modular transporter), a 3,600-tonne combined lift at the Numaligarh Refinery in India (deploying 1,600T and 2,200T crawler cranes to install four reactors), and heavy lifting works at Jurong Island petrochemical facilities.

Only listed pure-play in SEA: After Tat Hong Holdings was taken private in 2018, Tiong Woon became the only publicly listed pure-play heavy lift specialist in Southeast Asia. Most competitors, Mammoet (Netherlands), Sarens (Belgium), Moh Seng, Pollisum, Hiap Tong, are private. This is both a competitive dynamic (less public scrutiny on competitors) and a scarcity factor for investors who want exposure to this niche.

Mammoet MoU (FY2024): The company signed a Memorandum of Understanding with Mammoet, the global leader in heavy lift. While MoUs don’t always materialise into revenue, a partnership with the world’s largest heavy lift company could unlock projects that neither party could win alone.

The industry backdrop is favourable. Singapore’s infrastructure pipeline (Tuas expansion, MRT network extensions, petrochemical investments on Jurong Island) represents multi-decade demand. The broader SEA mobile crane market is projected to grow at 8.4% CAGR through 2029.

Ownership and Governance

Tiong Woon is family-controlled. The Ang family holds approximately 39% through Ang Choo Kim & Sons Pte. Ltd. Executive Chairman Ang Kah Hong has led the business since its early days; CEO Ang Guan Hwa (appointed 2020) represents the next generation.

The family’s significant stake creates alignment - they’re eating their own cooking. But it also means limited free float (roughly 50% retail), which constrains liquidity and institutional participation.

The board includes two independent directors who chair the Audit, Nominating, and Remuneration committees, meeting SGX’s governance requirements. Capital allocation decisions over the past decade have been sensible: deleveraging during the downturn, preserving cash, then investing aggressively into the upcycle.

Valuation: Why Is It So Cheap?

Let’s look at the numbers from multiple angles.

P/E of ~9.2x (based on FY2025 EPS of 8.29 cents at a ~S$0.76 midpoint). For a company that’s delivered 7 consecutive years of profit growth and just posted record revenue, this is modest. Regional industrial companies on SGX typically trade at 10–15x earnings.

P/B of ~0.43x–0.58x. Net asset value per share is S$1.39 versus a share price of S$0.60–0.81. The stock would need to roughly double to reach book value. While specialised equipment may carry an asset-realisation discount, the earning power of these assets is being demonstrated year after year.

EV/EBITDA of ~3.6x. EBITDA from first-party data is approximately S$63.3M (PBT S$24.4M + interest expense S$4.2M + PPE depreciation S$33.9M + ROU depreciation S$0.9M). Enterprise value is roughly S$230M (market cap S$183M + total borrowings S$111.8M – cash S$64.5M). At 3.6x EV/EBITDA, the company still trades at a significant discount to typical industrial multiples of 6–8x.

Dividend yield of ~2.3%. Not a screaming yield, but the nearly 6x growth over six years suggests this will continue climbing. If DPS reaches 3.0 cents in the next 2–3 years (plausible at a 19% payout ratio with modest earnings growth), the yield on today’s price would be ~4%.

Why the discount? Several structural factors likely explain it:

• Small market cap (~S$183M) keeps it below the radar of most institutional mandates

• Family’s 39% stake reduces free float to ~50%

• “Boring” industrial sector that doesn’t attract growth or thematic investors

• Cyclicality risk. Investors remember the FY2016–2017 losses

• Limited sell-side coverage for a micro-cap SGX name

For investors who can look past these structural factors, the valuation gap between intrinsic value and market price looks compelling.

What Could Go Right (and Wrong)

The bull case rests on:

• Singapore’s multi-decade infrastructure pipeline sustaining demand

• The XGC12000 investment unlocking ultra-heavy lift projects at premium margins

• India and Middle East scaling to 15–20% of revenue

• Continued deleveraging and dividend growth

• A potential re-rating as the market recognises the sustained earnings improvement

If EPS reaches 10–12 cents by FY2027–28 and the market assigns a more reasonable 12x P/E (still below typical SGX industrial multiples), that would imply S$1.20–S$1.44 per share. Even a modest re-rating to 0.7x P/B would yield S$0.97.

The bear case centres on:

• A macro or sector-specific slowdown hitting Singapore infrastructure spending

• The FY2025 margin compression (41% → 38%) continuing as competition intensifies

• Fleet utilisation declining from 54% towards the 48% levels of FY2022–23

• The S$45M capex not generating adequate returns if demand softens

• Currency risk from multi-country operations

In a downturn scenario, EPS could revert to 3–4 cents (the FY2020–21 range), and the stock could trade down to S$0.40–0.50 at 10–12x depressed earnings.

The base case sits somewhere in between: continued but moderating growth, margins stabilising in the 36–39% range, EPS of 8–10 cents, with the stock gradually re-rating as the dividend grows and the earnings track record lengthens.

The Bottom Line

Tiong Woon is a well-run, family-controlled industrial company with a 45-year track record, trading at a significant discount to its tangible asset value. The improving earnings trajectory, conservative balance sheet, and growing dividends all point in the right direction.

The key risk is cyclicality. This business has been through very tough times. The FY2016–2017 losses demonstrate what happens when demand turns. But the balance sheet is materially stronger today (net gearing 0.15x vs 0.48x), the receivables book is cleaner, and the company has a larger, more capable fleet positioned for the infrastructure upcycle.

At 0.5x book value, 9x earnings, and 3.6x EV/EBITDA, you’re getting a lot of asset and earning power for the price. The cumulative free cash flow over the past decade (S$204M) exceeds the current market cap (S$183M). That’s the kind of number that makes value investors pay attention.

This is a stock that doesn’t show up on most screens. It’s too small for institutions, too boring for retail momentum chasers, and too niche for thematic funds. Sometimes that’s exactly where the opportunities are.

All financial data extracted directly from publicly available annual reports filed with SGX. Market data from public financial data providers as of April 2026..

IMPORTANT DISCLAIMERS

General Disclaimer: This article is published for informational and educational purposes only. It does not constitute financial advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The views expressed are based on publicly available data from Tiong Woon Corporation Holding Ltd’s SGX filings and publicly accessible market data, and may not reflect the most current developments.

Not Licensed Financial Advice: The author is not a licensed financial adviser, and this publication is not issued by a holder of a Capital Markets Services Licence under the Securities and Futures Act 2001 of Singapore. This content does not fall within the definition of “financial advisory service” under the Financial Advisers Act 2001 of Singapore. Readers in Singapore should note that this content is exempt from the requirements of the Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication.

MAS Compliance Notice: In accordance with the Monetary Authority of Singapore’s guidelines, this publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, you should consult a licensed financial adviser who can provide advice tailored to your personal circumstances. Past performance of any security discussed herein is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author may or may not hold positions in the securities discussed. No compensation has been received from any company mentioned in this article.

If that’s true, Kimly Limited might be one of the best businesses in Singapore. The company operates traditional coffee shops across the island’s heartland estates - the kind of neighbourhood kopitiam where aunties and uncles queue for S$3 mixed vegetable rice at 6am and zi char dinners come in at under S$10 a head. It’s not sexy. It’s not tech. But it throws off cash like a vending machine.

The stock currently trades at roughly S$0.39, giving it a market capitalisation of around S$486 million. It pays a 5.1% dividend yield, generates over S$85 million in annual operating cash flow, and has compounded earnings at a respectable clip since its 2017 IPO. And yet, at ~14.5x trailing earnings, it’s not priced like a compounder.

So the question is: what are you actually paying for, and is it enough?

The Origin Story: From Hawker Heritage to SGX Listing

Kimly’s story begins in the early 1990s, when founder Lim Hee Liat started managing traditional coffee shops in Singapore’s heartland HDB estates. The name “Kimly”, rendered in Chinese as 金味 (jin wei, meaning “golden flavour”), reflects the company’s roots in Singapore’s hawker and kopitiam culture, a culinary tradition so distinctive that it earned UNESCO Intangible Cultural Heritage status in 2020. [1]

For over two decades before its IPO, Kimly quietly built what would become one of the largest kopitiam networks on the island. The model was deceptively simple: lease coffee shop premises (typically from HDB), fit them out, recruit and manage food stall tenants, and operate in-house stalls selling staples like dim sum, mixed vegetable rice, and seafood zi char. By the time of its 2018 annual report, the company described itself as having “more than 25 years of experience” in the trade. [2]

The company listed on the Catalist board of the SGX-ST on 20 March 2017, raising net proceeds of S$43.5 million in its IPO. [3] At that point, Kimly operated 67 food outlets and 129 food stalls across the island, with approximately 40% of stalls open 24 hours. [2]

The IPO proceeds were earmarked for outlet expansion, central kitchen upgrades, and working capital - a disciplined deployment that, as of FY2025, has been substantially completed with S$42.8 million utilised out of S$43.5 million raised. [4]

Two pivotal moves reshaped the company after listing. In July 2018, Kimly acquired the Tonkichi and Rive Gauche businesses from Sapporo Lion, adding Japanese dining and confectionery to its portfolio. [2]

Then, in a far more consequential deal, the company acquired Tenderfresh Group in 2021, gaining a halal-certified central kitchen and a network of quick-service restaurants that opened up the Muslim dining market, roughly 15% of Singapore’s population and a fast-growing regional opportunity. [5]

By FY2025, the network had expanded to 84 food outlets, 5 halal food outlets, 142 food stalls and restaurants, and 53 halal food stalls, restaurants, and kiosks, with an occupancy rate of 97.5% across 638 managed stalls. [4]

In FY2025, the company accelerated a shift from pure operator to landlord-operator, acquiring freehold and leasehold properties to secure strategic long-term locations. While a small property rental division had existed since FY2021, the capital deployment escalated dramatically in FY2025 with S$24.1 million in acquisitions.

The Business: Three Pillars, One Ecosystem

Kimly isn’t just a coffee shop operator. It runs a vertically integrated F&B ecosystem built on three complementary divisions.

Outlet Management (40.8% of FY2025 revenue, S$131.7M) is the engine room. Kimly leases coffee shop premises from HDB or private landlords, fits them out, then sub-leases individual stalls to food hawkers. Think of it as a platform business: Kimly provides the location, infrastructure, cleaning, and management; tenants bring their food and pay rent. As of FY2025, the Group manages 68 traditional coffee shops, four industrial canteens, five Halal outlets under the Kedai Kopi brand, and two food courts. The occupancy rate across 638 stalls sits at 97.5%.

Food Retail (56.8% of revenue, S$182.8M) is where Kimly operates its own food stalls. The portfolio is impressively diverse: 49 Dim Sum stalls, 60 Mixed Vegetable Rice stalls, 28 Zi Char stalls, 3 Teochew Porridge stalls, 2 Tonkichi Japanese restaurants, and the entire Tenderfresh halal food operation (53 outlets). Supporting everything is a central kitchen network that supplies sauces, marinades, and semi-finished products.

Outlet Investment (2.4% of revenue, S$7.7M) is the strategic ace. Kimly buys freehold or long-term leasehold coffee shop properties outright. This eliminates lease renewal risk, locks in prime locations permanently, and generates steady rental yields. In FY2025, Kimly acquired two coffee shop properties for S$24.1 million (excluding prior-year prepayments), with a third acquired shortly after the balance sheet date, and this strategy is accelerating.

Signal from the data: Food Retail revenue actually declined from S$185.0M to S$182.8M in FY2025, even as total revenue grew 0.9%. Growth came entirely from Outlet Management (+S$4.5M) and Outlet Investment (+S$0.4M). For a segment that makes up 57% of revenue, this is worth watching closely.

These three divisions create a self-reinforcing flywheel. The outlet management platform generates traffic and tenant demand. The food retail stalls anchor the outlets with popular, consistent food. And the property acquisitions secure the best locations for the long term. The geographic exposure is entirely Singapore: 89 food outlets (84 under the Kimly/foodclique brands plus 5 halal Kedai Kopi outlets) distributed across the island's heartland estates, with 57 operating 24 hours daily.

The Numbers: Boring in the Best Way

Kimly has grown revenue from S$202M in FY2018 to S$322M in FY2025, a CAGR of roughly 6.9%. But the honest story is that most of the growth came in one leap: the Tenderfresh acquisition in 2021, which pushed FY2022 revenue from S$239M to S$318M overnight. Since then, growth has been pedestrian at 1-2% annually. This is a mature, Singapore-only business. You’re not buying a growth stock.

* Excluding S$2.5M gain on disposal of Confectionery Business. ^ Excluding S$1.6M corporate income tax rebate. Net Profit figures represent Group Profit after Tax. EPS is calculated on net profit attributable to owners of the Company.

The FY2021 margins were anomalously high, likely reflecting pandemic-era government support measures and cost relief, though the annual report does not break out the exact impact. The normalised picture since FY2022 shows gross margins stabilising in the 28-29% range, with FY2025 ticking up slightly to 29.2%. EBITDA margins sit at 15-16%, and net margins hover around 11%. Margins have held up well despite relentless cost pressures from manpower, raw materials, and utilities.

ROE has trended downward from a peak of 29.5% in FY2021 to 17.3% in FY2025. This looks concerning in isolation, but it's primarily a function of the equity base growing from S$133M (FY2021) to S$192M (FY2025) through retained earnings and the Tenderfresh acquisition. A 17% ROE still comfortably exceeds any reasonable cost of equity for a consumer F&B business.

Where the Cash Goes

This is where Kimly shines - and where the FY2025 story gets interesting. Operating cash flow of S$85.3M on S$322M revenue is a 26.5% cash conversion rate. But the Group deployed over S$30 million on property acquisitions (including capitalised amounts from prior-year prepayments), S$11.4M repaying bank loans, and S$24.9M on dividends. Cash dropped from S$98.5M to S$68.1M. The balance sheet remains healthy (S$192M equity, no net debt beyond lease liabilities), but the aggressive property spending bears watching - it can’t continue at this pace indefinitely without either slowing down or re-levering.

Total dividends have grown from 0.96 cents per share in FY2018 to 2.00 cents in FY2025, with a payout ratio of approximately 75%. At S$0.39, that’s a 5.1% yield: well-covered by free cash flow even in a heavy investment year. The Board has demonstrated a clear commitment to consistent shareholder returns.

The Moat: Wider Than You’d Think

Traditional coffee shops don’t scream “competitive advantage.” But Kimly has built a quietly formidable position through several reinforcing factors.

HIGH DURABILITY: Scale and Network Density. With 89 food outlets and 195 food stalls, Kimly is one of the largest operators in Singapore. This scale provides procurement leverage, brand visibility, and operational efficiencies. Building a comparable network from scratch would take decades.

HIGH DURABILITY: Central Kitchen Infrastructure. The central kitchens supply sauces, marinades, and semi-finished food products across the network, ensuring consistency, reducing per-unit costs, and easing manpower constraints. This infrastructure took years to develop and is difficult to replicate.

MODERATE (IF EXECUTED WELL): Property Ownership Strategy (Early Stage).Owning coffee shop properties would theoretically eliminate lease renewal risk, but this strategy is unproven at Kimly. In FY2025, the company deployed S$24.1 million to acquire Block 204 Serangoon Central and 110 Yishun Ring Road, with a third property (12 Haig Road) acquired post-balance sheet. The durability of this strategy depends on: (i) actual returns on these properties exceeding the cost of capital, (ii) management’s ability to sustain capex without impairing dividends, and (iii) avoidance of overpaying for real estate. Returns data are not yet disclosed. [6]

MODERATE-HIGH: Tenant Loyalty. Decades of reliable management have built trust with food stall tenants. A 97.5% occupancy rate [4] across 638 stalls reflects this. However, the dip from the historical 98%+ benchmark warrants attention.

Worth watching: After years of high occupancy (98%+ per the FY2018 report), the rate dipped to 97.5% in FY2025. That's roughly 10 fewer occupied stalls. Management attributes this to tenant turnover and outlet renovations. If it stabilises or recovers, it's noise. If it trends toward 95%, it signals structural weakening.

MODERATE: Halal Credentials via Tenderfresh. The 2021 acquisition positioned Kimly in the growing Singapore halal market, with a certified Halal central kitchen and 53 outlets. A notable innovation is the “shared kitchen” concept at two Kedai Kopi locations, housing three Tenderfresh brands (380 Nasi Lemak, Pasta Pizza, Tenderbest) under one roof. This optimises kitchen space, reduces staffing needs, and gives customers multiple options at a single outlet. If replicable across more locations, this model could be meaningful.

Overall moat assessment: moderate to wide within Singapore’s traditional coffee shop industry, with the caveat that it’s geographically bounded to a city-state of 5.9 million people.

Growth Drivers and Headwinds

What Could Drive Upside

Network expansion of 3-5 new outlets annually continues. Recent additions include Blk 302 Ubi Avenue 1 (October 2024) and Block 727 Clementi West (July 2025), plus a joint venture at Block 206 Toa Payoh North. Based on the FY2025 Financial Review, 24 new food stalls collectively contributed approximately S$10.9 million in revenue, though per-outlet economics vary widely by location and format.

Halal segment growth is the biggest lever, but needs to prove itself. The Nasi Kari range sold over 20,000 portions since its May 2025 launch. Hawkerman partnered with Chef Eric Low to launch six regional halal dishes. Tenderfresh was invited to host an immersion visit for international delegates at the Singapore Halal International Seminar 2025. These are promising signals, but management’s own description of halal performance as “stable” rather than “growing” tempers expectations.

Property acquisitions represent a strategic shift beginning in FY2025, with S$24.1 million deployed to acquire Block 204 Serangoon Central and 110 Yishun Ring Road. The company’s rationale is to de-risk locations through ownership rather than lease agreements. However, the financial returns on these acquisitions (cap rate, internal rate of return) are not disclosed, and the company has not guided on the pace or scale of future property purchases. This unproven strategy bears close monitoring.

Operational efficiency gains from rotary ovens, self-service ordering kiosks, shared kitchen concepts [4], and central kitchen automation are designed to offset the industry’s structural manpower shortage.

What Could Go Wrong

HIGH RISK: Manpower. Singapore’s tight labour market and restrictive foreign worker policies make F&B hiring exceptionally difficult. Wage inflation is structural and ongoing.

HIGH RISK: Cost pressures. Food ingredients, utilities, and rentals continue rising. Kimly’s positioning as an affordable dining option limits pricing power.

MODERATE RISK: Geographic concentration. Kimly is 100% Singapore. A severe local downturn or policy change would impact the entire business with no offset.

MODERATE RISK: Management transition at Tenderfresh. Changes in Tenderfresh’s senior leadership, with Mr. Chee Kok Chew Gabriel appointed as Executive Officer to oversee the Tenderfresh Group (per the FY2025 annual report, p.8), introduce execution uncertainty around the halal expansion thesis.

Management and Capital Allocation

Kimly’s Board is chaired by Mr. Lau Chin Huat, a Non-Executive Independent Chairman with over 40 years in audit and advisory. The operational team includes veteran managers with 10+ years at the Group. Founder Lim Hee Liat and his concert parties hold approximately 39.9% of shares [8], with total insider ownership around 66-68% [8]. There is no evidence of recent insider selling.

The capital allocation scorecard is solid. IPO proceeds of S$43.5M have been substantially deployed (S$42.8M utilised) [4]. The Tenderfresh acquisition was transformative. Property purchases are strategically sound and funded internally. Four bank loans totalling S$11.4M were fully repaid in FY2025 [6]. And 74-75% of net profit is returned to shareholders through dividends. One latent observation: with 68% insider ownership, a cash-rich balance sheet, and the Koufu privatisation precedent (2022) [9], a take-private scenario is not far-fetched.

Valuation: Fair, Not Cheap

At 14.5x trailing P/E, Kimly trades in the middle of its historical 10-18x range. A simplified DCF using 2-3% revenue growth, 15.5-16% EBITDA margins, and an 8-9% WACC suggests fair value of S$0.42-0.46. Direct peers are limited since Koufu’s delisting, but against the broader Singapore consumer sector (17-20x P/E), Kimly trades at a discount reflecting its small-cap status and single-country exposure.

The FCF yield of 11.5% stands out. If you view Kimly as a cash flow machine with modest growth optionality, the current price arguably under-appreciates the quality of the cash generation. However, the FY2025 property acquisitions warrant scrutiny: the company deployed S$24.1 million while cash reserves fell by S$30.4 million despite positive operating cash flow, suggesting the landlord strategy is in early stages. The actual cap rate and return on these S$24M+ acquisitions are not disclosed. Investors should monitor whether the property pivot becomes accretive to earnings or merely locks up capital in lower-yielding real estate.

On the other hand, the 1-2% top-line growth caps re-rating potential. Without a catalyst to accelerate growth, the stock is likely to remain range-bound, with total returns driven primarily by dividends.

The Bottom Line

Kimly Limited is a high-quality, boring, cash-generative business trading at a fair but not bargain valuation. The investment thesis is simple: a dominant Singapore kopitiam operator with a durable moat, strong cash generation, a 5.1% dividend yield, and an evolving strategy that’s gradually shifting toward asset ownership.

After reviewing the full trail of SGX filings, the thesis is intact but has nuance. Revenue growth is anaemic (sub-1%). Food Retail, the largest segment, is actually shrinking. The Tenderfresh growth narrative needs more evidence. On the other hand, the property acquisition strategy is adding real, tangible value. The shared kitchen concept [4] is a clever operational innovation. And the massive insider ownership provides alignment and a latent privatisation option.

Bull case: Network expands to 95-100 outlets, Tenderfresh scales via shared kitchens, margins improve through automation. Revenue reaches S$360-380M by FY2028 with net profit of S$40-45M. At 16-18x P/E: S$0.51-0.65 (30-67% upside plus cumulative dividends).

Base case: Steady 1-2% growth, margins hold, dividends maintained at 2.0 cents. At 14-16x P/E: S$0.41-0.51 (5-30% upside plus 5.1% annual yield).

Bear case: Cost pressures compress earnings to S$28-30M, dividend cut to 1.5 cents. At 10-12x P/E: S$0.23-0.29 (25-40% downside).

This is not a multi-bagger candidate. The realistic total return profile is 7-12% annually (5.1% dividend plus 2-7% capital appreciation), which is attractive for a defensive, income-oriented position with a hard asset floor. For value investors who appreciate consistent cash flows, owner-operator mentality, and getting paid to wait, Kimly merits a closer look. The downside is cushioned by tangible assets and a resilient business model. The upside is capped by modest growth but sweetened by yield and optionality.

Revision History

4 May 2026 — Reader corrections incorporated

Two substantive corrections were made following reader comments. Both affect how Kimly’s cash generation should be interpreted, and neither changes the core thesis, but both matter for intellectual honesty.

1. IFRS 16 and true FCF (Cash Flow section)

The original article presented operating cash flow of S$85.3M and FCF of S$56M without flagging the IFRS 16 lease accounting effect. Under IFRS 16, when Kimly signs a new lease the ROU asset and lease liability are recognised simultaneously with no cash changing hands at inception. Lease principal repayments flow through financing cash flows, not operating cash flows, meaning reported OCF is higher than it would be under pre-IFRS 16 treatment where all rent sat as an operating expense.

2. FCF yield overstated (Valuation section)

The original article cited an FCF yield of ~11.5% as a valuation argument. A reader correctly pointed out that this figure does not account for lease principal repayments, which are a real and recurring cash obligation for a lease-heavy operator like Kimly. Once adjusted, the true FCF yield falls to approximately 2–3% in FY2025. The valuation table has been updated accordingly. The underlying investment case that is anchored on dividend sustainability (5.1% yield, well-covered by earnings) and the property acquisition strategy remains unchanged.

References

All factual claims in this article are sourced from the following publicly available documents filed with the Singapore Exchange (SGX) or published by the company:

[1] UNESCO, “Hawker culture in Singapore, community dining and culinary practices in a multicultural urban context,” Intangible Cultural Heritage, inscribed 2020.

[2] Kimly Limited, Annual Report 2018, “Corporate Profile” and “Message to Shareholders,” pp. 1-7.

[3] Kimly Limited, Annual Report 2018, Catalist listing date: 20 March 2017, p. 1.

[4] Kimly Limited, Annual Report 2025, “Corporate Profile,” “Our Businesses,” and “Message to Shareholders,” pp. 1-8.

[5] Kimly Limited, Annual Report 2021 and subsequent reports, Tenderfresh acquisition details.

[6] Kimly Limited, Annual Report 2025, “Financial Review” and “Financial Highlights,” pp. 19-24.

[7] Kimly Limited, Annual Report 2025, “Message to Shareholders — Rewarding Shareholders,” p. 8.

[8] Kimly Limited, SGX filings, substantial shareholder notifications and annual report disclosures (FY2024-FY2025).

[9] “Koufu Group announces privatisation offer at S$0.790 per share,” SGX announcement, 2022.

IMPORTANT DISCLAIMERS

General Disclaimer: This article is published for informational and educational purposes only. It does not constitute financial advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The views expressed are based on publicly available data from Kimly Limited’s SGX filings and publicly accessible market data, and may not reflect the most current developments.

Not Licensed Financial Advice: The author is not a licensed financial adviser, and this publication is not issued by a holder of a Capital Markets Services Licence under the Securities and Futures Act 2001 of Singapore. This content does not fall within the definition of “financial advisory service” under the Financial Advisers Act 2001 of Singapore. Readers in Singapore should note that this content is exempt from the requirements of the Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication.

MAS Compliance Notice: In accordance with the Monetary Authority of Singapore’s guidelines, this publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, you should consult a licensed financial adviser who can provide advice tailored to your personal circumstances. Past performance of any security discussed herein is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author may or may not hold positions in the securities discussed. No compensation has been received from any company mentioned in this article.

Data Sources: Kimly Limited SGX filings, public market data from SGX, Yahoo Finance, and Bloomberg as of April 2026.